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C H A P T E r  1
GENErAL iNTroDUCTioN AND 
oUTLiNE oF THESiS
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Venous thrombosis is a common disorder with an annual incidence of around 1-2 cases per 
1.000 individuals and is the third leading cause of cardiovascular morbidity and mortality 
in developed countries.1-4 Thrombosis may arise in any section of the venous system, but 
it typically occurs in the deep veins of the lower extremities. The major concern in these 
patients is pulmonary embolism, which can be fatal. A more common, but often disabling, 
complication of deep vein thrombosis and its sequelae is the post-thrombotic syndrome.5 
Rarely, thrombosis may involve other venous sites. One of these uncommon manifestations 
of thrombosis is located in the splanchnic veins, which is accompanied by a considerable 
morbidity and mortality. 
SPLANCHNiC VEiN THromBoSiS
Splanchnic vein thrombosis (SVT) encompasses hepatic vein thrombosis (Budd-Chiari 
syndrome, BCS), portal vein thrombosis (PVT), and mesenteric vein thrombosis. BCS and 
PVT are the two most frequent manifestations of SVT, and although in these disorders 
distinct venous sites are affected, simultaneous involvement of these venous districts is 
frequently encountered.6 
 The splanchnic venous system comprises the portal vein and its branches that direct 
blood flow from the gastrointestinal organs to the liver. The portal vein is formed by the 
union of the superior mesenteric vein and the splenic vein, and subdivides in a left and right 
branch, which are segmentally distributed throughout the liver. The terminal portal venules 
drain into the sinusoids, after which the blood flows from the small to large hepatic veins, 
ultimately reaching the inferior vena cava. 
 BCS is defined as an obstruction of the hepatic venous outflow tract from the level of the 
small hepatic veins to the entrance of the inferior vena cava into the right atrium. Outflow 
obstruction caused by hepatic veno-occlusive disease and cardiac disorders is excluded 
from this definition. BCS is considered primary when obstruction of the venous tract is the 
result of an endoluminal lesion, i.e. thrombosis, and secondary when obstruction results 
from invasion by a local malignant tumor or from extrinsic compression by a tumor, cyst 
or abscess.7 BCS is a rare disorder with an annual incidence of about 0.2-0.8 per million 
inhabitants in the Western world, predominantly affecting young females.8-10 Main 
complications are the result of portal hypertension and liver dysfunction. The classical 
triad of symptoms in BCS consists of abdominal pain, ascites and hepatomegaly, frequently 
accompanied by a variable degree of alterations in liver biochemical tests. However, 
clinical presentation may range from absence of symptoms, in case of preservation of 
hepatic veins and/or formation of collaterals, to fulminant hepatic failure, with an acute 
or chronic development of symptoms ranging from weeks to months.6 With contemporary 
management, the survival rate is 87% at one year and 82% at two years.11 
Ch
ap
te
r 1
9Introduction | 
In PVT, the obstruction is located in the extra-hepatic portal vein, but involvement of the intra-
hepatic portal, superior mesenteric and splenic vein may occur. Although PVT is considered 
a rare disorder, a recent autopsy study reported a prevalence of 1%.12 Clinically, PVT can 
be classified as acute or chronic, which represent successive stages of the same disease 
and share similar causes. Complications of portal hypertension, such as gastrointestinal 
bleeding from oesophageal varices and splenomegaly, are the most important clinical 
manifestations of PVT.6 Furthermore, if thrombosis extends into the mesenteric vein, there 
is a substantial risk of bowel infarction, which is the most severe complication of acute PVT.13 
The prognosis of patients with PVT is mainly determined by the underlying cause. Survival 
of patients with non-cirrhotic, non-malignant PVT can be considered good. In this group of 
PVT patients, five- and ten-year survival rates are 90% and 80%, respectively.14 PVT patients 
with an underlying liver cirrhosis or hepato-biliary malignancy generally have an inferior 
prognosis.
Etiology
Local risk factors for the development of BCS include solid malignancies, parasitic masses, 
cysts or abscesses that either compress or invade the venous tract.7 In the Western world, BCS 
is infrequently caused by local risk factors. PVT, on the other hand, is most often encountered 
as a complication of liver cirrhosis or hepatobiliary malignancies. Other frequent local risk 
factors for PVT are surgical trauma to the portal vein and inflammatory foci in the abdomen, 
which are often accompanied by an additional prothrombotic condition. 
 The etiology of primary BCS and non-malignant, non-cirrhotic PVT often involves 
systemic, prothrombotic conditions. Recent studies with a near complete work-up showed 
that prothrombotic factors are present in up to 84% and 42% in primary BCS and non-
malignant, non-cirrhotic PVT, respectively.11,15 These conditions largely overlap with the risk 
factors for common venous thrombosis and can be divided into genetic and acquired risk 
factors. Genetic risk factors include protein C, protein S and antithrombin deficiencies, the 
factor V Leiden mutation and the prothrombin G20210A gene variant. Acquired risk factors 
include antiphospholipid antibodies, paroxysmal nocturnal hemoglubinuria, hormonal 
factors, auto-immune diseases and myeloproliferative neoplasms (MPNs), which remarkably 
are the most prominent risk factor for the development of both BCS and PVT. 
 MPNs are chronic clonal hematopoietic stem cell disorders characterized by an 
overproduction of mature and functional granulocytes, red blood cells and/or platelets.16 
The exact pathogenetic mechanism of thrombosis in MPNs remains elusive, but besides 
characteristic erythrocytosis and thrombocytosis, platelet and leukocyte functional 
abnormalities appear critical.17 MPNs have been reported in approximately one third 
and one half of BCS and PVT patients, respectively.18 Diagnosis of MPNs in these patients 
is notoriously difficult. Portal hypertension, resulting from pre- or post-hepatic venous 
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obstruction, can lead to hypersplenism and hemodilution. Both these conditions may mask 
the characteristic peripheral blood cell changes and make diagnosis of MPN more difficult. 
Previously, diagnosis of MPNs in these patients often relied on bone marrow (BM) biopsy 
findings and growth of erythroid colonies in the absence of exogenous erythropoietin, 
referred to as spontaneous endogenous erythroid colonies (EEC). Patients were labelled as 
having so-called occult MPN when either bone marrow biopsy was highly suggestive of 
MPN or EEC was present, but in whom traditional criteria for MPN could not be fulfilled due 
to normal peripheral blood cell counts.19 In 2005, the JAK2V617F gain of function mutation 
was discovered, which is present in more than 95% of cases of polycythemia vera and 50% 
to 60% of essential thrombocythemia and primary myelofibrosis. JAK2V617F has radically 
changed the diagnostic landscape of MPNs and has been included as one of the cornerstones 
in the 2008 World Health Organization classification for hematological malignancies.20 
Interestingly, the JAK2V617F mutation is not seen in nonmyeloid malignancies21 and 
therefore offers an additional tool to detect occult MPNs in BCS and PVT patients. 
 Recent studies have consistently shown that the etiology of primary BCS and non-
cirrhotic, non-malignant PVT must be considered multifactorial, as in common forms of 
venous thrombosis. Recent studies reported a combination of two or more genetic or 
acquired prothrombotic factors in 46% of BCS and 48% of PVT patients.11,15 In this large 
cohort of BCS patients, 18% of the patients even displayed three risk factors.
Treatment
Randomized clinical studies on the efficacy of the treatment options of BCS and PVT are 
lacking and current therapy guidelines are therefore based on cohort studies and expert 
opinions. In both disorders, prompt recognition and treatment of underlying disorders is 
recommended. As in common forms of venous thrombosis, anticoagulant therapy is the 
cornerstone of the management of BCS and PVT. The aim of anticoagulation is to reduce the 
risk of thrombus progression into adjacent vessels and to improve the rate of recanalization. 
 Immediate therapy with low molecular weight heparin followed by life-long oral 
anticoagulant therapy is recommended for all patients with primary BCS, irrespective of 
whether an underlying prothrombotic disorder has been identified.22 Previous portal 
hypertension related bleeding is not considered a contraindication, provided that 
appropriate prophylaxis for recurrent bleeding is undertaken, for example using beta-
blockers and/or endoscopic therapy. In BCS percutaneous transluminal angioplasty or 
insertion of a transjugular intrahepatic portosystemic shunt (TIPS) is warranted to induce 
decompression of the liver vasculature. Liver transplantation should be considered in 
deteriorating BCS patients in whom the disease cannot be controlled with the above 
described options.7,10,22
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There is currently much debate on the optimal strategy of anticoagulant treatment in PVT 
patients, as potential beneficial effects of preventing extension or recurrent thrombosis 
may be outweighed by the inherent risk of bleeding complications. According to current 
consensus, non-cirrhotic patients with acute PVT should be treated with anticoagulant 
therapy for at least three months, unless a persisting underlying prothrombotic factor is 
present, in which case life-long treatment is recommended.22 Non-cirrhotic patients with 
chronic PVT may also be treated life-long in case of persisting prothrombotic factors, 
whereas it is generally discouraged in patients without a hypercoagulable state.22 There is 
currently no evidence to support the use of anticoagulant therapy in either acute or chronic 
PVT patients with concomitant cirrhosis.23 Adequate prophylaxis for bleeding complications 
by means of beta-blockers or endoscopic therapy in patients receiving anticoagulation 
therapy is essential. Although two recent series demonstrate that TIPS is feasible and 
effective in treating complications of portal hypertension in patients with liver cirrhosis and 
extensive PVT,24,25 there is currently insufficient evidence in favour of interventional therapy 
such as TIPS placement in patients with non-malignant, non-cirrhotic PVT.22 
 Thrombolytic therapy using streptokinase or recombinant tissue-plasminogen activator 
in patients with thrombosis of the splanchnic veins is controversial and its place in the 
treatment of these disorders is not fully established. Successful treatment has been reported 
either in patients with acute, extended thrombosis of the splanchnic veins, or as a rescue 
therapy in case of acute thrombosis during percutaneous transluminal angioplasty or TIPS 
insertion.26-33 However, evidence is mostly based on single case studies and small case series 
and these findings should therefore be interpreted with caution. 
AimS AND oUTLiNE oF THiS THESiS
The focus of this thesis is on the etiology and treatment of patients with primary BCS and 
non-malignant, non-cirrhotic PVT. For this purpose, several studies addressing different 
aspects of the etiology and treatment of these disorders will be performed. 
 In chapter 2, the current insights in the risk factors for commonly occurring venous 
thrombosis, in particular deep vein thrombosis and pulmonary embolism, are reviewed. We 
will also provide an overview of the risk factors for BCS and PVT. We discuss similarities, but 
some apparent differences in the risk profiles between these forms of venous thrombosis 
that may provide new insights into to the site-specificity of venous thrombosis. 
 In chapter 3 we explore the etiology of BCS by means of a single-center cohort study 
and evaluate the presence of concomitant prothrombotic factors in patients who were 
previously diagnosed with an underlying MPN. In addition, we assessed the prevalence of 
the JAK2V617F mutation and investigate its clinical utility in the detection of occult MPNs.
12 | Chapter 1
Since the discovery of the somatic JAK2V617F mutation in 2005, numerous studies have 
been performed on the association between JAK2V617F and the development of SVT. In 
chapter 4 we report a meta-analysis in which we assess the prevalence of MPNs and its 
subtypes and JAK2V617F in both BCS and PVT, and evaluate the clinical value of screening 
for JAK2V617F in the detection of MPNs in patients without elevated peripheral blood 
counts. 
 The discovery of the JAK2 46/1 haplotype in 2009 represents another crucial advance in 
the field of MPNs since the discovery of the JAK2V617F mutation. Individuals carrying the 
JAK2 46/1 haplotype not only preferentially acquire the JAK2V617F mutation, but also JAK2 
exon 12 and MPL mutations. In chapter 5 we investigate whether the JAK2 46/1 haplotype 
is associated with the development of SVT, and determine whether JAK2 46/1 is associated 
with clinical and laboratory characteristics of SVT. This study is based on data obtained from 
a large cohort study of BCS and PVT patients initiated by the European Network of Vascular 
Disorders of the Liver (EN-Vie).
 In chapter 6 and 7 we explore a potential new risk factor for the development of PVT and 
BCS, respectively. Recent studies have shown that variation in the fibrinogen gamma gene 
(FGG) is associated with decreased fibrinogen γ’ levels and an increased risk of deep vein 
thrombosis. Using data obtained from the EN-Vie study, we assessed whether fibrinogen 
γ’ levels and variation in the FGG gene contribute to the development of non-malignant, 
non-cirrhotic PVT and primary BCS. 
 Thrombolytic therapy in patients with SVT is controversial. In chapter 8 we present our 
single-center experience with locally delivered thrombolytic therapy in patients with acute, 
extended splanchnic venous thrombosis. 
 Relatively little is known about the natural course of SVT in patients with an underlying 
MPN. In chapter 9 we study the long-term outcome and optimal management of PVT 
patients with an underlying MPN by means of a single-center retrospective cohort study. 
We focus on complications and treatment strategies that are relevant to this specific patient 
group. Interestingly, the value of treatment with aspirin in these patients has not yet been 
investigated.
 Finally, in chapter 10 the findings of our studies will be summarized and discussed.
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ABSTrACT
In this review we provide an overview of the risk factors for venous thromboembolism, 
focussing on hypercoagulability and hypofibrinolysis. In the first part of this review we 
discuss the risk factors for commonly occurring venous thrombosis, in particular deep vein 
thrombosis and pulmonary embolism. In the second part, we provide an overview of the risk 
factors for the Budd-Chiari syndrome (BCS) and portal vein thrombosis (PVT). These are two 
rare, life-threatening forms of venous thromboembolism located in the splanchnic veins. 
There are many similarities in the risk profiles of patients with common venous thrombosis 
and splanchnic vein thrombosis (SVT). Inherited thrombophilia and hypofibrinolysis increase 
the risk of both common venous thrombosis and SVT. However, there are also apparent 
differences. Myeloproliferative neoplasms and paroxysmal nocturnal hemoglobinuria have 
a remarkably high frequency in patients with thrombosis at these unusual sites, but are 
rarely seen in patients with common venous thrombosis. There are also clear differences 
in the underlying risk factors for BCS and for PVT, suggesting site-specificity of thrombosis 
even within the splanchnic venous system. These clear differences in underlying risk factors 
provide leads for further research on the site-specificity of venous thrombosis and the 
development of thrombosis at these distinct sites. 
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iNTroDUCTioN
Venous thromboembolism (VTE), with deep vein thrombosis (DVT) and pulmonary 
embolism (PE) as its two most common manifestations, is the third leading cause of 
cardiovascular morbidity and mortality in developed countries.1 VTE has an age-dependent 
incidence of 1 to 2 cases per 1.000 person-years, ranging from 1 in 100.000 in children to 1 
in 100 in advanced age.2-4 Main complications of VTE are the post-thrombotic syndrome in 
DVT and acute death in case of PE.5
 The term thrombophilia defines conditions that are associated with an increased risk 
of VTE, and is characterized by a hypercoagulable state or alterations in the fibrinolytic 
system leading to hypofibrinolysis.5,6 Common clinical features of thrombophilia are 
thrombosis at a young age, recurrent venous thrombosis, a positive family history of VTE, 
obstetric complications, and thrombosis located at unusual venous sites, such as the upper 
extremities veins, cerebral sinus and veins, retinal or the splanchnic veins.7 The role of 
thrombophilia in the pathogenesis of common VTE has been long established. Traditionally, 
the role of thrombophilia in the development of thrombosis at these uncommon venous 
locations has received relatively little attention. 
 However, the understanding of the etiology of splanchnic vein thrombosis (SVT) has 
considerably increased during the past 10 years. SVT includes hepatic vein thrombosis 
(Budd-Chiari syndrome, BCS) and portal vein thrombosis (PVT), which are two rare, but 
life-threatening forms of venous thrombosis.8 In the first part of this review, we provide a 
concise overview of the risk factors that are associated with the development of DVT and 
PE, with an emphasis on the role of hypercoagulability and hypofibrinolysis. In the second 
part, we focus on the risk factors for BCS and PVT. Finally, we discuss similarities but also 
apparent differences in the risk profile between common VTE and BCS and PVT.
riSK FACTorS For CommoN VENoUS THromBoEmBoLiSm
Risk factors for common venous thrombosis can be divided into acquired or environmental 
factors and genetic risk factors. Acquired risk factors include immobilization, plaster 
casts, surgery, trauma, cancer, obesity, increasing age, myeloproliferative neoplasms, 
antiphospholipid syndrome, hormone replacement therapy, use of oral contraceptives, 
pregnancy and puerperium. Most of these acquired factors are causing stasis or 
hypercoagulability of blood, both known to predispose to venous thrombosis. Known 
genetic risk factors for venous thrombosis are deficiencies of antithrombin, protein C, 
protein S, and the Factor V Leiden (FVL) mutation and prothrombin 20210A gene variant 
(reviewed in 7). 
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High plasma levels of hemostasis factors, especially factors stimulating secondary hemostasis 
(hypercoagulability), for example FVIII, and factors inhibiting fibrinolysis (hypofibrinolysis), 
for example plasminogen activator inhibitor type 1 (PAI-1), have been associated with 
increased risk of VTE. Both hypercoagulability and hypofibrinolysis factors are often the 
result of the above mentioned acquired and genetic factors and are considered to be direct 
intermediates in the pathophysiology of VTE (Figure 1). 
Hypercoagulability and/or
hypobrinolysis
  
 
Genetic risk factors  
Acquired risk factors  
Venous thrombosis
 
 
Figure 1. Venous thrombosis is the result of the interplay of genetic and acquired risk factors that 
influence the coagulation and fibrinolytic system, resulting in hypercoagulability and an impaired 
fibrinolytic potential. 
Venous thrombosis is a multifactorial disease, and is only rarely caused by a single risk factor. 
Thrombosis occurs most often when two or more risk factors are present at the same time.9 
The addition of a temporary risk factor in a patient with genetic thrombophilia can trigger 
the development of venous thrombosis, as is for instance observed in Factor V Leiden (FVL) 
carriers who start to use oral contraceptive use.10 A general population study showed that 
about half of all VTEs were secondary to the presence of one or more triggering risk factors. 
Most common triggering factors were hospitalization (52%), cancer (48%), and surgery 
(42%).11 
 An overview of the main risk factors for VTE is provided in the Table, and will be further 
discussed in the next sections. 
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Hypercoagulability in common VTE
Hypercoagulability can be the result of common variation or specific mutations in 
coagulation factor genes. Testing for genetic risk factors has been shown to be effective in 
identifying individuals at risk for venous thrombosis. However, not all these genetic variants 
are consistently associated with risk of VTE. 
 The strongest association with risk of a first venous thrombosis is seen for genetic 
variations that result in antithrombin, protein C or protein S deficiencies, with approximately 
5 to 10-fold, 4 to 6-fold, and 1 to 10-fold increases in risk, respectively.12,13 Since these 
deficiencies are rare, the estimates come from retrospective studies, although prospective 
studies in asymptomatic family members showed similar results.14 These deficiencies are 
also associated with an increased risk of VTE recurrence. 
 Consistent associations with venous thrombosis are observed with the prothrombin 
G20210A variant and Factor V Leiden mutation, which are associated with 3 and 7-fold 
increased risks, respectively.15,16 However, the association with VTE recurrence is unclear. 
Some studies reported an increased risk of recurrence for heterozygous carriers,17,18 but 
other, more recent studies did not confirm these findings.19-22 Heterozygosity for these 
genetic variants therefore does not have any consequence for the duration or intensity of 
anticoagulant treatment, but homozygosity and combinations with other risk factors are 
associated with an increased recurrence risk, and may need long-term treatment.23 However, 
a recent study found that homozygosity for the FVL mutation and/or the prothrombin 
variant or double heterozygosity for the FVL mutation and the prothrombin variant did 
not result in a high risk of recurrent venous thrombosis.24 Interestingly, the FVL mutation 
is a stronger risk factor for DVT than for isolated PE, which has been designated as the FVL 
paradox.25 To date, no explanation for this remarkable difference has been found.26 
 Individuals with antiphospholipid antibodies (APA) have also a rather pronounced 
(5-fold) increase in risk of a first venous thrombosis, and also the risk of recurrence is 
consistently increased.27 The combination of venous or arterial thrombosis and the presence 
of APA, or a combination of obstetric complications and the presence of APA, is defined as 
the antiphospholipid syndrome (APS).
 For prothrombotic conditions or changes in coagulation factors levels, such as acquired 
activated protein C resistance and increased levels of factor VIII, IX, XI and fibrinogen, the 
effects are moderate and not consistent.7,28,29 Determining these conditions or factor levels 
may increase the knowledge on the etiology, but will not directly affect the treatment of the 
patients. 
 Hypercoagulability can be assessed using overall tests of coagulation, such as the 
endogenous thrombin generation potential. Thrombin converts fibrinogen into fibrin 
and is essential for acceleration of the coagulation cascade by activating several other 
coagulation factors. An increased endogenous thrombin potential has been associated 
with an increased risk of first VTE.30,31 Measurement of thrombin generation has also been 
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shown to be of use in identifying patients with a high recurrence risk of VTE,29,32-34 although 
this was not observed in all studies.31
Hypofibrinolysis in common VTE 
Fibrinolysis is the process of degradation of a fibrin clot and limits thrombus extension beyond 
the site of endothelial damage. Plasmin, formed upon activation of its inactive precursor 
plasminogen, is the key enzyme of fibrinolysis and cleaves fibrin into fibrin degradation 
products. Regulation of the fibrinolytic system is a complex interaction of several proteins. 
Eventually plasminogen can be converted from plasminogen to the active plasmin by 
tissue-type plasminogen activator (t-PA) and urokinase plasminogen activator (u-PA). 
Several proteins control the fibrinolytic system. Plasminogen activator inhibitor-1 (PAI-1) is 
the primary inhibitor of t-PA and u-PA, thereby reducing the conversion of plasminogen to 
plasmin. Thrombin activatable fibrinolysis inhibitor (TAFI) potently attenuates fibrinolysis by 
removing carboxy-terminal lysine residues form partially degraded fibrin, thereby reducing 
the binding of plasminogen and t-PA to fibrin. Finally, α2-antiplasmin (plasmin inhibitor) is 
responsible for directly inhibiting plasmin (Figure 2, reviewed in 35).
t-PA u-PA
PAI-1
Plasminogen Plasmin
TAFI
Fibrin
α2-AP
FDP
Figure 2. A schematic representation of the fibrinolytic system. Abbreviations: t-PA, tissue-type 
plasminogen activator; u-PA, urokinase plasminogen activator; PAI-1, plasminogen activator 
inhibitor-1; TAFI, thrombin activatable fibrinolysis inhibitor; a2-AP, α2-antiplasmin; FDP, fibrinogen 
degradation products. 
The overall fibrinolytic potential, which is the net effect of both activating and inhibitory 
factors on fibrinolysis, can be assessed using global tests of fibrinolysis. Until 2005, no 
clear indications for a role of a decreased overall fibrinolytic potential in the pathogenesis 
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of venous thrombosis were observed. In these older studies, the fibrinolytic potential was 
studied using global tests such as the euglobulin clot lysis time and the dilute whole blood 
clot lysis assay. Both these tests have a number of limitations.6 However, recent findings in 
two large case-control studies demonstrated an association between hypofibrinolysis and 
risk of VTE. In these studies, a plasma-based, tissue factor initiated and t-PA induced clot 
lysis assay was used. The clot lysis time (CLT) denotes the time needed from half maximal 
clot formation to half-maximal lysis of a plasma clot and represents a marker for the over-
all fibrinolytic capacity.36 In the Leiden Thrombophilia Study (LETS)-study, a case control 
study on 469 patients with a first DVT and 469 healthy controls, a 2-fold increase in risk 
of DVT in individuals with a CLT above the 90th percentile was observed.37 In the Multiple 
Environmental and Genetic Assessment of risk factors for venous thrombosis (MEGA)-
study, involving over >2000 patients with VTE and >2500 controls, these findings were 
confirmed, showing a similar relationship between risk of DVT or PE and hypofibrinolysis.38 
The combination of hypofibrinolysis and risk factors associated with hypercoagulability was 
shown to result in a substantially greater risk than expected on the basis of the individual 
risks.38 In this study, oral contraceptive use in women with hypofibrinolysis was associated 
with a more than 20-fold increased risk of VTE. Hypofibrinolysis does not appear to be 
associated with risk of recurrence of VTE.39
 When considering individual fibrinolytic factors, the literature on the role of PAI-1 and 
t-PA in venous thrombosis has been controversial. In the Longitudinal Investigation of 
Thromboembolism Etiology (LITE)-study, a large population-based prospective study on 
venous thrombosis in middle-aged and elderly patients, no association was found between 
levels of PAI-1 or t-PA/PAI-1 complex and the risk of venous thrombosis.40 Several other 
studies also failed to show an association between t-PA and PAI-1 and the risk of venous 
thrombosis.41-43 However, more recently, the above mentioned LETS-study demonstrated 
that elevated PAI-1 levels were associated with an elevated CLT, indicative of hypofibrinolysis, 
and with the risk of venous thrombosis.44 In this study t-PA levels were associated with 
venous thrombosis, but not with CLT, suggesting that t-PA levels are more likely to reflect 
other underlying risk factors. 
 High TAFI levels have also been shown to be associated with a mildly increased risk 
of VTE, although not in thrombophilic families.45 In the LETS-study, TAFI levels above the 
90th percentile increased the risk for VTE 1.7-fold compared to TAFI levels below the 90th 
percentile,46 which was later confirmed in an independent cohort.47 In addition, high TAFI 
levels have been associated with an increased risk of recurrence of VTE.48 TAFI levels and 
activity are partly determined by several common genetic variations, which have also been 
associated with risk of VTE.49
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Studies on levels of plasminogen or α2-antiplasmin and the risk of venous thrombosis are 
scarce and often in small patient groups only.50-52 To this point, there is no clear evidence for 
a role of plasminogen or α2-antiplasmin levels in the development of VTE.6
other acquired risk factors for common VTE
Hospitalized patients have an increased risk for VTE since they are often exposed to one 
or more acquired risk factors for VTE, such as immobility, cancer, surgery, congestive heart 
failure, infections, or chronic kidney disease.53 Recent hospitalization for an acute medical 
disease is independently associated with 8-fold increased risk of VTE and accounts for 
almost one fourth of all VTE events.53
 Cancer patients have an increased risk of venous thrombosis as a result of multiple 
factors, like activation of coagulation by tumor cells resulting in hypercoagulability, 
compression of veins by the tumor, hospitalization, surgery, and chemotherapy.54,55 VTE can 
be diagnosed in 4-20% of patients with cancer and is one of the leading causes of death in 
these patients.56 Myeloproliferative neoplasms are also associated with an increased risk of 
thrombotic complications including venous and arterial thrombosis and microcirculatory 
disorders, such as erythromelalgia. Risk of these complications is most pronounced in 
polycythemia vera and essential thrombocytosis.57
 The risk of venous thrombosis in surgery depends on the type of surgery and patient 
characteristics.58 Surgery induces an acute phase reaction and plasma levels of many 
hemostasis factors increase in the days after surgery, which contributes to the prothrombotic 
condition in that period.59
 Another well-known triggering risk factor is immobility. Immobility, mostly defined as 
bed rest for at least 4 days, increases the risk probably by stasis of blood flow in the venous 
system. Clinical settings with immobility are bed rest, and plaster casts or paresis of the 
legs. Also shorter periods of bed rest60 and minor injuries61 have been associated with an 
increased risk of venous thrombosis. 
 Obesity (body mass index above 30 kg/m²) leads to a 2-3 fold increase in the risk of VTE 
and this increase in risk is even larger with severe obesity.40,62 Obesity is associated with 
hypercoagulability and hypofibrinolysis due to, amongst others, increased plasma levels of 
fibrinogen, factor VIII and especially of PAI-1.63
 
riSK FACTorS For SPLANCHNiC VEiN THromBoSiS
BCS is defined as an obstruction of the hepatic venous outflow tract from the level of the 
small hepatic veins to the entrance of the inferior vena cava into the right atrium.64 BCS 
is a rare disorder with an annual incidence of about 0.2-0.8 per million inhabitants in the 
Western world, predominantly affecting young females.65,66 The classical triad of symptoms 
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in BCS consists of abdominal pain, ascites and hepatomegaly, frequently accompanied by 
a variable degree of alterations in liver biochemical tests. However, clinical presentation 
may range from absence of symptoms, in case of preservation of hepatic veins and/or 
formation of collaterals, to fulminant hepatic failure, with an acute or chronic development 
of symptoms ranging from weeks to months.8,67 With contemporary management, the 
survival rate is 87% at one year and 82% at two years.68
 In PVT, the obstruction is located in the extra-hepatic portal vein, but involvement 
of the intra-hepatic portal, superior mesenteric and splenic vein may occur. Although 
PVT is considered a rare disorder, a recent autopsy study reported a prevalence of 1%.69 
Clinically, PVT can be classified as acute or chronic, which represent successive stages of 
the same disease and share similar causes. Complications of portal hypertension, such 
as gastrointestinal bleeding from oesophageal varices and splenomegaly, are the most 
important clinical manifestations of PVT.70 Furthermore, if thrombosis extends into the 
mesenteric vein, there is a substantial risk of bowel infarction, which is the most severe 
complication of acute PVT. The prognosis of patients with PVT is mainly determined by the 
underlying cause of thrombosis.70
 BCS is considered primary when obstruction of the venous tract is the result of thrombo-
sis and secondary when obstruction results from invasion by a local malignant tumor or 
from extrinsic compression by a tumor, cyst or abscess. The latter can also be accompanied 
by a hypercoagulable state.64 PVT is considered primary in the absence of liver cirrhosis 
and local malignant tumors, which are the leading risk factors. Other frequent local risk 
factors are inflammatory foci in the abdomen and surgical trauma to the portal vein, which 
are often accompanied by an additional prothrombotic condition.8,70 A local precipitating 
factor can be identified in approximately one-third of PVT patients, whereas local factors 
related to the development of thrombosis are rarely identified in patients presenting with 
BCS. 
 In many patients with BCS and PVT a genetic or acquired disorder in hemostasis is 
present. Several well known risk factors that predispose to common forms of venous 
thrombosis also contribute to the pathogenesis of thrombosis at these unusual sites. 
However, some marked differences also exist. 
 The most prominent risk factors for SVT are displayed in the Table, and will be further 
explored below. 
Hypercoagulability in splanchnic vein thrombosis
The prevalence of inherited deficiencies of the natural anticoagulants antithrombin, 
protein C and protein S is difficult to determine in BCS and PVT patients, because acquired 
deficiencies of these coagulation inhibitors can occur due to liver synthetic dysfunction, 
which is a frequent complication in these patients. In addition, most of these patients are 
treated with long-term anticoagulant treatment with vitamin K antagonists, which hampers 
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Table. Prothrombotic or other predisposing factors in deep vein thrombosis / pulmonary embolism, 
the Budd-Chiari syndrome and portal vein thrombosis
  DVT/PE BCS PVT
Hypercoagulability factors
 Protein C deficiency ++ + +
 Protein S deficiency + + +
 Antithrombin deficiency ++ + +
 Factor V Leiden mutation + ++ +
 Prothrombin gene G20210A + + ++
 Fibrinogen levels + NS NS
 Factor VIII levels + NS +/-
 Antiphospholipid antibodies ++ + +
Hypofibrinolysis 
 Overall hypofibrinolysis + + NS
 PAI-1 + + NS
 TAFI + +/- NS
Other risk factors
 Immobilization ++ - -
 Malignancy* ++ - -
 Surgery† ++ - +
 Obesity ++ NS NS
 Hormonal factors‡ + + +
 Myeloproliferative neoplasms + +++ +++
 Paroxysmal nocturnal hemoglobinuria + ++ +
 Behcet’s disease + ++ +
 Other auto-immune diseases§ + + +
Local factors
 Liver cirrhosis - - ++
 Liver cyst, parasitic mass - + -
 Local inflammation¶ - - +
 Hepatobiliary malignancies* - + ++
- = not considered a risk factor; +/- = contradictory results in the literature; + = weak risk factor; ++ = strong risk factor;  
+++ = very strong risk factor; NS: not studied
*Hepatobiliary malignancies are associated with the development of PVT and, to a lesser extent, BCS. 
†Abdominal surgery in which iatrogenous injury to the portal vein may occur, e.g. splenectomy, and general abdominal 
surgery are associated with development of PVT.
‡Includes oral contraceptive use, hormone replacement therapy, pregnancy, and puerperium.
§Other auto-immune diseases including, inflammatory bowel disease, sarcoidosis, vasculitis, connective tissue disease.
¶Intra-abdominal infection / inflammation, e.g. pancreatitis, cholecystitis, diverticulitis, appendicitis, omphalitis. 
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the diagnosis of protein C and protein S deficiency. In these patients, an inherited deficiency 
may be diagnosed by evaluating a panel of coagulation tests (e.g. factor II, V, and X). A clear 
isolated deficiency in comparison to other coagulation tests may be indicative of a genetic 
deficiency. Studies that have taken these factors explicitly into account, have reported a 
prevalence of antithrombin deficiency of 0-5% in both BCS and PVT, a prevalence of protein 
C deficiency of 4-20% in BCS and 0-7% in PVT, and a prevalence of protein S deficiency of 
0-7% in BCS and 0-30% in PVT.68,71-74 A case-control study by Janssen et al. showed that, 
among the three factors, only protein C deficiency was significantly associated with both 
BCS and PVT,72 whereas Primignani et al. did not find a significant association between 
these factors and PVT.75 Although the data are not entirely consistent, primary deficiencies 
of these coagulation inhibitors are likely to contribute to the pathogenesis of BCS and PVT, 
and should be included in diagnostic work-up.
 In BCS patients the prevalence of the FVL mutation ranges between 7% and 
32%,65,68,71,72,74,76-78 which is in the same order of magnitude as in patients with DVT. The 
prevalence of the FVL mutation in patients with PVT is lower, ranging between 3% and 
9%.71,73,75,78-81 Case-control studies have confirmed that the FVL mutation is more strongly 
associated with BCS than with PVT. FVL carriers have a 4 to 11-fold increased risk of BCS, 
whereas a recent meta-analysis reported a 2-fold risk of PVT in FVL carriers.80 As in patients 
with more common forms of venous thrombosis, the FVL mutation is often accompanied 
by other prothrombotic states or risk factors in these patients.66 On the contrary, the 
prothrombin G20210A gene variant is more common in PVT than in BCS with a prevalence 
ranging from 3%-8% in BCS68,71,72,74,78 compared to 3%-22% in PVT.71,73,75,78-81 A recent meta-
analysis reported a 4 to 5-fold increase in risk of PVT in carriers of the prothrombin gene 
variant,80 whereas the risk of BCS is approximately 2-fold increased.72 So far, the mechanism 
behind the difference in prevalence of the FVL mutation and the prothrombin gene variant 
in BCS and PVT remains unknown.
 Although considered a risk factor for BCS and PVT, APA have received relatively little 
attention in etiological studies. The prevalence of APA in BCS and PVT has been estimated 
to be around 5-15%,66,71,73,75 but its importance as a risk factor is difficult to assess because 
anti-cardiolipin antibodies are also frequently found in patients with chronic liver disease 
without thrombosis. However, large studies confirming and quantifying the relationship 
between APS and BCS and PVT are still lacking, in particular studies correctly using the 
recently updated Sapporo criteria for the APS.82
 The contribution of increased levels of individual coagulation factors to the pathogenesis 
of thrombosis of the splanchnic veins has yet not been fully established. Few case reports 
and small series have suggested a potential role of increased factor VIII levels in the etiology 
of PVT.83-85 However, the interpretation of factor VIII levels in these disorders is complicated. 
Factor VIII is an acute phase protein and is also increased in patients with liver insufficiency, 
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which is frequently seen in BCS and PVT patients. Recently, Martinelli et al. described 
significantly elevated factor VIII levels in patients with primary PVT.86
 Few studies have focused on the recurrence risk of thrombosis in SVT patients. Condat 
et al. assessed the outcome of PVT in relation to prothrombotic conditions in a cohort of 
136 patients of whom 84 received anticoagulant therapy.87 In this study, an incidence rate of 
5.5 per 100 person-years for all types of thrombotic events was reported and an underlying 
prothrombotic state was shown to be an independent predictor of recurrent thrombosis. 
 An elevated endogenous thrombin potential has been associated with an increased 
risk of VTE. It might be expected that an increased endogenous thrombin potential also 
contributes to the development of BCS or PVT, but this has not yet been investigated.
Hypofibrinolysis in splanchnic vein thrombosis
Only few studies have assessed the role of the fibrinolytic system in the pathogenesis of 
BCS and PVT. De Bruijne et al. observed an association between SVT and genetic variation 
in the TAFI gene.88 A decreased risk of SVT in 147Thr/Thr homozygotes and a slightly, but 
not significantly, increased risk in carriers of the 325Ile variant was observed, suggesting 
a role for TAFI in the pathogenesis of SVT. Interestingly, the genotypes associated with an 
increased risk of SVT are associated with decreased TAFI levels,89 whereas an association 
between high TAFI levels and VTE risk has been consistently reported. There was a high 
degree of linkage disequilibrium between these two SNPs, making it difficult to assess the 
contribution of the individual SNPs. The increased risk of SVT in carriers of the 325Ile allele 
may be related to a TAFI variant with a greater antifibrinolytic potential but lowered antigen 
levels.90,91 The mechanism behind the contribution of the Ala147Thr SNP to an increased risk 
of thrombosis is unknown. 
 Dayal et al. measured t-PA and PAI-1 levels in a relatively small study of 27 BCS patients.92 
In this study, only three patients showed mildly increased levels of t-PA and PAI-1 compared 
to healthy controls. More recently, Hoekstra et al. extensively investigated components 
of the fibrinolytic system in 101 BCS patients.93 This study found significantly higher PAI-1 
levels in BCS patients compared to controls, whereas TAFI and α2-antiplasmin levels were 
significantly lower. A subgroup of BCS patients showed clearly elevated CLTs, indicative 
of hypofibrinolysis. A CLT above the 90th or 95th percentile of controls was associated 
with a 2.4-fold and 3.4-fold increase in risk of BCS, respectively. Of note, analysis of SNPs 
of fibrinolysis proteins revealed no significant differences between cases and controls, 
but the number of studied individuals was limited and probably too small for analysis of 
genetic factors. These findings suggest that an impaired fibrinolytic potential contributes 
to the development of BCS. Although additional studies are warranted, both these studies 
indicate that, like in other forms of venous thrombosis, impaired fibrinolysis may also play a 
role in the pathogenesis of thrombosis of the splanchnic veins.
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other risk factors for splanchnic vein thrombosis
Myeloproliferative neoplasms (MPNs) are the most common underlying cause and 
can be identified in nearly half of BCS and about one-third of PVT patients,68,73,74,76,79,94-96 
which is strikingly higher than in other forms of VTE. The most common gain of function 
mutation leading to development of MPN is JAK2V617F, which is found in nearly all cases 
of polycythemia vera and about half the cases of essential thrombocythemia and primary 
myelofibrosis.97 The JAK2V617F mutation has been described in 17% to 45% of unselected 
BCS and PVT patients.68,73,74,76,79,94-96 Screening for JAK2V617F is an important diagnostic tool 
to detect MPN in these patients and is now part of the standard diagnostic work-up in BCS 
and PVT.98 Portal hypertension, resulting from pre- or post hepatic venous obstruction, can 
lead to hypersplenism and hemodilution. Both these conditions may mask the characteristic 
peripheral blood cell changes and make diagnosis of MPN notoriously difficult. Therefore, 
also bone marrow histology should be performed, allowing for MPN diagnosis in patients 
without the JAK2V617F mutation. About half of the BCS and PVT patients with the 
JAK2V617F mutation as the only indication of an underlying MPN, develop an overt MPN 
during follow-up.99 A recent meta-analysis showed that JAK2V617F is rare in other forms of 
venous thrombosis, confirming the unique role of MPN in the pathogenesis of thrombosis 
at these distinct sites.99 The exact pathogenic mechanism of thrombotic complications in 
MPN remains elusive, but besides the characteristic erythrocytosis and thrombocytosis, 
platelet and leukocyte functional abnormalities seem critical.100
 Paroxysmal nocturnal hemoglobinuria (PNH) is a rare, acquired haematological disorder 
of haematopoietic stem cells, which frequently has a devastating course and is specifically 
related to thrombosis at unusual sites. Remarkably, thrombosis of the splanchnic veins 
is a frequent complication, particularly of the hepatic veins and the inferior vena cava in 
which more than 45% of the thrombotic episodes are located, accounting for the majority 
of deaths in this disorder.101 PNH has been reported in 9-19% of tested BCS patients,74,102 
whereas a prevalence of 0-2% has been reported in PVT.72,73 Several mechanisms, including 
intravascular hemolysis, increased platelet activation and aggregation, procoagulant 
microparticles resulting from complement-mediated platelet damage, hypofibrinolysis and 
increased tissue factor expression may contribute to the pathogenesis of venous thrombosis 
in PNH.103,104 Patients with a PNH cell population above 60% of the granulocytes, appear to 
be at greatest risk for thrombosis.103 Testing for PNH should be routinely performed in all 
BCS and PVT patients. 
 A number of systemic, auto-immune-mediated diseases have been implicated in the 
pathogenesis of both BCS and PVT. Of these, Behcet’s disease is particularly associated 
with BCS. It represents the leading cause of BCS in areas where Behcet’s disease is highly 
prevalent.66 Other systemic diseases include inflammatory bowel disease, vasculitis, 
sarcoidosis and connective tissue disease. However, these account for only a minority of 
cases.66,70
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Oral contraceptive use, pregnancy and puerperium are known risk factors for venous 
thrombosis, and are also established in BCS and PVT.66,105 However, an additional 
prothrombotic condition is often present in these women. 
 Recently, a potentially new factor in the pathogenesis of BCS was identified. Talens 
et al. initially showed, using a proteomic approach, that apolipoprotein A1 (Apo A1) was 
decreased in 9 BCS patients compared to controls and subsequently validated these 
findings in a cohort of 101 BCS patients, in which Apo A1 levels were also significantly lower 
compared to controls.106 Apo A1 is the principal component of high density lipoprotein 
(HDL) cholesterol, which has been shown to be inversely associated with other forms of 
venous thrombosis,107-109 although this association was not observed in all studies.110 Low 
Apo A1 levels have also been associated with an increased risk of recurrence of common 
VTE.111
multifactorial etiology in splanchnic vein thrombosis
Even more outspoken than in patients with DVT or PE, the etiology of primary BCS and PVT 
must be considered multifactorial. The recent EN-Vie studies reported a combination of two 
or more genetic or acquired prothrombotic factors in 46% of BCS and 48% of PVT patients.68,73 
In this series of BCS patients, 18% of the patients even displayed three risk factors. Based 
on these findings, a complete hematological work-up, including inherited thrombophilia, 
APA, MPN and PNH should always be performed in BCS and PVT patients, irrespective of 
whether one prothrombotic factor has already been identified. This is in particular relevant 
for identifying MPN, which are also often accompanied by other prothrombotic factors, and 
require additional treatment, such as aspirin, or anti-proliferative treatment. 
CLUES For SiTE-SPECiFiCiTY oF THromBoSiS
It is still unresolved why some patients develop thrombosis of the splanchnic veins, whereas 
most others with similar prothrombotic factors develop DVT or PE. In contrast to the vas-
culature of the lower extremities, the splanchnic vasculature does not contain venous valves, 
which are well-known to be involved in the pathogenesis of DVT.112 Further research is 
needed to identify local factors that are involved in the pathogenesis of thrombosis at these 
distinct sites. In this respect, it has been speculated that endothelial cells of the splanchnic 
veins may interact with activated platelets and/or leukocytes and increased microparticles, 
which are characteristic features of MPN and PNH, two haematological disorders with a 
remarkable high frequency in SVT.113 Recently, the JAK2V617F mutation was demonstrated 
in the endothelial cells of two BCS patients, which indeed suggests a contribution of the 
endothelium to the development of thrombosis.114 An underlying mechanism, however, 
remains elusive. In addition, endothelial cells of the splanchnic veins are exposed to gut-
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derived oral antigens and bacterial components from the gastrointestinal tract. Hepatic 
sinusoidal endothelial cells display immune tolerance which prevents a response to these 
factors.115 However, there is no evidence that the endothelial cells of the portal vein are 
similarly protected.113 It has therefore been hypothesized that these endothelial cells are 
chronically activated, making them particularly vulnerable to the disease-specific changes 
of PNH and MPN.113 These factors may be prothrombotic, resulting in an increased risk for 
SVT. 
 Interestingly, there are also apparent differences in the etiology of BCS and PVT (Table). 
Although MPNs are the most frequent prothrombotic factor in both BCS and PVT, MPNs 
are clearly more common in BCS than in PVT. In addition, it is clear that the FVL mutation 
is more strongly associated with BCS than with PVT, whereas the opposite is true for the 
prothrombin gene variant. In BCS patients, the FVL mutation has even been specifically 
associated with involvement of thrombosis of the inferior vena cava.77 Finally, it is evident 
that PNH is more strongly associated with the development of BCS than of PVT. 
 The understanding of the interaction of prothrombotic disorders and local factors in the 
etiology of BCS and PVT will play an essential role in the understanding of the pathogenesis 
of thrombosis at these unusual sites. Identification of distinct differences in the etiology 
with more common forms of venous thrombosis, and the remarkable differences in etiology 
even between BCS and PVT, needs further research. 
CoNCLUSioN
The understanding of the etiology of VTE has improved over the years. VTE must be 
considered a multifactorial disease, in which the interplay of genetic or acquired factors is 
required for thrombosis formation. This prothrombotic tendency is caused by abnormalities 
in the coagulation or fibrinolysis pathways, leading to hypercoagulability or an impaired 
fibrinolysis. More general risk factors also contribute, partly through these pathways, to the 
development of thrombosis. An interesting aspect of VTE is its site-specificity. In contrast 
to DVT or PE, the cause of venous thrombosis at unusual sites, such as the splanchnic 
veins, remains to be elucidated. Although the etiology shows a considerable overlap with 
common forms of VTE, there are several remarkable differences that may prove to be a 
means towards a better understanding of the site-specificity of venous thrombosis. 
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ABSTrACT
Myeloproliferative neoplasms (MPNs) are the leading predisposing factor for Budd-Chiari 
syndrome (BCS). There are several issues concerning the etiology, diagnosis and prognosis 
of MPNs in this rare form of venous thrombosis that need to be clarified. The aim of this 
study was to evaluate multifactorial etiology in BCS patients with an underlying MPN, to 
assess potential added value of the JAK2V617F mutation in the diagnostics of MPN in BCS 
and to determine the survival of MPN patients in BCS. All patients referred to a tertiary 
hospital with primary, non-malignant BCS between January 1980 and January 2006 were 
included in this study (n = 40). Patients were evaluated for MPN using current World Health 
Organization criteria. In addition to standard MPN work-up, JAK2V617F mutation analysis 
was performed in 17 patients. MPNs were present in 33% of the patients. In 38% of patients 
with an MPN, additional pro-thrombotic factors were present. In two patients suspect for 
essential thrombocythemia, who failed to meet WHO criteria, JAK2V617F mutation analysis 
lead to the identification of occult MPN. Ten-year survival was 92% (95% CI: 78%–100%) 
in patients with MPN versus 53% (95% CI: 28%–79%) in patients without MPN (P = .18). In 
conclusion, the multifactorial etiology in BCS patients with MPN highlights the necessity of 
extensive screening for other underlying pro-thrombotic conditions. JAK2V617F mutation 
analysis is of diagnostic importance in patients with BCS. Survival of BCS patients did not 
differ significantly between individuals with and without MPN. 
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iNTroDUCTioN
Budd-Chiari syndrome (BCS) is a rare disorder caused by obstruction of the hepatic veins 
or the suprahepatic inferior vena cava.1 Clinically, the disease is characterized by a classic 
triad of hepatomegaly, ascites and abdominal pain. Patients may exhibit signs of portal 
hypertension and some develop acute liver failure. BCS is associated with one or more 
underlying pro-thrombotic conditions in at least 75% of the patients, including acquired 
and inherited coagulation disorders and paroxysmal nocturnal hemoglobinuria. However, 
the most important etiological factors for BCS are myeloproliferative neoplasms (MPNs).2
 MPNs are chronic clonal haematopoietic stem cell disorders, characterised by 
proliferation in the bone marrow of one or more of the myeloid lineages, resulting in 
increased numbers of mature granulocytes, red blood cells and/or platelets in the peri-
pheral blood.3 Increased red blood cells and platelets are the hallmarks of polycythemia 
vera (PV) and essential thrombocythemia (ET), respectively. The main clinical complication 
in these disorders is thrombosis, although haemorrhage may also occur. The prevalence of 
MPN in BCS patients depends on the diagnostic criteria used and is approximately 23–49% 
using conventional criteria for diagnosis,4,5 such as the World Health Organisation (WHO) 
criteria and Polycythemia Vera Study Group (PVSG) criteria.
 Several studies have focussed on the criteria for the diagnosis of MPN in patients 
with BCS. Particularly, these studies discussed the potential added value of spontaneous 
endogenous erythroid colony formation (EEC) in detecting so-called occult MPN.6 This term 
has been designated for patients who do not fulfil the conventional criteria for MPN, but 
in whom bone marrow culture showed spontaneous EEC. In a meta-analysis conducted in 
1997, the diagnostic yield of spontaneous EEC as the sole criterion in the establishment of 
MPN in patients with BCS was reported to be 78%.7 However, diagnostic criteria for MPN 
and the additive value of spontaneous EEC are still a matter of debate.8,9
 Recently, a clonal mutation in the JAK2 tyrosine kinase (JAK2V617F) is reported in a high 
proportion of patients with MPN. JAK2V617F is found in nearly all patients with PV and is 
seen in half of the patients with ET and myelofibrosis (MF).10-13 Interestingly, JAK2V617F 
was recently shown to occur in 59% of BCS patients and was reported to be of use in the 
characterization of occult MPN in BCS.14 However, its role in the diagnostics of MPN in BCS 
has not yet been fully determined. 
 The aim of this study was to evaluate multifactorial etiology in BCS patients with MPN, 
to assess potential added value of the JAK2V617F mutation in the diagnostics of MPN in 
BCS and to determine the survival of MPN patients in BCS. To this end, we evaluated a large 
group of BCS patients for MPN and other pro-thrombotic conditions in a single center 
follow-up study.
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PATiENTS AND mETHoDS
Patients 
Between January 1980 and January 2006, all patients referred to our hospital with primary, 
non-malignant Budd-Chiari Syndrome (BCS) were included in this study. Clinical records 
of all patients were reviewed and patient characteristics at the time of diagnosis, results 
of diagnostic work-up, treatment and follow-up were reported in a standardized way by 
one single investigator. BCS was defined as hepatic venous outflow obstruction at any 
level from the small hepatic veins to the junction of the inferior vena cava and the right 
atrium, regardless of the cause of obstruction.1 Outflow obstruction caused by sinusoidal 
obstruction syndrome (previously veno-occlusive disease) and cardiac failure were 
excluded by definition. All cases can be considered as primary BCS, i.e. the result of an 
endoluminal venous lesion (thrombosis or web).1 The diagnosis of BCS was established 
by the demonstration of an obstructed outflow tract by Doppler Ultrasound, computed 
tomography (CT), magnetic resonance imaging (MRI) or venography.1 The date of diagnosis 
of BCS was defined as the date of first evidence on radiologic imaging and was used as 
t0. Patients were followed up from this date until death, study closure (January 1, 2006), 
or, in case of loss to follow up, the last date of visit. Patients were evaluated for pro-
thrombotic conditions including coagulation disorders, MPN, and paroxysmal nocturnal 
haemoglobinuria (PNH). Other potential etiological factors (such as oral contraceptive 
use, pregnancy and recent surgery) were collected by chart review. The medical ethical 
committee approved these studies. 
Coagulation assays
Venous blood samples were collected in 3.2% sodium citrate (final concentration) by 
venapuncture in the antecubital vein, using the Vacutainer® system (Beckton Dickinson). 
Plasma was centrifuged at 2000 g for 10 min at 4ºC. Routine coagulation assays were 
performed immediately, or plasma was frozen at -80°C till further use. Genomic DNA was 
isolated from the white cell fraction citrated blood, using the salt concentration standard 
procedure.
 Antithrombin, protein C and protein S activity were measured by standard clotting 
assays (the normal range for antithrombin activity 0.8–1.2 U/ml, for protein C and protein 
S activity 0.7–1.4 U/ml). Free protein S levels were assesed using an ELISA (Biopool, Umeå, 
Sweden) (normal range 0.76–1.28 U/ml). In case of potential liver failure, the presence of 
hereditary deficiencies in antithrombin, protein C and S was only diagnosed if there was a 
clear isolated deficiency of either coagulation inhibitor in comparison to other coagulation 
tests and liver synthesis markers such as albumin. In patients on long-term oral anticoagulant 
treatment, protein C and S levels were not determined. A multiplex PCR was performed 
on whole blood for the determination of factor V Leiden mutation and prothrombin gene 
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variant, as has been described earlier.15 The presence of lupus anticoagulant was tested by 
an APTT based and a diluted PT assay and anticardiolipin antibodies were tested by ELISA, 
as described earlier.16 Diagnosis of paroxysmal nocturnal hemoglobinuria (PNH) was based 
on flow cytometric analysis using antibodies directed against glycosylphosphatidylinositol-
anchored proteins.
Diagnostic work-up and diagnostic criteria for myeloproliferative neoplasms
For standardization of our MPN work-up, all available data were used to classify MPN 
according to the 2001 WHO guidelines.17-19 Since these guidelines have changed over 
time, and patients were evaluated for MPN according to the existing guidelines at time of 
diagnosis of BCS, this approach is limited by some missing data (e.g. bone marrow biopsies), 
especially in patients diagnosed in the beginning of the study. The designation “unclassified 
MPN” was applied to cases with definite features of MPN, but that failed to meet the criteria 
for a specific subtype, such as PV or ET. In addition to standard MPN work-up, the recently 
described JAK2V617F somatic point mutation was determined in patients of whom DNA 
was available. 
 Total red blood cell (RBC) mass was determined as described before and expressed as 
a percentage of the mean normal predicted value. A value above 125% of the theoretical 
value was considered a significant increase. If RBC mass was not measured, hemoglobin 
(Hb) levels were used to assess the level of erythrocytosis. A significant increase was defined 
as a Hb level above 18.5 g/dl in men or 16.5 g/dl in women.
 The spontaneous erythroid colony formation (EEC) was determined in clonogenic assays 
as described earlier.20 Mononuclear cells (MNC) were isolated by ficoll density gradient 
centrifugation (d = 1.077, Nycomed, Oslo, Norway). MNC were added to Methocult H4230 
(StemCell Technologies, Vancouver, Canada) supplemented with 2.5 ng/ml IL-3 with or 
without 3 U/ml Epo. Cells were plated at 0.4 x 105 cells per ml in 24 well plates (0.25 ml/well) 
and incubated at 37°C in humidified atmosphere and 5 % CO2. After 14 days, BFU-e and 
Epo-independent (spontaneous) BFU-e were counted. Spontaneous BFU-e was considered 
positive when one or more Epo-independent BFU-e colonies had developed. 
 For JAK2V617F mutation analysis, high-molecular-weight DNA was isolated from the 
white cell fraction of citrated blood, using the salt concentration standard procedure. 
The quality of the genomic DNA was verified by amplification of exon 11 of the FMS-like 
tyrosine kinase (FLT3) gene, using the primer set FLT3-11F 5’-CAATTTAGGTATGAAAGCC-3’ 
and FLT3-11R 5’-CAAACTCTAAATTTTCTCT-3’. Subsequently, a double allele-specific PCR 
was performed on each individual sample using the allele-specific forward primer JAK2-
ASP 5’-TTTTAAATTATGGAGTATATT-3’ in combination with the reverse primers GJAK2MUT1 
5’-TATAACTGAATAGTCCTACAGTG-3’ or GJAK2MUT2 5’-GTTGAACCTGCCATAATCTC-3’, i.e., the 
allele specific PCR with the primer set JAK2-ASP and GJAK2MUT1 was confirmed by the PCR 
using the primer set JAK2-ASP and GJAK2MUT1. All PCR’s were performed on 50ng high-
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molecular-weight DNA (25mM dNTP, 15 pmol primers, 2mM MgCl2, Taq polymerase and 
10xbuffer (Invitrogen Life Technologies, Breda, The Netherlands)). Cycling conditions were 
as follows: 1 cycle 5’ 94°C, 35 cycles 1’ 94°C, 1’ 54°C (FLT3) or 61.5°C (JAK2V617F), 1’ 72°C, and 
1 cycle 7’ 72°C. PCR products were visualized using EtBr-gel electrophoresis.
Statistical analysis
Results are expressed as median ± SD. All tests were 2-tailed with the level of significance set 
at P < .05. Comparison between patients with and without MPN was performed using the 
non-parametric Mann-Whitney U test for continuous variables and the Chi-square test for 
categorical variables. Survival rates were calculated by means of the Kaplan-Meier method 
and comparison of survival functions was based on log-rank testing. Statistical analyses 
were carried out in SPSS 11.5.0 for Windows (SPSS, Chicago, IL).
rESULTS
Patient characteristics
Forty-one patients with the diagnosis of BCS were identified in our hospital. One patient 
with hepatic outflow obstruction resulting from malignancy was excluded. This left a total 
of 40 patients with primary BCS who were eligible for analysis. Median age was 28.4 years 
(18.4–53.3) and 26 patients (65%) were female. In nine patients (23%) additional portal vein 
thrombosis (PVT) was present. Ascites, hepatomegaly and abdominal pain were the most 
prevalent clinical symptoms. Sites of outflow obstruction were the hepatic veins (63%), 
inferior vena cava (5%) or both (33%). At liver biopsy, performed in 24 patients, evidence for 
cirrhosis was found in four (17%). Patient characteristics are presented in Table 1. 
Underlying or concomitant disorders
Coagulation disorders were found in 14 patients (35%). Antiphospholipid antibodies (APA) 
were detected at diagnosis of BCS in ten patients. In six patients aCL or lupus anticoagulant 
was measured only once. Four patients had APA that were confirmed after 12 weeks. Only 
patients in whom APA were confirmed were regarded as having APA. Oral contraceptives 
were used in 13 patients (52%). In four patients (10%) no underlying disorder could be 
found. The underlying or concomitant disorders are shown in Table 2. 
myeloproliferative neoplasms in BCS 
A summary of the performed diagnostic work-up for MPN according to bone marrow 
biopsy and EEC is shown in Figure 1. Twenty-nine patients underwent complete MPN 
diagnostic work-up. In 21 of these patients an EEC was also performed. Eleven patients 
did not undergo a bone marrow biopsy nor was an EEC performed, for various reasons, 
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Table 1. Patient characteristics at the time of diagnostic-work up in 40 patients with primary Budd-
Chiari syndrome
  N obtained data
Age (yrs)* 40 28.4 (18.4–53.3) 
Male: female (%) 40 14:26 (35:65)
Clinical manifestations (%)
 Abdominal pain 38 30 (79)
 Jaundice 38 3 (8)
 Leg edema 38 12 (32)
 Ascites 39 33 (85)
 Hepatomegaly 39 34 (87)
 Splenomegaly 38 19 (49)
 Encephalopathy 33 3 (8)
 Variceal bleeding 33 2 (6)
Site of outflow obstruction (%)
 Hepatic veins 40 25 (63)
 Inferior vena cava 40 2 (5)
 Combined hepatic veins and inferior vena cava 40 13 (33)
Membranous obstruction of inferior vena cava (%) 40 1 (3)
Portal vein obstruction (%) 40 9 (23)
Serum levels*
 Albumin (g/L) 37 38 (21–50)
 Bilirubin (μmol/L) 38 29.5 (7–143)
 Platelet count (10E9/L) 36 243 (18–520)
 ALT (ULN) 37 1.1 (0.2–68.0)
 Alkaline phosphatase (ULN) 37 1.2 (0.5–4.2)
 Hemoglobin (g/dl) 37 13.5 (7.3–18.7)
 Sodium (mmol/L) 35 137 (123–144)
 Creatinin (μmol/L) 35 66 (11.2–137)
 Prothrombin time (sec) 34 16.8 (11.5–133.0)
Cirrhosis at liver biopsy (%) 24 4 (17)
Abbreviations: ULN, upper limits of normal value.
*Median (range).
including refusal (n = 1), deteriorating clinical condition (n = 2), or the absence of peripheral 
blood count abnormalities and clinical features of MPN (n = 8). This latter group of patients, 
who were not suspect for having a primary haematological disorder, did not undergo bone 
marrow biopsy since they were worked-up earlier in our study period and biopsies were 
not yet part of the routine diagnostic work-up for BCS. However, most of these patients 
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were already diagnosed with another eligble cause for BCS. Screening for the JAK2V617F 
mutation could be performed in 17 patients (43%).
Table 2. Etiological factors in 40 patients with primary Budd-Chiari syndrome
  N* %†
Myeloproliferative Neoplasms 13 33
 Overt MPN 11 28
 JAK2V617F positive 7 41
 Spontaneous EEC, without MPN features 2 10
Coagulation disorder 14 35
 Protein C deficiency‡ 2 7
 Protein S deficiency‡ 2 7
 Factor V Leiden mutation 5 15
 Homozygote 2 6
 Heterozygote 3 9
 Prothrombin gene variant 2 8
 Homozygote 0 0
 Heterozygote 2 8
 Antiphospholipid antibodies§ 4 11
 Anticardiolipin antibodies IgM/IgG 4 11
 Lupus anticoagulant 1 3
 Plasminogen deficiency 1 3
Others 21 53
 Oral contraceptive use 13 52
 Paroxysmal nocturnal hemoglobinuria 2 9
 Auto-immune¶ 5 13
 Ulcerative colitis 1 3
 Abdominal surgery 1 3
No underlying disorder 4 10
*Patients can have more than one etiological factor simultaneously.
†Percentage of tested patients; not all investigations could be performed in the individual patients.
‡Patients treated with oral anticoagulants or hepatic failure during diagnostic work-up were excluded in this analysis.
§Diagnosis of antiphospholipid antibodies was made if lupus anticoagulant or aCL was present and confirmed after 12 
weeks.
¶Auto-immune diseases: Behcet’s disease (n = 1), Sjögren’s disease (n = 1), systemic lupus erythematosus (n =2) and mixed 
connective tissue disease (n = 1).
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Budd-Chiari syndrome (BCS)
(n = 40)
No BMM
(n = 11)
BMM
  (n = 29)
No BMM 
performed 
for various
reasons. 
   EEC
   (n = 21)
EEC +
(n = 8)
EEC -
(n = 13)
No EEC
(n = 9)
MPN +
(n = 5)
MPN -
(n = 3)
MPN +
(n = 3)
MPN -
(n = 10)
MPN +
(n = 5)
MPN -
(n = 4)
MPN - 
(n = 11)
Figure 1. Diagnostic work-up for myeloproliferative neoplasms in 40 patients with primary Budd-Chiari 
syndrome, according to bone marrow biopsy and morphology (BMM) and spontaneous endogenous 
erythroid colony formation (EEC).
The results of MPN work-up are shown in Table 3. Eleven patients were diagnosed with MPN 
according to current WHO criteria. Two other patients, who were suspect for MPN (high 
platelet counts), but failed to meet WHO criteria, harboured the JAK2V617F mutation and 
were therefore classified as MPN. Therefore, MPNs were present in 13 BCS patients (33%). 
Five patients were diagnosed with PV, six patients with ET and two patients with unclassified 
MPN. In two of these patients, MPN had existed for a considerable period prior to the 
development of BCS (9 and 11 years), based on high peripheral blood counts for several 
years. BCS was the first clinical presentation of MPN in the other eleven MPN patients. 
 Comparison of baseline characteristics between patients with (n = 13) and without 
(n = 27) MPN were as follows: median age (35.7 years vs. 29.6 years, P = .10) and male:female 
ratio (44%:56% vs. 59%:41%, n.s.). Combined BCS-PVT was observed in nine patients, all 
without MPN. In five MPN patients (38%) additional pro-thrombotic factors were present, 
indicating multifactorial aetiology. Of these patients, three (23%) had one additional risk 
factor and two (15%) had two additional risk factors (Table 3). Multifactorial etiology was 
present in six patients (22%) of the patients without MPN.
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The JAK2V617F mutation was identified in seven out of the 17 tested BCS patients (41%). 
None of the ten patients without JAK2V617F were diagnosed with MPN according to WHO 
criteria. EEC testing showed a sensitivity of 63% (5/8), specificity of 77% (10/13), and a 
positive and negative predictive value for MPN of 63% (5/8) and 77% (10/13), respectively. 
Three patients showed spontaneous EEC without the classical WHO features of MPN, 
potentially indicating occult forms of MPN. The JAK2V617F mutation was present in two of 
these patients, while absent in the third, who exhibited an isolated spontaneous EEC. 
Follow-up of myeloproliferative neoplasms in BCS
Overall mean follow-up was 7.1 ± 6.9 years (8.2 ± 6.6 years in patients with MPN and 6.5 ± 7.1 
years in patients without MPN). Only two patients were lost to follow-up, one in each group. 
One patient without, and three patients with MPN underwent liver transplantation. Eleven 
patients (28%) died during follow-up, of which two had MPN. In both patients, cause of 
death was not MPN, but newly developed epitheloid abdominal sarcoma after liver 
transplantation (n = 1) and liver failure (n = 1). Causes of death in patients without MPN were 
liver failure (n = 3), sepsis (n = 3), cardiovascular disorders (n = 1), variceal bleeding (n = 1) 
and mesenteric vein thrombosis, resulting in gastrointestinal ischemia (n = 1). Both patients 
with MPN died in the first year after diagnosis and hence the survival rates in patients with 
MPN at 1, 5, and 10 years remained constant at 92% (95% CI: 78%–100%). Survival rates 
in patients without MPN at 1, 5, and 10 years were 89% (95% CI: 77%–100%), 64% (95% 
CI: 44%–85%) and 53% (95% CI: 28%–79%), respectively (Figure 2). There was no significant 
difference in survival between the two (P = .18). During follow-up, bone marrow evaluation 
was repeated in eight patients. None of the patients without MPN clinically developed MPN 
during follow-up. 
DiSCUSSioN
In this study we evaluated 40 consecutive patients diagnosed with primary, non-malignant 
BCS at our hospital, thereby focussing on multifactorial aetiology, the potential added value 
of the JAK2V617F mutation in MPN diagnostics and survival of MPN patients in BCS. MPNs 
were present in 33% (13/40) of these patients. BCS was the first clinical manifestation of 
MPN in 85% (11/13) of the patients. In 38% (5/13) of the patients with MPN, additional pro-
thrombotic factors were present. JAK2V617F mutation analysis facilitated diagnosis of MPN 
in two patients who did not fulfil traditional WHO criteria. Long term follow-up did not show 
a significant difference in survival between patients with and without MPN. 
 It is widely recognized that MPNs are the leading etiological factor in BCS. Prevalence 
ranges from 23%–49% when conventional criteria for diagnosis of MPN are used, i.e. the 
PVSG criteria or the WHO criteria.4,5,21,22 Consistent with these results, we report a prevalence 
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Figure 2. Survival in non-MPN patients (n = 27) and MPN patients (n = 13) with primary, non-malignant 
Budd-Chiari syndrome. Survival rates in patients with an underlying MPN at 1, 5, and 10 years were 
92% (95% CI, 78%–100%), with number of patients at risk being 12, 8 and 5, respectively. Survival rates 
in patients without MPN at 1, 5, and 10 years were 89% (95% CI, 78%–100%), 64% (95% CI, 44%–84%) 
and 53% (95% CI, 28%–79%), with number of patients at risk being 22, 10 and 5, respectively. 
of MPN of 33%. This is based on a population of consecutive patients over 26 years in a single 
center, therefore minimizing the risk of selection bias. None of our BCS patients without 
MPN at diagnosis developed MPN during follow up. In a meta-analysis conducted in 1997, 
a MPN prevalence of 78% has been reported when spontaneous EEC was used as the only 
diagnostic criterion.7 This result necessitates a balanced interpretation. First, several case 
series have suggested that EEC is a sensitive indicator for diagnosis of MPN.6,7,23,24 However, 
the value of EEC as the sole criterion has been questioned and it has been suggested that 
this variable should only be used as a minor criterion in diagnosing MPN. EEC has been 
reported in non-clonal causes of erythrocytosis and in healthy controls (false positive), 
while it has not been observed in about 50% of patients with well documented ET and in 
some patients with PV (false negative).25-29 Second, EEC assays are technically demanding 
and not amenable to external quality assurance. Third, the predictive value of spontaneous 
EEC as an indication for occult MPN has not yet been fully elucidated in large prospective 
studies. Furthermore, it should be noted that the meta-analysis with a reported prevalence 
of 78% is based on selected case reports and data-pooling of small case series, endangering 
a selection bias. Our view is strengthened by successive studies from one of the research 
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groups where reported prevalence of occult or overt MPN decreased from 75% to 31% after 
15 years of follow up.6,21
 Recently, a clear association between MPNs and the somatic point mutation JAK2V617F 
has been described.10 The acquired mutation in JAK2 is found in most patients with PV and 
is seen in half of the patients with ET and MF.10 This mutation has recently been shown to 
occur in 59% of BCS patients and is reported to be of use in the characterization of occult 
MPN in BCS.14 Our study showed a JAK2V617F prevalence of 41%. Interestingly, JAK2V617F 
identified two patients with MPN who failed to meet WHO criteria. This, combined with 
the report by Patel et al., clearly suggests that JAK2V617F mutation analysis is of additional 
value in identifying occult MPN and should be included in standard MPN work-up in BCS 
patients. One patient was diagnosed with MPN despite an elevated erythropoietin level, as 
it has been shown that this does not exclude MPN.30 Unfortunately, this patient died during 
follow-up, making JAK2V617F analysis impossible. 
 Diagnosis of MPN using conventional criteria may be difficult in patients with BCS, 
since the typical peripheral blood changes may be less pronounced. Thrombocytosis may 
be masked by hypersplenism due to portal hypertension. Furthermore, iron deficiency is a 
frequent finding in BCS and hemodilution may be present.31 Therefore we believe that in all 
patients diagnosed with BCS, a complete MPN work-up, including a bone marrow biopsy is 
mandatory. When definite features of MPN are met, aspirin may be added to the therapy as 
has been shown to reduce thrombotic complications in the future.32 Eleven patients in our 
study did not undergo bone marrow biopsy for various reasons. However, none of these 
patients developed a clinically overt form of MPN at a mean follow-up of 7.7 ± 8.0 years. 
 To date, survival in BCS patients with MPN had not yet been systematically investigated. 
In our study, 10-years survival was 92% for BCS patients with MPN. It has been suggested 
that a shortened survival in MPN patients with additional BCS is primarily related to 
complications of hepatic dysfunction and portal hypertension, and not to complications 
of MPN. Indeed, the two BCS patients with MPN died of causes unrelated to MPN. Our 
results showed no statistically significant difference in survival between BCS patients with 
and without MPN. However, it should be noted that in the 27 BCS patients without MPN, 
a wide range of pro-thrombotic factors were present that differ in nature and prognosis, 
varying from oral contraceptive use, homozygote factor V Leiden mutation to PNH.33 Since 
individual prevalence of these etiological factors is low, comparative sub-group analysis 
was not possible. It has been shown that more extensive thrombosis in the splanchnic area 
is associated with poorer survival.34 PVT was only present in patients without MPN in our 
BCS population, which may account for the slightly lowered survival of these patients in 
our study. In addition, three patients with and one patients without MPN underwent liver 
transplantation, which may have affected survival rate in favour of MPN patients. 
 Several studies have shown the coexistence of multiple pro-thrombotic factors in 
patients with BCS, including patients with MPN.21,22 Denninger et al. reported a multifactorial 
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aetiology in 41% of BCS patients with either occult or overt MPN. Our results showed that in 
38% of the patients with MPN additional risk factors were present. These results enforce the 
necessity of extensive screening for additional pro-thrombotic conditions when one cause 
has already been found to optimize treatment options.
 In conclusion, we report MPNs in 33% of our BCS patients. In 38% of the patients with 
MPN, additional pro-thrombotic factors were present. Our study clearly confirms the 
importance of JAK2V617F mutation analysis in patients with BCS. Long term follow-up did 
not show a significant difference in survival between patients with and without MPN.
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ABSTrACT
Myeloproliferative neoplasms (MPNs) are the most common cause of Budd-Chiari syndrome 
(BCS) and non-malignant, non-cirrhotic portal vein thrombosis (PVT). In this meta-analysis 
we determined the prevalence of MPNs and their subtypes as well as JAK2V617F prevalence 
and its diagnostic role in these uncommon forms of venous thrombosis. MEDLINE and 
EMBASE databases were searched. Prevalence of overt MPNs, JAK2V617F, and MPN 
subtypes were calculated using a random-effects model. A total of 1.062 BCS and 855 
PVT patients were included. In BCS, mean prevalence of overt MPNs and JAK2V617F was 
28.5% (95% CI: 22.5%–35.5%) and 41.1% (95% CI: 32.3%–50.6%), respectively. In PVT, mean 
prevalence of overt MPNs and JAK2V617F was 19.4% (95% CI: 13.7%–26.7%) and 27.7% 
(95% CI: 20.8%–35.8%), respectively. Overt MPN and JAK2V617F were more frequent in BCS 
compared to PVT (P < .001 and P = .03, respectively). Identification of otherwise undiscovered 
MPNs without characteristic increased peripheral blood counts by means of JAK2V617F was 
comparable between BCS and PVT (17.1% vs. 15.4%, P = .68). Forty-one and 15% of these 
patients developed overt MPN during follow up, respectively. Polycythemia vera was more 
prevalent in BCS. These results validate inclusion of JAK2V617F in the diagnostic work-up of 
BCS and PVT and confirm that marked differences in their etiology exist.
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iNTroDUCTioN 
Splanchnic vein thrombosis (SVT) includes the Budd-Chiari syndrome (BCS) and portal 
vein thrombosis (PVT). Primary BCS is characterized by thrombosis of the hepatic veins 
and/or the suprahepatic inferior vena cava, resulting in obstruction of the hepatic venous 
outflow tract.1 A distinct disorder that also includes the liver vasculature is portal vein 
thrombosis (PVT), which often occurs in association with local factors such as liver cirrhosis 
or malignancy.2,3 PVT in the absence of liver cirrhosis or local malignancy is less frequently 
encountered and shows a considerable overlap in etiology with primary BCS. In this meta-
analysis, we will focus exclusively on primary BCS and non-malignant, non-cirrhotic PVT.
 Philadelphia-negative myeloproliferative neoplasms (MPNs) are the most frequent 
underlying prothrombotic factor in BCS and PVT, with a reported prevalence of 30–50%4-9 
and 15–30%,2,6,10-12 respectively. However, peripheral blood cell counts often remain within 
a normal range, due to portal hypertension and its sequelae (splenomegaly, hemodilution, 
iron deficiency). Despite suggestive features of an MPN, fulfilment of usual diagnostic 
criteria can thus often be lacking, which is a notorious problem in MPN diagnostics in these 
patients. The term occult MPN has been used in the literature for patients who lack these 
typical peripheral blood changes, but who harbour clear features of MPN, for example 
by means of bone marrow (BM) biopsy findings and growth of erythroid colonies in the 
absence of exogenous erythropoietin, referred to as spontaneous endogenous erythroid 
colonies (EEC), both of which have several limitations.12-14 BM biopsy is invasive and the 
distinction between MPN and reactive BM is not unambiguous. EEC assays are performed 
only in specialized centers, are difficult to standardize and the possibility of false positives in 
nonclonal causes of erythrocytosis and healthy controls.15
 The discovery of the JAK2V617F gain-of-function mutation in 2005, found in 95% 
of patients with polycythemia vera (PV) and in about 50% of patients with essential 
thrombocythemia (ET) and myelofibrosis (MF), represented a crucial advance in the 
diagnostic approach to MPNs.16-19 The close relationship between MPNs and BCS and PVT 
was confirmed by the high frequency of JAK2V617F among these patients, present in 
30–45%4,9,20 and 17–35%,11,20,21 respectively. Interestingly, JAK2V617F screening offered a 
new diagnostic tool to detect these so-called occult MPNs in SVT patients, as this mutation 
was frequently demonstrated in SVT patients without characteristic elevated peripheral 
blood counts.22 JAK2V617F screening has since become part of the standard diagnostic 
work-up in SVT. 
 Other advances in the field of MPNs were the identification of the MPL515 mutations in 
the thrombopoietin receptor gene in approximately 5 and 10% of patients with JAK2V617F 
negative ET and MF, respectively, and JAK2 exon 12 mutations in less than 5% of JAK2V617F 
negative PV patients.23-27 Both mutations have been described in small numbers of SVT 
patients, but their clinical relevance has not yet been fully clarified.28,29
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The aims of this  systematic review and meta-analysis were: 1) to assess the prevalence of 
overt MPNs and JAK2V617F in BCS and PVT patients; 2) to quantify the detection rate of 
MPNs without characteristic increased peripheral blood counts by means of JAK2V617F 
screening; 3) to determine the frequency of MPN subtypes in BCS and PVT patients, and; 
4) to evaluate the clinical relevance of the MPL and JAK2 exon 12 mutations in BCS and PVT 
patients.
mETHoDS 
Search strategy and selection criteria
One of the authors (J.S.) searched Ovid MEDLINE and EMBASE from 1980 to August 1st 2011. 
The search strategy was restricted to published data and the English language using the 
subject headings presented in the appendix. The search was supplemented by manually 
reviewing the reference list of retrieved articles and relevant reviews. Titles and abstracts 
of retrieved citations were screened and potentially suitable studies were read in full by 
J.S. and F.L. Studies were selected when the following criteria were met: 1) patients were 
diagnosed with primary BCS or non-cirrhotic, non-malignant PVT, or patients with an 
underlying malignancy or cirrhosis were explicitly mentioned; 2) information on MPNs and/
or JAK2V617F, JAK2 exon 12 or MPL515 was provided; 3) the cohort consisted of patients 
in which patients with overt MPNs or other thrombophilic factors were not excluded; 4) 
splanchnic vein thrombosis was subdivided in BCS and PVT; 5) a minimum of ten patients 
were included. Disagreements were resolved after discussion or after having collected the 
opinion of a third reviewer (H.J.). 
Data extraction
J.S. extracted data on each selected study (year of publication, study design, demograhics, 
criteria for diagnosing MPNs, number of patients included). Patients with BCS in the 
presence of a malignancy and PVT patients with a malignancy or cirrhosis were excluded 
from the analysis. Patients with combined BCS and PVT were classified as BCS patients 
according to common practice.4 Prevalence of MPNs, JAK2V617F, JAK2 exon 12 and MPL515 
mutations were subsequently extracted. Patients fulfilling the traditional MPN criteria 
used in the various studies (mostly World Health Organization or Polycythemia Vera 
Study Group), either in the presence or absence of JAK2V617F, were considered to display 
characteristic increased peripheral blood counts and were classified as overt MPN. Patients 
not fulfilling the traditional criteria for MPN were assumed to lack these typical hematologic 
features. In these patients, MPNs identified by means of JAK2V617F were classified as 
MPN unclassifiable. To assess the diagnostic yield of JAK2V617F, these cases of otherwise 
undiscovered MPN were expressed as a proportion of total amount of patients tested for 
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the JAK2V617F mutation. Corresponding authors were contacted in case essential data were 
not mentioned, with a reminder sent after two weeks. 
Statistical analysis
Weighted mean proportion and 95% confidence intervals (CI) of MPNs, JAK2V617F, and 
MPN subtypes prevalence were calculated using a random effects model. Differences in 
prevalence were calculated by means of Pearson’s chi square. All statistical tests were two-
sided and P-values < .05 were considered statistically significant. Statistical heterogeneity 
was evaluated using the I2 statistic, which describes the percentage of variation across 
studies that is due to heterogeneity rather than chance, with a P-value < .05 representing 
statistically significant heterogeneity. If heterogeneity was present, the analyses were 
repeated removing one study a time to identify the source of heterogeneity. All analyses 
were performed with Comprehensive Meta Analysis 2.2 for Windows (Biostat, Englewood, 
USA) and the overall effects are presented as event rates with 95% CI.
rESULTS
Study identification and selection
We identified 821 potentially relevant publications: 255 from MEDLINE and 566 from 
EMBASE. A total of 109 studies were duplicate, and 665 studies were excluded after title 
and abstracts screening according to predefined inclusion criteria. The remaining studies 
were retrieved in full for detailed evaluation. Six additional studies were identified: five from 
reference lists and one from our center30 which was under submission. Figure 1 shows the 
study selection process. 
 Of the 53 retrieved studies, 21 were excluded because of the following reasons: in 
two studies patients with malignancies or liver cirrhosis were not excluded or explicitly 
mentioned,31,32 five studies were based on selected cohorts in which patients with overt 
MPNs or other thrombophilic factors were excluded,33-37 one study did not differentiate SVT 
into BCS and PVT,38 in four studies MPN criteria were not acceptable or unclear,14,39-41 and two 
studies included less than 10 patients.29,42 In addition, seven studies contained duplicate 
data.43-49 This resulted in 32 studies eligible for inclusion.
Study characteristics and quality
Table 1 and 2 summarizes the characteristics of the included studies for BCS and PVT, 
respectively. Study size ranged between 10 and 237 patients. Nineteen studies including 
1.062 patients reported on MPNs and/or the JAK2V617F mutation in BCS patients. Fifteen 
studies including 855 patients reported on MPNs and/or the JAK2V617F mutation in PVT 
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patients. Three studies including 268 patients reported on JAK2 exon 12 mutations.20,28,50 
Two studies including 305 patients reported on MPL515 mutations.20,28 Five studies included 
a healthy control population,21,48,51-53 all other studies were essentially retrospective cohort 
studies. Nineteen of these studies enrolled patients consecutively.2,4,5,7-9,11,12,21,28,53-62 Studied 
populations partly overlapped in nine publications.2,5-7,9,14,20,48,63
712 studies screened by title and abstract
665 studies excluded after title and abstract 
reading, including reviews and editorials
Inclusion criteria not met:
   Malignancies/cirrhosis not excluded (n = 2)      
   Selected cohorts (n = 5)
   SVT not subdivided in BCS/PVT (n = 1)
   MPN criteria unaccepted/unclear (n = 4)
   < 10 patients included (n = 2)
Duplicate data (n = 7)
47 studies retrieved for detailed evaluation
Additional identied studies:
   5 studies from bibliographies
   1 study from our center under submission
32 studies included in analysis
Figure 1. Flow diagram study selection process.
mPNs and JAK2V617F in Budd-Chiari syndrome
A total of 276 out of 1.002 BCS patients had an overt MPN, for a mean prevalence of 28.5% 
(95% CI: 22.5%–35.5%) (Figure 2A). JAK2V617F mutation was present in 159 of 401 tested 
patients, for a mean prevalence of 41.1% (95% CI: 32.3%–50.6%) (Figure 2B). JAK2V617F 
mutation analysis detected MPNs in 59 patients without increased peripheral blood 
counts, identifying otherwise undetected MPN in 17.1% of patients tested for the mutation 
(95%CI: 7.9%–33.3%). Prevalence of PV, ET, MF and unclassifiable MPNs were 52.9% (95%CI: 
42.2%–63.4%), 24.6% (95%CI: 18.0%–32.5%), 6.7% (95%CI: 3.7%–11.9%) and 20.4% (95%CI: 
12.6%–31.2%), respectively. 
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A. overt mPNs in patients with Budd-Chiari 
syndrome
B. JAK2V617F in patients with Budd-Chiari 
syndrome
Study name Year Event rate 
and 95%CI
Mahmoud et al. 1996
Janssen et al. 2000
Denninger et al. 2000
Darwish Murad et al. 2004
Attwell et al. 2004
Khuroo et al. 2005
Smalberg et al. 2006
Patel et al. 2006
Primignani et al. 2006
Eapen et al. 2006
DeStefano et al. 2007
Kiladjian et al. 2008
Colaizzo et al. 2008
Uskudar et al. 2008
Xavier et al. 2009
Darwish Murad et al. 2009
Rajani et al. 2009
Zahn et al. 2010
0,00 0,50 1,00
Study name Event rate 
and 95%CI
Smalberg et al. 2006
Patel et al. 2006
Primignani et al. 2006
DeStefano et al. 2007
Kiladjian et al. 2008
Colaizzo et al. 2008
Xavier et al. 2009
Darwish Murad et al. 2009
Smira et al. 2010
0,00 0,50 1,00
Year
Figure 2. Forest plots showing the mean prevalence of overt MPNs (a) and JAK2V617F (b) in patients 
with Budd-Chiari syndrome.
Four studies made a distinction between diagnosis of overt MPN prior or simultaneous to 
SVT, in which 13 out of 50 patients were diagnosed with MPN prior to SVT, whereas SVT 
was the presenting symptom of MPN in 37 out of 50 patients.7,9,54,61 Follow-up of JAK2V617F-
positive MPNs without increased peripheral blood counts was provided in two publications, 
in which 11 out of 28 patients (41%) developed overt MPNs during follow-up.52,61,64 
mPNs and JAK2V617F in portal vein thrombosis 
A total of 173 out of 855 PVT patients had an overt MPN, resulting in a mean prevalence of 
MPNs of 19.4% (95% CI: 13.7%–26.7%) (Figure 3A). JAK2V617F mutation was present in 166 
of 595 tested patients, for a mean prevalence of 27.7% (95% CI: 20.8%–35.8%) (Figure 3B). 
JAK2V617F mutation analysis detected MPNs in 70 patients without increased peripheral 
blood counts, identifying otherwise undetected MPNs in 15.4% of patients tested for the 
mutation (95%CI: 9.7%–23.7%). Prevalence of PV, ET, MF and unclassifiable MPNs were 
27.5% (95%CI: 19.0%–38.1%), 26.2% (95%CI: 19.1%–34.8%), 12.8% (95%CI: 8.0%–19.9%) 
and 38.3% (95%CI: 26.3%–52.0%), respectively. 
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Five studies differentiated between diagnosis of MPN prior or simultaneous to SVT diagnosis, 
showing that 17 out of 64 patients were diagnosed with MPN prior to SVT, whereas SVT was 
the presenting symptom of MPN in 47 out of 64 patients.10,14,30,57,61 Follow-up of JAK2V617F 
positive MPNs without increased peripheral blood counts was provided in four publications 
in which seven out of 48 patients (15%) developed overt MPNs during follow-up.21,57,61,64 
One study described the long-term follow-up of 44 PVT patients with an underlying MPN.30 
Five PV and two ET patients developed secondary MF, three patients with MF progressed to 
end-stage MF, and four patients developed acute myeloid leukemia after a median period 
of 9.7 years (range 1–17) following MPN diagnosis. Twenty-nine and 18% of the deaths in 
this cohort were attributable to end-stage MF and progression to acute myeloid leukemia, 
respectively. 
A. overt mPNs in patients with portal vein 
thrombosis
B. JAK2V617F in patients with portal vein 
thrombosis
Study name
0,00 0,50 1,00
Valla et al. 
Denninger et al. b 
Janssen et al. b 
Kocher et al. 
Colaizzo et al. b 
Primignani et al. b 
DeStefano et al. b 
McMahon et al. 
Kiladjian et al. b 
Bayraktar et al. 
Rajani et al. 
Xavier et al. b 
Orr et al. 
Plessier et al.
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Figure 3. Forest plots showing the mean prevalence of overt MPNs (a) and JAK2V617F (b) in patients 
with portal vein thrombosis.  
JAK2 exon 12 and MPL515 mutations in splanchnic venous thrombosis
A total of 268 SVT patients (ratio BCS/PVT unknown) were tested for JAK2 exon 12 and 305 
for MPL515 mutations. Three of these patients were found to carry MPLW515K mutation. The 
JAK2 exon 12 mutation was not present in any of these patients.
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Differences between BCS and PVT
Prevalence of both overt MPNs and JAK2V617F was significantly higher in BCS than in 
PVT (P < .001 and P = .03, respectively). There was no difference in identification rate of 
MPNs without increased peripheral blood counts by means of JAK2V617F between the 
two disorders (17.1% vs. 15.4%, P = .68). With regards to the subtype analysis, prevalence 
of PV was significantly higher in BCS patients (P = .001), whereas prevalence of MPNs 
unclassifiable was higher in PVT compared to BCS (P = .03) and there was a trend towards an 
increased frequency of MF in PVT (P = .09). There was no difference between the prevalence 
of ET (P = .77). These analyses were repeated including only publications since 2005 and 
excluding papers with potentially duplicated inclusion of patients, which showed the same 
results (data not shown). 
i2 and heterogeneity amongst studies
A considerable heterogeneity amongst the studies was observed (P < .05). We therefore 
performed an additional analysis in which we excluded one study per analysis. This analysis 
showed that no single study significantly affected the point estimate of overt MPNs, 
JAK2V617F, or MPN subtypes in both BCS and PVT. 
DiSCUSSioN
In this meta-analysis we assessed the role of MPNs in the etiology of primary BCS and non-
malignant, non-cirrhotic PVT. The results showed a higher prevalence of overt MPNs in BCS 
compared to PVT patients, as well as a higher prevalence of the JAK2V617F mutation in 
BCS. Identification rate of MPNs without characteristic increased peripheral blood counts by 
means of JAK2V617F was comparable between the two disorders. Interestingly, our results 
indicate a difference in the distribution of underlying MPN subtype between BCS and PVT 
patients, PV being the most frequent MPN in BCS. Finally, MPL515 mutations were present 
in less than 1% of BCS and PVT series, whereas JAK2 exon 12 mutations have never been 
published so far in SVT patients. 
 Two meta-analyses have previously evaluated the impact of the JAK2V617F mutation in 
SVT patients. In 2009, Dentali et al assessed the role of JAK2V617F in patients with various 
venous thrombosis, including SVT, deep vein thrombosis of the lower extremities or 
pulmonary embolism, cerebral vein thrombosis and retinal vein thrombosis.65 In this study, 
a remarkable high prevalence of JAK2V617F in SVT was reported, whereas its prevalence in 
other forms of VTE was similar to that of the general population. SVT was not subdivided 
into BCS and PVT which impedes comparison of MPNs and JAK2V617F prevalence between 
the two disorders. Qi et al. calculated the prevalence of JAK2V617F in BCS and PVT separately, 
and assessed its prevalence after exclusion of cases with pre-existing MPNs.66 In contrast to 
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those previously published studies, we set out to provide a complete overview of MPNs 
in the etiology of BCS and PVT. This included assessment of the prevalence of overt MPNs 
and JAK2V617F. Moreover, we quantified the identification of MPNs without characteristic 
increased peripheral blood counts by means of JAK2V617F and the rate of evolution to overt 
MPNs during follow-up. Finally, we determined the prevalence of MPN subtypes. In addition, 
we have compared BCS and PVT for each of these variables, as it is increasingly recognized 
that, despite several similarities, risk profiles are different between these patients.67 To 
achieve this goal, we have assessed all the publications regarding MPNs in SVT since 1980. 
 The results of this meta-analysis indicate a high prevalence of overt MPNs in patients 
with SVT. The strong relation between MPNs and SVT is confirmed by the high prevalence 
of JAK2V617F in these patients. Interestingly, prevalence of both overt MPNs and JAK2V617F 
was significantly higher in BCS compared to PVT. This difference may be partially explained 
by the more prominent role of local risk factors, such as focal inflammatory lesions and 
injury to the portal venous system, in the development of PVT.68 This might contribute to 
the relatively limited role of general prothrombotic conditions reported in the etiology of 
PVT. Why MPNs and JAK2V617F are so strongly related to thrombosis of the splanchnic veins 
remains an unresolved issue. Further research is needed to identify associated factors that 
could be involved in the pathogenesis of thrombosis at these specific sites. In this respect, 
it has been speculated that endothelial cells of the splanchnic veins may interact with 
activated platelets and/or leukocytes and increased microparticles, which are characteristic 
features of MPNs.69 In addition, these endothelial cells have been shown to carry the 
JAK2V617F mutation and could be part of the malignant process.70
 Being rare in patients with thrombosis outside the splanchnic area, and virtually absent 
in healthy individuals, JAK2V617F may be considered pathognomonic for MPNs in SVT 
patients. In these patients, portal hypertension and hypersplenism may mask elevated 
peripheral blood counts, even in the presence of active myeloproliferation. This meta-
analysis for the first time systematically assessed the diagnostic yield of JAK2V617F screening 
in SVT patients. JAK2V617F screening identified MPN without characteristic increased 
peripheral blood counts in 17.1% and 15.4% of tested BCS and PVT patients, respectively. 
Its presence was associated with subsequent development of overt MPNs in 41% and 
15% of BCS and PVT patients, respectively, which is lower than reported by Dentali et al.65 
These findings clearly substantiate inclusion of JAK2V617F in the routine diagnostic work-
up of SVT patients. Whether MPN specific treatment should be initiated in these patients, 
such as cytoreductive therapies or addition of aspirin to oral anticoagulant treatment, is 
a question that remains to be answered. One study described the long-term outcome of 
PVT patients with an underlying MPN.30 Twenty-nine and 18% of the deaths in this cohort 
were attributable to end-stage MF and progression to acute myeloid leukemia, respectively, 
indicating that risk of MPN progression is a clinical significant issue in these patients. 
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We observed a marked difference between BCS and PVT patients regarding the distribution 
of MPN subtypes. PV was clearly more common in BCS compared to PVT. The prothrombotic 
effect of high hematocrit values in PV is well established.71 Under low-shear conditions, 
such as in the venous circulation, a high hematocrit has a more important impact on blood 
viscosity and causes a major disturbance to blood flow.72,73 This mechanism may be mediated 
by the interaction between adhesion molecules and red blood cells. Wautier et al described 
an increased adhesiveness of red blood cells in PV to human umbilical vein endothelial cells 
and elegantly showed that adhesion was inversely related to increasing shear stress, i.e. 
adhesion proved particularly increased at low shear rates.74 It is possible that variability in 
the expression of these molecules along the vascular tree along with differences in flow 
conditions might contribute to the site-specificity of thrombosis, as suggested by these 
authors.74 Indeed, the low-flow state in the hepatic veins compared to the portal venous 
system may participate in the higher frequency of PV in BCS. We also observed a statistical 
trend towards increased frequency of MF in PVT compared to BCS. Such difference could 
be due to the frequent presence of an important splenomegaly in MF, which may lead to 
external compression of the portal venous system and subsequent stasis of blood flow. 
These are new findings that deserve further evaluation in future studies. 
 MPL515 mutations were reported in less than 1% of SVT patients, while the JAK2 exon 12 
could not be found at all. The JAK2 exon 12 mutation has been described only once in both a 
PVT and BCS patient, but this was a case study.29 These results indicate that both mutations 
are infrequent in SVT patients, in agreement with their low frequency in MPNs compared 
to the JAK2V617F mutation.23-27 We therefore conclude that, unlike JAK2V617F, screening for 
these mutations is dispensable in the routine diagnostic approach of SVT patients. 
 However, our analysis has several potential limitations. First, because of the rarity of 
both diseases, only observational studies have been published and could be included 
in this analysis, with their inherent risks of bias. However, a prospective design for rare 
thrombotic manifestations as PVT and BCS is probably unachievable. Second, a considerable 
heterogeneity amongst the included studies was noticed. We therefore performed all 
analyses using a random-effects model, thereby accounting for between study variance, 
next to within study variance. In addition to the random-effects analysis, which generates a 
conservative estimate, we performed an analysis in which we excluded one study at a time 
to assess its individual impact on the results. This analysis showed that none of the included 
studies significantly affected the estimated prevalence of overt MPNs, JAK2V617F, and its 
subtypes in both BCS and PVT. Third, diagnostic criteria for MPNs were not similar across 
studies. Notably, BM biopsy was not always routinely performed regardless of peripheral 
blood cell counts, which may have resulted in an underestimation of the prevalence of MPNs. 
Since this applies to both BCS and PVT series, the effect on the comparison between these 
two groups is presumably small, if at all present. Lastly, since the discovery of JAK2V617F in 
2005, an increase in larger and better quality studies was observed. We therefore repeated 
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all analyses including only publications from that point in time. In addition, we excluded 
papers with potential overlap of patients. The same differences between BCS and PVT were 
observed. 
 In conclusion, this meta-analysis shows a higher prevalence of both overt MPNs and 
JAK2V617F in BCS compared to PVT. Identification of MPNs without characteristic increased 
peripheral blood counts, of which a significant percentage developed overt MPN during 
follow-up, clearly justifies the inclusion of JAK2V617F screening in the routine diagnostic 
work-up of SVT. On the contrary, JAK2 exon 12 and MPL515 mutations are extremely rare in 
SVT and should not be used in the routine diagnostic approach of SVT patients. Altogether, 
our results are in line with the advancing insight that despite well-established similarities, 
marked differences in the etiology of BCS and PVT do exist.
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APPENDix: mEDLiNE SEArCH STrATEGY 
Date: August 1st, 2011
Database: Medline
Limits: English, limits publication date 01/01/1980–01/08/2010
1. Myeloproliferative disorders [Mesh]: 23690
2. Myeloproliferative neoplasms: 2798
3. Janus Kinase 2 [Mesh]: 2880
4. MPL protein, human [Substance Name]: 503
5. Colony-Forming Units Assay: 13111
6. Budd-Chiari Syndrome [Mesh]: 1539
7. Hepatic vein thmbosis: 2885
8. Hepatic venous thrombosis: 1544
9. Hepatic outflow obstruction: 295
10. Vascular liver disease: 11915
11. Thrombosis [Mesh] AND Vena Cava, Inferior [Mesh]: 1784
12. Portal System [Mesh] AND Thrombosis [Mesh]: 2535
13. Portal vein thrombosis: 3158
14. Portal venous thrombosis: 2015
15. Splanchnic vein thrombosis: 206
16. Splanchnic venous thrombosis: 163
17. Abdominal vein thrombosis: 2091
18. Abdominal venous thrombosis: 1587
19. 6 or 7 or 8 or 9 or 10 or 11 or 12 or 13 or 14 or 15 or 16 or 17 or 18: 19561
20. 1 and 19: 214
21. 2 and 19: 45
22. 3 and 19: 57
23. 4 and 19: 3
24. 5 and 19: 12
25. 20 or 21 or 22 or 23 or 24: 255
The search was supplemented by manually reviewing the reference list of retrieved articles.
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ABSTrACT
The germline JAK2 46/1 haplotype has been associated with the development of JAK2V617F 
positive as well as JAK2V617F negative myeloproliferative neoplasms (MPNs). In this study we 
examined the role of the 46/1 haplotype in the etiology and clinical presentation of patients 
with splanchnic vein thrombosis (SVT), in which MPNs are the most prominent underlying 
etiological factor. The single-nucleotide polymorphism rs12343867, which tags 46/1, was 
genotyped in 199 SVT patients. The 46/1 haplotype was overrepresented in JAK2V617F 
positive SVT patients compared with controls (P < .01). Prevalence of the 46/1 haplotype 
in JAK2V617F negative SVT patients did not differ from the controls. However, JAK2V617F 
negative SVT patients with a proven MPN also exhibited an increased frequency of the 
46/1 haplotype (P = .06). Interestingly, 46/1 was associated with increased erythropoiesis in 
JAK2V617F negative SVT patients. In conclusion, the 46/1 haplotype is associated with the 
development of JAK2V617F positive SVT. In addition, our findings in JAK2V617F negative 
SVT patients indicate an important role for the 46/1 haplotype in the etiology and diagnosis 
of SVT-related MPNs, independent of JAK2V617F, that requires further exploration. 
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The entity splanchnic vein thrombosis is used to indicate both the Budd-Chiari syndrome 
(BCS) and portal vein thrombosis (PVT). BCS is a rare disorder characterized by obstruction 
of the hepatic veins and/or the suprahepatic inferior vena cava.1,2 BCS is considered primary 
when resulting from thrombosis and secondary when obstruction of the venous tract results 
from compression or invasion by a tumour. Non-malignant, non-cirrhotic PVT is another 
infrequent thrombotic disorder involving the splanchnic vasculature.3 In both disorders, 
pathogenesis is largely dependent on the presence of systemic prothrombotic conditions 
which promote thrombus formation in the respective hepatic vessels. 
 Myeloproliferative neoplasms (MPNs) are the leading cause of SVT and are diagnosed 
in one third to half of the patients with SVT patients.4 The most common gain of function 
mutation leading to development of MPNs is the JAK2V617F mutation, which is present in 
more than 95% of cases of polycythemia vera and 50% to 60% of essential thrombocythemia 
and primary myelofibrosis.5 The high prevalence of the JAK2V617F mutation in SVT patients, 
approximately 35% in unselected cases, confirms the unique relationship between SVT and 
MPNs.6-10 Interestingly, the JAK2V617F mutation has proved to be an important diagnostic 
tool to detect MPNs in SVT patients, considering that MPNs can be notoriously difficult 
to diagnose in patients presenting with SVT. Portal hypertension, resulting from pre- or 
post-sinusoidal venous congestion, leads to hypersplenism and hemodilution - both 
conditions which mask the characteristic peripheral blood cell changes in MPNs. Screening 
for JAK2V617F is an objective tool to diagnose MPNs in these patients and is now part of the 
standard diagnostic work-up in SVT.8,11
 Recently, an association between a specific JAK2 haplotype and the risk of developing 
JAK2V617F positive MPNs was demonstrated.12-14 These studies show that the acquired 
JAK2V617F mutation is preferentially found within this particular, inherited haplotype, 
which we refer to as 46/1. The association is strong, with the odds of developing MPNs 
being three to fourfold higher in patients carrying 46/1 compared to non-carriers. One 
of the aforementioned studies also found an association between 46/1 and JAK2V617F 
negative MPNs,12 which has since been confirmed by other studies.15-17 Subsequently, it 
has been shown that 46/1 was also overrepresented in JAK2V617F negative MPNs carrying 
mutations across JAK2 exon 12 or MPL gene.18,19 These findings are of particular interest 
in SVT, because 46/1 may thus represent a new molecular marker for diagnosing MPNs in 
JAK2V617F negative SVT patients. 
 The aim of our study was to assess whether 46/1 is associated with SVT, and to determine 
whether JAK2 46/1 is associated with distinct clinical and laboratory characteristics of SVT. 
To this end, we genotyped patients and healthy controls from a large European series of 
newly diagnosed, consecutive BCS and PVT patients. 
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Study design
We performed a case-control study in which patients and controls were recruited from 
the European Network for Vascular Disease of the Liver (EN-Vie) study cohort, which has 
been described previously.6,9 The EN-Vie cohort consists of newly diagnosed patients with 
BCS or PVT, consecutively enrolled and prospectively followed in nine different European 
countries. At time of diagnosis and during follow-up, data concerning clinical condition and 
etiology and results of radiology, pathology and laboratory assessments were collected. 
From October 2003 to October 2005, a total of 163 BCS patients and 138 PVT patients were 
enrolled in the study. In addition, 105 healthy, unrelated, population-based controls, usually 
neighbours or friends of the patients, fulfilling the same age criteria and without a history 
of thrombosis were recruited. The EN-Vie study was approved by national and, if necessary, 
local ethical committees. Patients and controls agreed to participate in the study by written 
informed consent, in accordance with the Declaration of Helsinki. 
Definitions
BCS was defined as hepatic outflow obstruction regardless of the cause or level of 
obstruction, from the small hepatic veins to the entrance of the inferior vena cave into the 
right atrium. BCS was confirmed by radiographic imaging (ultrasonography, computed 
tomography, magnetic resonance imaging, or venography). Sinusoidal obstruction 
syndrome was excluded from this definition, as well as outflow obstruction occurring in the 
setting of heart failure, orthotopic liver transplantation or hepatobiliary cancer. Diagnostic 
criteria for PVT included radiographic imaging evidence of solid material in the portal vein 
lumen or in its left or right branch. PVT patients with cirrhosis or abdominal malignancies as 
well as patients with clinical, laboratory, or imaging evidence of non-cirrhotic liver disease, 
within a context of chronic alcoholism, viral hepatitis, autoimmune disease, Wilson’s disease, 
or iron overload were excluded.
Blood sampling
Blood samples were collected from patients at time of diagnosis and controls by 
venapuncture in tubes containing 0.11M trisodium citrate. DNA was extracted from whole 
blood according to local standard methods. DNA samples were transported to the Erasmus 
University Medical Center in Rotterdam and stored at -70°C until analysis.
JAK2 46/1 genotyping and JAK2V617F mutation analysis 
Granulocyte DNA samples were genotyped using a Taqman single nucleotide polymorphism 
(SNP) assay for rs12343867 (C/T) (Applied Biosystems). The 46/1 haplotype is tagged by the 
C allele of this SNP.14 JAK2V617F mutation analysis was performed as previously described.8
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Statistical analysis
Results are expressed as proportions for categorical variables and as medians and interquartile 
range (IQR; 25th–75th percentile) for continuous variables. Comparison between categorical 
variables was performed with chi-square testing and between continuous variables with 
the Kruskall-Wallis test. Odds ratios (OR) for SVT associated with 46/1 and corresponding 
95% confidence intervals (CI) were calculated using logistic regression, adjusted for age and 
gender. To assess the association between 46/1 and SVT in the presence of other risk factors 
for SVT, a multivariate model was constructed in which the factor V Leiden mutation and 
the prothrombin G20210A variant were added, adjusted for age and gender. JAK2V617F was 
only present in SVT patients and not in controls, and could therefore not be included in the 
multivariate model. P-values were two-tailed and statistical significance was set at P < .05. 
All statistical analyses were conducted with PASW Statistics, version 17.0 (SPSS, Chicago, 
Illinois).
rESULTS
Patient characteristics
The total EN-Vie cohort contains 163 BCS and 138 PVT patients and DNA samples for this 
study were available of 116 BCS patients, 96 PVT patients and 105 healthy controls. Of 
these, 107 BCS patients (92%), 92 PVT patients (96%) and 100 healthy controls (95%) were 
successfully genotyped and included in the current analysis. 
 Patient characteristics and underlying thrombophilic risk factors are shown in Table 1. 
In BCS patients, median age at diagnosis was 38.1 years (IQR: 28–51) and 45 were males 
(42%). Twenty-three BCS patients (21%) had an underlying inherited thrombophilic factor, 
while in 83 patients (78%) an acquired prothrombotic disorder was diagnosed. MPNs were 
present in 42 patients, of which 34 were JAK2V617F positive. In PVT, median age at diagnosis 
was 49.8 years (IQR: 42–57) and 43 were males (47%). Twenty-two PVT patients (24%) were 
diagnosed with an inherited thrombophilia, whereas 56 patients (61%) had an acquired 
prothrombotic factor. MPNs were present in 24 PVT patients, of which 20 were JAK2V617F 
positive. Median age in the controls was 36.8 years (IQR: 27–50) and 40 were males (40%). 
None of the controls carried the JAK2V617F mutation, whereas the factor V Leiden mutation 
and prothrombin G20210A variant were present in 4% and 3% of the controls, respectively.
JAK2 46/1 haplotype and risk of SVT-related mPN
SNP rs12343867 genotype distributions and the OR for SVT are presented in Table 2. 
Genotype distribution of our control group was in Hardy-Weinberg equilibrium and similar 
to those reported by previous studies and the Wellcome Trust Case-Control Consortium 
(WTCCC).12,17,20 In the overall group of SVT patients, there was no significant difference in 
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Table 1. Clinical characteristics and prothrombotic factors in patients with Budd-Chiari syndrome and portal 
vein thrombosis
  BCS (n = 107) PVT (n = 92)
Median age, y (Q1-Q3) 38.1 (28–51) 49.8 (42–57)
Males (%) 45 (42) 43 (47)
Inherited thrombophilia* (%) 23 (21) 22 (24)
Protein C deficiency  2 (2)  2 (2)
Protein S deficiency  1 (1)  5 (6)
Antithrombin deficiency  3 (3)  3 (4)
Factor V Leiden mutation 12 (11)  3 (3)
Prothrombin gene G20210A  5 (5) 12 (13)
Acquired thrombophilia* (%) 83 (78) 56 (61)
Myeloproliferative neoplasms 42 (39) 24 (26)
Polycythemia vera 24 (57)  3 (13)
Essential thrombocytosis  7 (17) 10 (42)
Primary myelofibrosis  2 (5)  4 (17)
Unclassifiable  9 (21)  7 (29)
JAK2V617F positive 34 (32) 20 (22)
Prior history of myeloproliferative neoplasms 10 (24)  6 (25)
Antiphospholipid antibodies 27 (25) 25 (28)
Paroxysmal nocturnal hemoglobinuria 12 (21)  0 (0)
Hormonal (%) 23 (37) 18 (37)
Systemic disorder† (%) 12 (11)  3 (3)
Local risk factor (%)‡ 15 (14) 25 (28)
Single risk factor (%)§ 49 (46) 29 (32)
Multiple risk factors (%)§ 44 (41) 43 (47)
No risk factor (%) 14 (9) 20 (22)
Abbreviations: BCS, Budd-Chiari syndrome; PVT, portal vein thrombosis.
*Patients can have more than one thrombophilic factor simultaneously, not all investigations could be performed in the 
individual patients.
†M Behcet, sarcoidosis, vasculitis or connective tissue disease.
‡Intra-abdominal inflammation, infection, or abscess.
§Single risk factor: presence of an inherited or acquired thrombophilic factor or the presence of a local risk factor. Multiple 
risk factors: presence of two or more risk factors.
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frequency of the minor C allele compared to the controls (32% vs. 27%; P = .18). However, 
when stratified for presence of the JAK2V617F mutation, we observed a significant difference 
in C allele frequency (43% vs. 27%; P < .01) in JAK2V617F positive individuals compared 
to controls. An allele dependent increase in risk of JAK2V617F positive SVT was seen in 
subjects with the CT genotype (OR 2.1; 95% CI: 1.01–4.5) and the CC genotype (OR 4.1; 95% 
CI: 1.3–13.2). In JAK2V617F negative SVT patients in whom MPNs were excluded, C allele 
frequency was comparable to controls (27% vs. 27%; P = .98). However, JAK2V617F negative 
SVT patients with a proven MPN (n = 12) also showed an increased frequency of the C 
allele (46% vs. 27%; P = .06). The increased risk of JAK2V617F negative MPNs corresponded 
with an OR of 5.3 (95% CI: 1.1–26.2) for subjects with the CC genotype. In a multivariate 
model, where the factor V Leiden mutation and the prothrombin G20210A variant were 
added, only minimal effect on the association between 46/1 and SVT was seen. SVT patients 
homozygous for 46/1 had a 4.7-fold increased risk of an underlying MPN compared to 
heterozygous or non-carriers (Figure 1). 
CC (n = 14)
TT (n = 76)
CT (n = 55)
17 MPNs (100%)
5 MPNs (6.6%)
3 MPNs (5.5%)
4 MPNs (28.6%)
28 MPNs (100%)
9 MPNs (100%)CC (n = 9)
TT (n = 17)
CT (n = 28)
SVT (n = 199)
JAK2V617F + (n = 54)
JAK2V617F - (n = 145)
Figure 1. This figure depicts the number (percentage) of splanchnic vein thrombosis patients who 
were diagnosed with MPNs, according to rs12343867 genotype, after stratification for JAK2V617F 
status. SVT, splanchnic vein thrombosis; MPNs, myeloproliferative neoplasms.
In the group of only BCS patients, the minor C allele was present more frequently than 
in controls (36% vs. 27%; P = .04). The risk for BCS in subjects with the CC genotype was 
elevated compared to subjects with the common TT genotype (OR 2.7; 95% CI: 1.01–7.1). 
When we stratified for presence of the JAK2V617F mutation, we observed a significantly 
higher frequency of the C allele in JAK2V617F positive individuals with BCS (44% vs. 27%; 
P = .01), with an OR for BCS in subjects with the CC genotype of 4.8 (95% CI: 1.4–16.6). No 
difference in C allele frequency was observed in JAK2V617F negative individuals with BCS 
compared to controls (33% vs. 27%; P = .24). 
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In the group of only PVT patients, frequency of the minor C allele was similar to that of the 
controls (28% vs. 27%; P = .88). In JAK2V617F positive individuals with PVT, we also observed 
a higher frequency of the C allele than in controls (40% vs. 27%; P = .10). The increased risk of 
JAK2V617F positive PVT in subjects with the CC genotype was 3.1 (95% CI: 0.5–20.2), which 
is comparable with BCS patients. Also in PVT, there was no significant difference in C allele 
frequency in JAK2V617F negative individuals compared to controls (24% vs. 27%; P = .57). 
 The frequency of inherited and acquired thrombophilia did not differ according to 46/1 
haplotype (P = .23 and P = .47, respectively), nor was there a difference in the frequency of 
inherited thrombophilia between JAK2V617F negative and JAK2V617F positive SVT patients 
(P = .98). JAK2V617F allele burden was determined in 47 out of 55 SVT patients. Allele 
burden was determined in 47 out of 55 JAK2V617F positive SVT patients. Frequency of the C 
allele was significantly increased compared to controls in SVT patients with an allele burden 
<20% (30 of 74 alleles; P = .03), and patients with an allele burden >20% (11 out of 16 alleles; 
P < .001). 
JAK2 46/1 haplotype and relationship with clinical characteristics in SVT
First, we stratified for JAK2V617F status and observed clear differences in hematologic 
and clinical features (Table 3). Hemoglobin, hematocrit, red blood cell count, white blood 
cell count, platelet count, serum alanine transaminase, serum bilirubin, and prevalence of 
splenomegaly at diagnosis were all significantly higher compared with unmutated SVT 
patients. Rotterdam BCS (1.18 vs. 1.15; P = .06) and Child-Pugh (8 vs. 7; P = .05) prognostic 
scores, which can only be assessed in BCS patients, were higher in JAK2V617F positive 
compared to JAK2V617F negative patients.
 We subsequently examined the association between JAK2 46/1 and clinical features of 
SVT patients (Table 4). Higher levels of hemoglobin (P < .01), hematocrit (P < .01), red blood 
cell count (P < .01), platelet count (P = .06), serum alanine transaminase (P = .04), and a 
higher prevalence of splenomegaly at diagnosis (P = .045) were seen in SVT patients with 
the CC genotype compared to patients with the common TT genotype. Rotterdam BCS and 
Child-Pugh prognostic scores did not differ significantly according to rs12343867 genotype 
in BCS patients (P = .63 and P = .74, respectively). 
 Finally, to avoid potential confounding, we assessed the association between the 
rs12343867 genotype and laboratory and clinical characteristics in the JAK2V617F negative 
group (Table 4). In this analysis, JAK2V617F negative patients with the CC genotype had 
higher hemoglobin levels (P < .01), hematocrit (P < .01), red blood cell count (P = .02) 
compared to individuals with the TT genotype (Figure 2). These associations remained 
significant when we excluded the 12 JAK2V617F negative patients in whom MPNs were 
objectively confirmed (data not shown). In JAK2V617F positive patients, we observed a 
higher prevalence of splenomegaly in those who were homozygous for JAK2 46/1 (P = .01), 
but we did not observe an association with peripheral blood cell counts (Table 5). 
82 | Chapter 5
Table 3. Characteristics and prognostic scores associated with the JAK2V617F mutation in 199 patients 
with splanchnic vein thrombosis
JAK2V617F positive  
(n = 54)
JAK2V617F negative  
(n = 145)
P 
Age, years 47.3 (31–54) 43.4 (31–55) 0.11
Males (%) 20 (37) 68 (47) 0.34
Hemoglobin (mmol/l) 9.2 (8.2–10.4) 8.1 (6.9–9.3) <0.001
Hematocrit, % 44.5 (39–50) 39.7 (35–44) <0.001
RBC count, ×109/L 5.2 (4.4–6.3) 4.5 (4.1–5.1) <0.01
WBC count, ×109/L 12.5 (9.7–17.3) 8.7 (6.4–11.4) <0.001
Platelet count, ×109/L 373 (220–538) 219 (139–347) <0.001
ALT, ULN 1.7 (0.9–5.8) 1.0 (0.7–2.2) <0.01
Serum bilirubin (μmol/L) 27 (15–43) 21 (13–35) 0.02
Albumin (g/L) 34 (30–40) 33 (28–39) 0.33
Splenomegaly (%) 36 (68) 60 (42) <0.01
Continuous data are presented as median (interquartile range); categorical data as mean (percentage). Abbreviations: SVT, 
splanchnic vein thrombosis; RBC, red blood cell; WBC, white blood cell; ALT, alanine aminotransferase; ULN, upper limit of 
normal value.
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Figure 2. The association between the rs12343867 genotype and haemoglobin levels (A) and red blood cell 
count (B) in patients with splanchnic vein thrombosis who were homozygous carriers of the common allele 
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Table 5. Characteristics and prognostic scores associated with the JAK2 46/1 haplotype in 55 JAK2V617F 
positive patients with splanchnic vein thrombosis
rs 12343867 genotype
  CC (n = 9) CT (n = 28) TT (n = 17) P1* P2* P3*
Age, years 45.5 (28–63) 46.7 (30–53) 49.9 (37–57) 0.83 0.77 0.49
Males (%) 0 (0) 13 (46) 7 (41) -- -- 0.67
Hemoglobin (mmol/l) 9.3 (8.4–10.6) 8.5 (7.2–9.9) 9.8 (9.0–10.6) 0.02 0.44 0.02
Hematocrit, % 47.3 (43–51) 40.6 (36–48) 46.0 (43–52) 0.09 0.97 0.18
RBC count, ×109/L 6.8 (4.8–7.2) 4.8 (3.9–5.8) 5.3 (5.0–6.7) 0.06 0.33 0.30
WBC count, ×109/L 12.7 (10.2–21.2) 11.8 (8.4–15.3) 13.1 (9.6–19.1) 0.57 0.73 0.61
Platelet count, ×109/L 462 (345–597) 308 (198–535) 381 (232–516) 0.19 0.19 0.99
ALT, ULN 1.8 (1.1–14.6) 1.9 (1.0–6.2) 1.1 (0.8–4.8) 0.42 0.15 0.24
Serum bilirubin (μmol/L) 32 (21–61) 24 (12–47) 27 (21–42) 0.54 0.48 0.78
Albumin (g/L) 35 (31–41) 34 (29–40) 34 (29–42) 0.86 0.63 0.90
Splenomegaly (%) 9 (100) 18 (67) 9 (53) 0.049 0.01 0.11
Continuous data are presented as median (interquartile range); categorical data as mean (percentage). Abbreviations: SVT, 
splanchnic vein thrombosis; RBC, red blood cell; WBC, white blood cell; ALT, alanine aminotransferase; ULN, upper limit of 
normal value.
*P1, P-value genotype comparisons (CC/CT/TT); P2, P-value for CC vs. TT genotype comparisons; P3, P-value for CC/CT vs. 
TT genotype comparisons.
DiSCUSSioN
Using a large multinational cohort of 199 newly diagnosed patients with SVT, we were able 
to show that 46/1 is associated with JAK2V617F positive SVT. This study also suggests an 
association between 46/1 and SVT in JAK2V617F negative SVT patients with MPNs, whereas 
no association was observed in JAK2V617F negative SVT patients without MPNs. Finally, 
JAK2 46/1 was associated with increased erythropoiesis in JAK2V617F negative SVT patients, 
which is a novel finding.
 In the current analysis, being the first including a large group of BCS patients, we observed 
an increased frequency of 46/1 in both JAK2V617F positive BCS and PVT. Presence of 46/1 
increased the risk of occurrence of JAK2V617F positive BCS or PVT in an allele dependent 
manner. These results are in line with recent studies that have convincingly shown an 
association between 46/1 and the risk of developing JAK2V617F positive MPNs.12-14 Only 
one previous study examined the role of 46/1 in PVT, in which only JAK2V617F negative 
patients were enrolled.21 In this study a significantly elevated risk for the occurrence of 
PVT in homozygous carriers of 46/1, compared to non-carriers, was reported. However, 
this study had several limitations. The 46/1 genotype distribution in the control group of 
this study differs from that of data provided by HapMap-CEU and the WTCCC population.20 
Ch
ap
te
r 5
85JAK2 46/1 in BCS and PVT | 
Most notable, the frequency of controls homozygous for the 46/1 was relatively low (2.8%) 
compared to the HapMap-CEU (6.0%) and WTCCC population (6.5%). In fact, the control 
group of that study was not in Hardy-Weinberg equilibrium. This has important implications, 
especially since the reported associations were for homozygous carriers of 46/1 compared 
to non-carriers. In our study, both controls and patients are representative samples from 
multiple European countries. This is supported by the fact that our control group is in 
Hardy-Weinberg equilibrium and distribution of 46/1 is consistent with HapMap-CEU and 
the WTCCC population. We therefore believe our results on the association between 46/1 
and PVT are valid and representative for the European population. The increased frequency 
of 46/1 was observed in JAK2V617F positive SVT patients with a mutant allele burden <20% 
as well as patients with a JAK2V617F allele burden >20%. 
 Interestingly, the frequency of 46/1 in JAK2V617F negative SVT patients with a proven 
MPN was higher compared to the controls (46% vs. 27%), although not significantly (P = .06). 
While we are aware that this group of patients is small, this finding is consistent with the 
increasing evidence that 46/1 is associated with both JAK2V617F positive and JAK2V617F 
negative MPNs.15-17
 An obvious question is whether 46/1 is of additional value in the diagnostic work-up 
of SVT patients. Our study suggests that 46/1 may be used as a diagnostic tool in the risk 
assessment of MPNs in SVT patients in addition to the JAK2V617F mutation. In a potential 
diagnostic algorithm, JAK2V617F clearly is the first tool to screen for MPNs in SVT patients 
– the presence of the JAK2V617F mutation is highly suggestive, if not pathognomonic, 
for MPNs in these patients. However, also JAK2V617F negative SVT patients may fulfill the 
criteria for MPNs. Our study shows, that in this specific subgroup of JAK2V617F negative 
SVT patients, homozygous carriers of 46/1 had a 4.7-fold higher chance of MPNs compared 
to heterozygous carriers or non-carriers. It can be argued that a more aggressive search 
for MPNs must be instituted in these patients. A bone marrow biopsy is quintessential in 
these patients, but it might also be considered to intensify the screening program for MPNs 
during follow up in these patients. This may facilitate timely recognition and treatment of 
underlying MPNs. Additional studies are needed to extend our observations, before definite 
conclusions on the potential role of 46/1 in the work-up of SVT patients can be drawn.
 We observed a strong association between JAK2V617F positivity and clinical and 
laboratory characteristics at the moment of diagnosis of SVT, which is in line with previous 
reports on the association between JAK2V617F and elevated peripheral blood cell 
counts,8,22-25 and that between JAK2V617F and splenomegaly.8,23,24 One of these studies 
also demonstrated an association between JAK2V617F and altered liver function tests and 
unfavourable prognostic scores in BCS.8 In the present study we confirm these findings. 
 The significant association between homozygous carriers of 46/1 and increased 
erythropoiesis in JAK2V617F negative SVT patients was unexpected. Hemoglobin, hematocrit 
and red blood cell count were all approximately 20% higher compared to individuals with 
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the TT genotype. Also, we observed a higher prevalence of splenomegaly in JAK2V617F 
positive patients homozygous for 46/1. This is the first study to demonstrate an association 
between 46/1 and laboratory and clinical characteristics. Up to this point, four studies 
examined this association earlier, in which no significant association was observed.15-18 One 
study examined the association between 46/1 and the number of granulocyte-macrophage 
colony forming units (CFU-GM) in peripheral blood.12 Carriers of 46/1 grew significantly 
fewer CFU-GM, consistent with the hypothesis that 46/1 might be functionally different 
from other JAK2 alleles. Our findings of an increased erythropoiesis support the theory that 
46/1 indeed might be functionally different. Theoretically, it is possible that this is specific 
for SVT patients, especially in light of the unique relationship between MPN and SVT. Clearly, 
these findings deserve further research. 
 In conclusion, we observed a clear association between the 46/1 haplotype and the 
development of JAK2V617F positive SVT. This study also provides the first support of an 
increased frequency of 46/1 in JAK2V617F negative SVT patients with a proven MPN, and 
suggests a potential role for 46/1 as a diagnostic tool in SVT in addition to JAK2V617F. 
Unexpectedly, 46/1 was associated with an elevated erythropoiesis in JAK2V617F negative 
SVT patients, indicating that the 46/1 allele might be functionally different from other 
alleles. 
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ABSTrACT
Fibrinogen γ’, a protein variant of fibrinogen, and genetic variation in fibrinogen γ genes 
(FGG) have been associated with susceptibility to venous thrombosis. In this study we 
evaluated whether fibrinogen γ’ and FGG haplotypes were associated with risk of portal 
vein thrombosis (PVT). We performed a case-control study using patients and healthy 
controls from the European Network for Vascular Disease of the Liver study cohort, a large 
multinational study of newly diagnosed, consecutive patients with non-cirrhotic, non-
malignant PVT. Fibrinogen γ’, total fibrinogen levels and FGG haplotypes were determined 
in 106 PVT patients and 103 healthy controls. We observed decreased levels of fibrinogen γ’ 
relative to total fibrinogen levels (γ’ ratio) in PVT patients (0.119 vs. 0.153; P < .001). A γ’ ratio 
in the lowest tertile was associated with a 5-fold increased risk of PVT (95% CI: 2.2–11.2). 
We observed an increased frequency of FGG-H2, which was significantly associated with a 
decreased γ’ ratio, in PVT patients compared to controls (OR 1.63; 95% CI: 0.94–2.81, P = .08). 
In conclusion, this case-control study provides the first evidence that the γ’ ratio and the 
FGG-H2 haplotype may contribute to the development of PVT.
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iNTroDUCTioN
Portal vein thrombosis (PVT) is a rare manifestation of venous thrombosis that often leads 
to portal hypertension.1 The etiology of PVT is diverse and involves both local and systemic 
prothrombotic factors. Liver cirrhosis and hepatobiliary malignancies are considered 
the most common local etiological factors. As with other types of venous thrombosis, it 
is increasingly recognized that the development of non-cirrhotic, non-malignant PVT is 
associated with systemic risk factors such as inherited and acquired thrombophilia. These 
include natural anticoagulant deficiencies, the factor V Leiden mutation and prothrombin 
G20210A gene variant, paroxysmal nocturnal hemoglobinuria, myeloproliferative 
neoplasms and hormonal factors. However, in around 25% of these patients still no 
underlying condition can be identified,2 which emphasizes the need to identify new 
etiological factors.
 Fibrinogen, the central protein in the haemostasis pathway, is composed of two sets 
of three different chains (α, β and γ), and these chains each consist of several forms with 
different properties.3 The distribution of these forms, in particular of the fibrinogen γ’ ratio, 
may contribute to an increased risk of venous thrombosis. Approximately 8–15% of a healthy 
person’s total fibrinogen is composed of fibrinogen γ’.4 The γ’ chain arises from an alternative 
splicing process and polyadenylation of the primary mRNA transcript, in which a unique 20 
amino acid extension substitutes four amino acids at the C-terminal of the more common 
γA chain.5 This extension has several important functional consequences, as fibrinogen γ’ 
has both antithrombotic (inhibits thrombin and platelet aggregation) and prothrombotic 
properties (enhances factor XIII activity and fibrin cross-linking).4
 There have been several reports on the plasma levels of fibrinogen γ’ and the ratio of 
fibrinogen γ’ to total plasma fibrinogen levels (γ’ ratio) and its relationship to thrombotic 
disease. Two independent studies demonstrated that reduced fibrinogen γ’ levels and a 
reduced γ’ ratio were associated with an increased risk of deep venous thrombosis (DVT).6,7 
In addition, both studies showed that a particular γ’ chain gene haplotype termed FGG-H2 
was associated with an increased risk of thrombosis. The association between FGG-H2 and 
risk of venous thrombosis was further established by Grünbacher et al and Uitte de Willige 
et al.8,9
 The aim of our study was to assess whether fibrinogen γ’ and genetic variation of the 
FGG gene are associated with risk of PVT. Therefore, we measured fibrinogen γ’ levels, total 
fibrinogen levels and genotyped patients and healthy controls from a large European series 
of newly diagnosed, consecutive PVT patients. 
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PATiENTS AND mETHoDS
Study design
We performed a case-control study in which patients and controls were recruited from 
the European Network for Vascular Disease of the Liver (EN-Vie) study cohort, which has 
been described previously.2 The EN-Vie cohort included newly diagnosed patients with PVT, 
consecutively enrolled in nine different European countries. From October 2003 to October 
2005, a total of 138 PVT patients were enrolled in the study. In addition, 105 healthy, 
population-based controls without a history of thrombosis were recruited. The EN-Vie study 
was approved by national or local ethical committees from participating centers. Patients 
and controls agreed to participate in the study by written informed consent, in accordance 
with the Declaration of Helsinki. 
Definitions
Diagnostic criteria for PVT included radiographic evidence of solid material in the portal vein 
lumen or in its left or right branch. PVT patients with cirrhosis or abdominal malignancies 
as well as patients with clinical, laboratory, or radiographic evidence of chronic liver disease, 
within a context of chronic alcoholism, viral hepatitis, autoimmune disease, Wilson’s disease, 
or iron overload were excluded. 
Blood sampling
Blood samples were collected from EN-Vie patients (at time of diagnosis) and controls 
by venipuncture in tubes containing 0.11M trisodium citrate. Plasma was prepared by 
centrifugation at 2000g for 10 minutes. DNA was extracted from whole blood according to 
local standard methods. Both plasma and DNA from the EN-Vie samples were transported 
to the Erasmus University Medical Center in Rotterdam and stored at -70°C until analysis.
Fibrinogen γ’ and fibrinogen measurement
Fibrinogen γ’ (γA/γ’ plus γ’/’γ’ fibrinogen) antigen levels were measured by an enzyme-
linked immunosorbent assay as described previously, with minor modifications.7 Plastic 
96-well microtiter plates (Nunc maxisorp, Roskilde, Denmark) were coated with mouse anti-
human γ’ fibrinogen (2.G2.H9; Millipore, Billerica, MA, USA). Fibrinogen γ’ was tagged with 
horseradish peroxidase-conjugated rabbit anti-human fibrinogen (DAKO A/S, Glostrup, 
Denmark). Pooled normal plasma, calibrated against purified human fibrinogen γ’, was 
used as a calibrator. For this study, the mean coefficient of intra-assay variation was 3.2%. 
Total fibrinogen levels were assessed according to von Clauss on a fully automated blood 
coagulation analyser (Sysmex CA-1500 system, Siemens Healthcare Diagnostics, Breda, the 
Netherlands). Normal reference plasma was used as reference plasma (Precision BioLogic, 
Dartmouth, Canada). 
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Genetic analysis
Haplotypes of FGG were determined by genotyping single nucleotide polymorphism 
(SNP) 10034C>T [rs2066865] and SNP 9340T>C [rs1049636] using a TaqMan assay (Applied 
Biosystems). Haplotypes could be determined in 97% of the subjects. Common alleles (CT) 
were designated FGG-H1; alleles with the minor allele for SNP 10034C>T were designated 
FGG-H2 (TT); and alleles with the minor allele for SNP 9340T>C were designated FGG-H3 
(CC). FGG-H1, FGG-H2, and FGG-H3 were defined as in previous publications.6-8
Statistical analysis
A log-transformation of fibrinogen γ’ levels, total fibrinogen levels and γ’ ratio was performed 
to obtain a normal distribution, which was assessed using the Kolmogorov-Smirnov test for 
normality. Differences of fibrinogen γ’, total fibrinogen levels, and γ’ ratio between groups 
were examined using analysis of variance (ANOVA), in which we routinely adjusted for age 
and gender. Tertiles of the fibrinogen γ’ ratio, based on levels in the control subjects, were 
constructed to study the association between the γ’ ratio and risk of thrombosis. Using 
logistic regression, with adjustment for age and gender, the odds ratios (OR) for thrombosis 
associated with an altered γ’ ratio and corresponding 95% confidence intervals (CI) were 
calculated. Correlations were assessed using the Pearson’s correlation coefficient. All P-values 
were two-tailed and statistical significance was set at P < .05. Hardy Weinberg equilibrium 
for each SNP was tested by chi-square analysis. These analyses were conducted with PASW 
statistics, version 17.0 (SPSS, Chicago, Illinois). The association between haplotypes, taking 
the haplotype ambiguity into account, and fibrinogen γ’ levels, total fibrinogen levels, 
fibrinogen γ’ ratio, and risk of PVT were determined using Haplo.Stats version 1.4.4 (http://
cran.r-projects.org/src/contrib/Descriptions/haplo.stats.html). 
rESULTS
Patient characteristics
The total EN-Vie cohort contains 138 PVT patients. Plasma and/or DNA samples for this 
study were available of 106 PVT patients and 103 healthy controls. Patient characteristics at 
baseline are shown in Table 1. In PVT, median age at diagnosis was 49.1 years (interquartile 
range, IQR: 41–58) and 52 were females (49%). Median age in the controls was 36.9 years 
(IQR: 28–50) and 60 were females (58%). 
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Table 1. Baseline characteristics in patients with portal vein thrombosis and controls
 
Portal vein thrombosis  
(n = 106)
Controls  
(n = 103)
P-value
Median age, y (Q1-Q3) 49.1 (41–58) 36.9 (28–50) <0.01
Females, n (%) 52 (49) 60 (58) 0.18
Clinical manifestations, n (%)
Abdominal distension 23 (22) – –
Gastrointestinal bleeding 12 (11) – –
Ascites 43 (41) – –
Hepatomegaly 30 (28) – –
Splenomegaly 47 (44) – –
Laboratory characteristics*
ALT (ULN) 1.0 (0.7–1.9) – –
AST (ULN) 1.0 (0.7–148) – –
Bilirubin (μmol/L) 16 (12–24) – –
Albumin (g/L) 35 (29–41) – –
Factor V (U/ml) 106 (88–132) – –
Creatinin (μmol/L) 77 (64–90) – –
Thrombophilia
Inherited thrombophilia 25 (24) – –
Acquired thrombophilia 59 (56) – –  
Data are presented as proportions for categorical variables and as median (interquartile range) for continuous variables. 
Abbreviations: ALT, alanine aminotransferase; AST, aspartate aminotransferase; ULN, upper limit of normal value. 
*Not all measurements were available in the individual patients.
Fibrinogen γ’ and risk of portal vein thrombosis
The ratio of fibrinogen γ’ levels to total fibrinogen levels (γ’ ratio) was significantly lower in 
PVT patients (0.119 ± 0.04) compared to controls (0.153 ± 0.05; P < .001). In PVT patients, 
the mean plasma level of fibrinogen γ’ (0.44 ± 0.22 g/L) patients was similar to controls 
(0.42 ± 0.15 g/L; P = .88), whereas the mean total plasma fibrinogen level (3.83 ± 1.33 g/L) 
was elevated when compared to controls (2.76 ± 0.54 g/L; P < .001) (Table 2). Adjustment for 
JAK2V617F, the factor V Leiden mutation and prothrombin G20210A gene variant did not 
alter these relationships.
 We calculated the risk for PVT using tertiles of the γ’ ratio. This analysis showed that a 
decrease in the γ’ ratio was associated with an increased risk for PVT. Individuals with a γ’ ratio 
in the lowest tertile (<0.123) had a strong increase in risk of PVT (OR 5.0; 95% CI: 2.2–11.2) 
compared to individuals with a γ’ ratio in the highest tertile. Individuals with a γ’ ratio in the 
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middle tertile (between 0.123–0.162) had an intermediate increased risk of PVT (OR 2.0; 95% 
CI: 0.8–4.8)
 There was no correlation between C-reactive protein (CRP) levels (measured in 69 
patients) and fibrinogen γ’ (R = 0.01, P = .96) and the γ’ ratio (R = -0.10, P = .42) in the PVT 
patients. We did not observe an association between quartiles of CRP and the γ’ ratio (P = 
.66). Furthermore, the mean γ’ ratio in patients with CRP levels < 10mg/L and > 100 mg/L 
were 0.13 and 0.12, respectively (P = .40).
Table 2. Fibrinogen γ’ levels, total fibrinogen levels, and γ’ ratio in patients with portal vein thrombosis 
and controls
Portal vein thrombosis  
(n = 102)
Controls  
(n = 103)
P-value
Fibrinogen γ’ (g/L) 0.44 ± 0.22 0.42 ± 0.15 0.88
Total fibrinogen (g/L) 3.83 ± 1.33 2.76 ± 0.54 <0.001
γ’ ratio 0.119 ± 0.04 0.153 ± 0.05 <0.001
Presented are means ± standard deviation.
P-value: PVT vs. controls, adjusted for age and gender. 
Variation in fibrinogen gamma gene and risk of PVT
The distribution of the FGG genotypes in the control subjects was in Hardy-Weinberg 
equilibrium for the two tested SNPs and was similar to those reported in previous studies.7-9 
Frequencies of FGG-H2 were 27.5% and 18.9% in PVT patients and controls, respectively. 
Frequencies of FGG-H3 were 27.3% and 30.0%, in PVT patients and controls, respectively. 
 FGG-H2 was associated with reduced fibrinogen γ’ levels and fibrinogen γ’ ratio in PVT (γ’ 
levels: β = -0.12 g/l, P < .001; γ’ ratio: β = -0.03, P < .001) and controls (γ’ levels: β = -0.10 g/l, 
P < .01; γ’ ratio: β = -0.03, P < .01) (Table 3). FGG-H3 was borderline associated with increased 
fibrinogen γ’ levels and an increased γ’ ratio in controls (γ’ levels: β = 0.04 g/l, P = .11; γ’ ratio: 
β = 0.02, P = .10), but not in PVT patients (γ’ levels: β = -0.03 g/l, P = .42; γ’ ratio: β = 0.002, 
P < .74). FGG-H2 and FGG-H3 were not associated with total fibrinogen levels in controls and 
PVT patients (data not shown). 
 FGG-H2 was significantly associated with an increased risk of PVT in the crude analysis 
(OR 1.70; 95% CI: 1.02–2.85, P = .04). However, this association did not reach the level of 
significance in the adjusted analysis (OR 1.63; 95% CI: 0.94–2.81, P = .08) (Table 4). No 
association between FGG-H3 and risk of PVT (OR 0.99; 95% CI: 0.60-1.62) was observed.
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Table 3. Association between FGG haplotypes and fibrinogen γ’ levels and γ’ ratio in portal vein 
thrombosis and controls
Fibrinogen γ’ levels Fibrinogen γ’ ratio
  Beta SD P-value   Beta SD P-value
Portal vein thrombosis
FGG-H1 0* - - 0* - -
FGG-H2 -0.12 0.04 <0.001 -0.03 0.01 <0.001
FGG-H3 -0.03 0.04 0.42 0.002 0.01 0.74
Controls
FGG-H1 0* - - 0* - -
FGG-H2 -0.10 0.03 <0.01 -0.03 0.01 <0.01
FGG-H3 0.04 0.03 0.11   0.02 0.01 0.10
Analyses were adjusted for age and gender. SD: standard deviation.
*FGG-H1 was the reference group. 
Table 4. Association between FGG haplotypes and portal vein thrombosis
  Crude or (95% Ci) Adjusted or (95% Ci)*
FGG-H1 1† 1†
FGG-H2 1.70 (1.02–2.85) 1.63 (0.94–2.81)
FGG-H3 1.03 (0.65–1.65) 0.99 (0.60–1.62)
*Adjusted for age and gender. 
†FGG-H1 was the reference group. 
 
DiSCUSSioN 
This case-control study is the first to evaluate the association between fibrinogen γ’ and 
variation in FGG genes and the risk of PVT. Using a large cohort, we were able to demonstrate 
an increased risk of PVT in individuals with a low fibrinogen γ’ ratio. Interestingly, our results 
also suggest that carriership of the FGG-H2 haplotype, which was associated with decreased 
γ’ levels and γ’ ratio, is associated with an increased risk of PVT.
 In the current analysis, we observed a decreased γ’ ratio in patients with PVT compared 
to healthy controls. Our results indicate a dose-dependent association between the γ’ ratio 
and the risk of PVT, that was increased up to 5-fold in individuals with a γ’ ratio lower than 
the 33rd percentile of the distribution in the controls. These findings are consistent with 
previous studies in patients with more common forms of venous thrombosis. Uitte de Willige 
et al. were the first to report a 2.4-fold increase in risk of DVT in patients with a reduced 
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γ’ ratio, using in a large, population based case-control study including 474 patients and 
474 controls.7 These findings were confirmed by Nowak-Göttl et al in a large family based 
association study in children with venous thromboembolism,6 and in a cohort of patients 
with the thrombotic microangiopathy syndrome.10 In contrast, one study has reported an 
elevated γ’ ratio in patients with pulmonary embolism, but the number of included patients 
was low (n = 29).11 Our study establishes additional evidence that a decreased γ’ ratio is 
associated with an elevated risk for venous thrombosis, in this case PVT. 
 Our data show that in this group of patients the absolute amount of synthesized γ’ 
fibrinogen was similar to controls. The relative amount of fibrinogen γ’ was decreased, since 
the total level of fibrinogen was increased compared to controls. Other studies reported 
both lower levels of fibrinogen γ’ and a lowered γ’ ratio in patients with VTE. 6,7 Thus, whether 
it is the absolute or relative amount of fibrinogen γ’ that corresponds with thrombosis risk, 
cannot be determined at this moment. One difference between our study and previous 
studies on fibrinogen γ’ in VTE is the moment of blood sampling. In our study samples were 
collected at the time of diagnosis, which was during the acute phase of the disease, whereas 
in the aforementioned studies samples were collected in the post-acute, stable phase of the 
disease. In these studies, fibrinogen γ’ and the γ’ ratio were similarly associated with risk of 
thrombosis, presumably because total plasma fibrinogen levels are a constant parameter in 
this phase of the disease. The increase of total fibrinogen levels in our PVT cohort is likely 
due to the moment of blood sampling during the acute thrombotic event. By calculating 
the γ’ ratio, we adjusted for the effects of the elevated total plasma fibrinogen on fibrinogen 
γ’ levels. In other words, the increase of γ’ levels in PVT patients was smaller than the increase 
of total fibrinogen levels.
 Previous studies cautiously suggested that the γ’ ratio is influenced by the acute phase of 
disease since a correlation with CRP levels was observed and altered γ’ ratios were observed 
during the acute phase of disease.11,12 To investigate a potential influence the acute phase 
reaction on our results, we evaluated the association between the γ’ ratio and CRP levels. We 
did not observe a significant correlation between the γ’ ratio and CRP levels in our population 
of PVT patients, nor was there a significant difference in γ’ ratio between patients with CRP 
levels >100 mg/L and those without an acute phase response (CRP < 10 mg/L). 
 Interestingly, our data show a function for FGG-H2 in the etiology of PVT. Firstly, we 
observed a clear association between FGG-H2 and decreased fibrinogen γ’ levels and γ’ 
ratio in both PVT patients and controls, which is in accordance with previous, reports in 
literature.6,7,12-14 Secondly, we observed a higher frequency of FGG-H2 in PVT patients than in 
controls, although not significantly (P = .08). The lack of a statistically significant association 
may be attributed to the relatively small sample size of cases and controls and therefore 
might represent a type II error. Interestingly, this finding is in line with earlier studies in 
which FGG-H2 is shown to be a risk factor for DVT. Uitte de Willige et al. were the first to 
show such an association in patients with DVT,7 which was later confirmed by three other 
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studies.6,8,9 The increased risk of PVT in carriers of the FGG-H2 haplotype corresponded with 
a 63% increase in risk per minor allele, which is in the same order of magnitude as reported 
earlier in other types of venous thrombosis.6-8 It has been proposed that FGG-H2 influences 
thrombosis risk by reducing fibrinogen γ’ levels and the γ’ ratio, which subsequently results 
in an elevated risk for venous thrombosis.6,7 Our findings may constitute additional evidence 
for this relation, although it is evident that additional studies are needed to extend our 
observations before we can evaluate the clinical relevance of these findings.
 An obvious question is how the fibrinogen γ’ chain may be related to the development 
of venous thrombosis. The alternative carboxy terminus of the fibrinogen γ’ variant contains 
an additional high-affinity binding site for thrombin. Studies indicate that this additional 
region inhibits thrombin activity,15 may act as an inhibitor of the intrinsic pathway by 
reducing thrombin generation,16,17 and may serve as a reservoir for active thrombin in the 
fibrin clot.18 Furthermore, the fibrinogen γ’ chain lacks the αIIbβ3 integrin which is required 
for platelet binding,19-21 and inhibits thrombin binding to GpIbα and thrombin cleavage of 
PAR1 on platelets,22,23 both of which inhibit platelet aggregation. Clearly, these mechanisms 
represent an antithrombotic tendency. A decrease in fibrinogen γ’ may therefore lead 
to a reduction of antithrombotic activity and subsequently result in an elevated risk of 
developing thrombosis. The γ’ chain also displays prothrombotic properties. It enhances 
plasma factor XIII activity and fibrin cross-linking, which have been shown to reduce 
fibrinolysis rates.24,25 In addition, clots made from purified fibrinogen γ’ display thinner fibers, 
increased branching and a reduced pore size, which are consistent with a prothrombotic 
phenotype.26,27 Our work, and that of others, suggests that the antithrombotic mechanisms 
of fibrinogen γ’ predominate in the pathogenesis of venous thrombosis.
 The strength of our study is that we used the largest cohort to date of consecutive 
patients with newly diagnosed non-cirrhotic, non-malignant PVT. Our study also has 
some limitations that need to be discussed. First, we performed a case-control study 
which has some inherent imperfections in its design. Because patients were included 
after the diagnosis, we cannot rule out the possibility that the altered fibrinogen γ’ ratio 
is the consequence rather than the cause of the disease. However, a prospective design 
is unfeasible for rare thrombotic manifestations as PVT. On the other hand, we found a 
clear association between genetic variation in FGG genes and fibrinogen γ’ levels and γ’ 
ratio, as has been reported before. In addition, our results suggest an association between 
FGG-H2 and risk of PVT. These associations are independent of time of blood sampling, and 
provide a clear indication that fibrinogen γ’ may indeed play a role in the pathophysiology 
of thrombosis at this uncommon site. Secondly, our control group had a mean age that was 
somewhat lower than in the group of PVT patients. Since there was a significant overlap in 
age between these groups, we statistically adjusted for the difference on this variable using 
regression methods. 
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In conclusion, we observed a clear association between a decreased γ’ ratio and PVT. In 
addition, this study provides the first support of an increased frequency of FGG-H2 in 
PVT, which may contribute to the development of thrombosis at this uncommon site by 
decreasing the γ’ ratio. 
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Fibrinogen γ’ is a common fibrinogen γ chain protein variant, which contains a unique 
extension with both antithrombotic (inhibits thrombin and platelet aggregation) and 
prothrombotic properties (enhances factor XIII activity and fibrin cross-linking).1 Fibrinogen 
γ’ and genetic variation in fibrinogen γ genes (FGG) have been associated with susceptibility 
to venous thrombosis.2-4 Recently, our group showed that decreased relative levels of 
fibrinogen γ’ to total fibrinogen (γ’ ratio) and the FGG-H2 haplotype may contribute to the 
development of non-cirrhotic, non-malignant portal vein thrombosis (PVT).5 In the current 
study, we investigated the potential role of variations in fibrinogen γ’ and FGG genes in 
primary Budd-Chiari syndrome (BCS). BCS is another manifestation of venous thrombosis 
located in the splanchnic veins, which is characterized by thrombosis of the hepatic veins 
and/or the suprahepatic inferior vena cava.6 In contrast to PVT patients, patients with 
BCS frequently have liver synthesis dysfunction, which may affect pre-mRNA splicing and 
therefore influence fibrinogen γ’ levels. 
 We performed a case-control study in which patients with primary BCS were recruited 
from the European Network for Vascular Disease of the Liver (EN-Vie) study and a cohort of 
healthy, age- and gender- matched controls.7 We additionally studied 75 patients with liver 
cirrhosis without thrombosis and 30 healthy controls to evaluate the potential association 
between the γ’ ratio and liver function. Total fibrinogen, fibrinogen γ’ antigen levels and 
FGG haplotypes were determined as described previously.5 Patients and controls agreed to 
participate in the study by written informed consent, in accordance with the Declaration of 
Helsinki. Statistical analysis was conducted with PASW statistics, version 17.0 (SPSS, Chicago, 
Illinois) and haplotype analysis was performed with Haplo.Stats version 1.4.4. 
 Median age in BCS patients (n = 118) was 37.8 years (IQR: 28-51) and 68 were females 
(58%) (Table 1). Median age in controls (n = 103) was 36.9 years (IQR: 28-50) and 60 were 
females (58%). Mean fibrinogen γ’ levels in BCS were higher (0.50 ± 0.24 g/L) compared 
to controls (0.42 ± 0.15 g/L; P < .01). Mean total fibrinogen levels (2.98 ± 0.96 g/L) were 
comparable with controls (2.76 ± 0.54 g/L; P = .42). As a result, the γ’ ratio was elevated 
(0.174 ± 0.08) compared to controls (0.153 ± 0.05; P = .02), corresponding with a mean γ’ 
ratio increase of 14% compared to controls (Table 2). The γ’ ratio was increased with 3% 
(P = .71), 16% (P = .02) and 23% (P = .02) according to Child-Pugh class A (n = 19), B (n = 43) 
and C (n = 21), respectively (Figure). 
 The distribution of the FGG genotypes in the control subjects was in Hardy-Weinberg 
equilibrium for the two tested SNPs and was similar to those reported in previous studies.2,4,8 
Frequencies of FGG-H2 and FGG-H3 were 19.0% and 27.3% and 18.9% and 30.0% in BCS 
patients and controls, respectively. FGG-H2 (OR 0.97; 95% CI: 0.57–1.63) and FGG-H3 (OR 
0.86; 95% CI: 0.57–1.33) were not associated with risk of BCS.
 To investigate the influence of liver synthesis function on the γ’ ratio, we assessed the 
γ’ ratio in patients with liver cirrhosis. In patients with liver cirrhosis, the mean γ’ ratio was 
increased with 13% (P = .01) compared to healthy controls. The mean γ’ ratio was increased 
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with 9% (P = .12), 15% (P = .04) and 21% (P = .01) in Child-Pugh class A (n = 34), B (n = 28) 
and C (n = 13) compared controls, respectively. The mean γ’ ratio was thus equally elevated 
in BCS and liver cirrhosis patients compared to their respective control groups. In addition, 
the γ’ ratio was similarly increased with increasing liver dysfunction in cirrhotics and BCS 
patients, as represented by the Child-Pugh classification (Figure). 
Table 1. Baseline characteristics in patients with Budd-Chiari syndrome and controls
 
Budd-Chiari syndrome  
(n = 118)
Controls  
(n = 103)
P-value
Median age, y (Q1–Q3) 37.8 (28–51) 36.9 (28–50) 0.74
Females, n (%) 68 (58) 60 (58) 0.93
Clinical manifestations, n (%)
Abdominal distension 82 (69) – –
Gastrointestinal bleeding 4 (4) – –
Ascites 99 (84) – –
Hepatomegaly 80 (68) – –
Splenomegaly 60 (51) – –
Laboratory characteristics*
ALT (ULN) 1.3 (0.8–4.7) – –
AST (ULN) 1.4 (0.9–3.6) – –
Bilirubin (μmol/L) 29 (17–46) – –
Albumin (g/L) 33 (29–38) – –
Factor V (U/ml) 61 (44–106) – –
Creatinin (μmol/L) 80 (67–95) – –
Thrombophilia
Inherited thrombophilia 26 (22) – –
Acquired thrombophilia 89 (75) – –  
Data are presented as proportions for categorical variables and as median (interquartile range) for continuous variables. 
Abbreviations: ALT, alanine aminotransferase; AST, aspartate aminotransferase; ULN, upper limit of normal value.
*Not all measurements were available in the individual patients
Table 2. Fibrinogen γ’ levels, total fibrinogen levels, and γ’ ratio in patients with Budd-Chiari syndrome 
and corresponding controls
Budd-Chiari syndrome  
(n = 105)
Controls  
(n = 103) P-value
Fibrinogen γ’ (g/L)  0.50 ± 0.24 0.42 ± 0.15 <0.01
Total fibrinogen (g/L) 2.98 ± 0.96 2.76 ± 0.54 0.42
γ’ ratio 0.174 ± 0.08 0.153 ± 0.05 0.02
Presented are means ± standard deviation.
P, BCS vs. controls, adjusted for age and gender. 
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Figure. This figure depicts the mean fibrinogen γ’ ratios in patients with Budd-Chiari syndrome and 
liver cirrhosis, which were standardized according to the levels in the corresponding, healthy controls. 
*denote P-values <0.05 and represent the difference in γ’ ratio in Child-Pugh class compared to 
corresponding, healthy controls, adjusted for age and gender. 
Our study shows that the γ’ ratio is strongly dependent upon liver function and that the 
observed elevated γ’ ratio in BCS is likely to be caused by liver dysfunction. It is well known 
that liver synthesis function is often affected in patients presenting with BCS due to the 
venous outflow obstruction and subsequent damage of liver parenchymal cells.9 Alterations 
in pre-mRNA splicing have also been reported for other proteins in patients with chronic 
liver dysfunction.10 The γ’ ratio was comparable to controls in the subgroup of BCS patients 
with a preserved liver synthesis function (Child-Pugh A), suggesting that the γ’ ratio is not 
associated with BCS. Neither did we observe an association between risk of thrombosis and 
FGG haplotypes, as has been reported for other forms of venous thrombosis2-4 and appears 
to be present in PVT.5
 Our data thus indicate a difference in the involvement of the fibrinogen γ’ chain in the 
pathogenesis of BCS and PVT, which is an unexpected finding. Both are forms of venous 
thrombosis and their etiology generally shows a considerable overlap.9 On the other hand, 
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it is increasingly recognized that despite several similarities, also apparent differences in 
the risk profile of patients with BCS and PVT exist.11 The different role of fibrinogen γ’ in clot 
formation may be related to differences in shear stress conditions or vascular bed specific 
factors, as has been suggested previously.1
 In conclusion, the results of this multicenter case-control study indicate that fibrinogen 
γ’ is not associated with the development of BCS. These findings provide additional evidence 
that clear differences in the risk profile of BCS and PVT patients exist. 
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ABSTrACT
Thrombolytic therapy in patients with acute, extended splanchnic venous thrombosis 
is controversial. Here we present our single-center experience with locally delivered, 
thrombolytic therapy in these patients. All consecutive patients (n = 12) with acute, extended 
splanchnic venous thrombosis who underwent local thrombolytic therapy in our hospital, 
were included in this study. Thrombolytic therapy was successful for three thrombotic 
events and partially successful for four thrombotic events. Two patients developed minor 
procedure related bleeding (17%). Six patients (50%) developed major procedure related 
bleeding, with a fatal outcome in two. In conclusion, local thrombolytic therapy in patients 
with acute, extended splanchnic vein thrombosis is found to be associated with a high rate 
of procedure related bleeding. Therefore, thrombolysis should be reserved for patients in 
whom the venous flow cannot be restored by using conventional anticoagulant therapy or 
stent placement across the thrombosed vessel segment. 
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iNTroDUCTioN
Splanchnic venous thrombosis (SVT) comprises thrombosis of the hepatic veins and 
the portal venous system. It includes the Budd-Chiari syndrome (BCS), characterized 
by hepatic outflow obstruction,1 and portal vein thrombosis (PVT).2 SVT is often related 
to prothrombotic disorders3,4 or caused by underlying haematological diseases that 
predispose to hypercoagulability, such as myeloproliferative diseases and paroxysmal 
nocturnal haemoglobinuria.5,6 One of the treatment options in SVT patients is locally 
delivered transcatheter thrombolytic therapy, which is mainly used in patients with acute, 
combined thrombosis of both portal and hepatic veins. Several case studies or small case 
series describe successful thrombolytic therapy in SVT patients with a low incidence of 
bleeding complications.7-14 However, these reports should be interpreted with caution in 
view of a potential publication bias of successful cases. Only two larger studies have been 
performed in which success and complication rates vary widely.15,16 Therefore, it is difficult 
to properly assess the risk/benefit ratio and thrombolytic therapy remains controversial. 
Here we present our single-center experience with local thrombolytic therapy in a series of 
consecutive patients with SVT. 
PATiENTS AND mETHoDS
All SVT patients who underwent locally delivered thrombolytic therapy in our hospital, 
between January 1996 and December 2007, were included in this study. Clinical records 
of all patients were reviewed and demographics, etiology, clinical presentation, duration 
of symptoms, details of thrombolytic therapy, outcome, complications and follow-up 
were reported in a standardized way. The diagnosis of SVT was established by computed 
tomography, transcatheter portography, magnetic resonance imaging or Doppler 
Ultrasound. The obstruction was graded partially when there was a significant remaining 
patent vein lumen or complete. The Child-Pugh score was used as an indication of liver 
function prior to thrombolytic therapy in patients with cirrhosis and BCS. Patients were 
followed from initiation of thrombolysis until death, study closure (December 31, 2007), or, 
in case of loss to follow up, the last date of visit. Survival rates were calculated by means of 
the Kaplan-Meier method.
 Patients were considered for thrombolysis if they met the following criteria. First, only 
patients with an acute thrombosis (duration of symptoms ≤14 days) were considered 
for thrombolytic therapy. Second, thrombolytic therapy was only used in patients with 
thrombosis in two or more vessel systems in the splanchnic area, e.g. thrombosis of the 
hepatic veins combined with PVT. Third, in most patients thrombolysis was considered 
after standard anticoagulant therapy had proven insufficient, i.e. in patients exhibiting 
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a progressive thrombosis or a clinical deterioration despite anticoagulation. Informed 
consent was obtained from each patient after informing them on the possible risks and 
benefits of the treatment. 
 To facilitate creation of the transhepatic tract from the liver vein (inferior caval vein 
in BCS) to the portal vein during transjugular intrahepatic portosystemic shunt (TIPS) 
placement, a marker catheter was introduced in the portal vein by the direct percutaneous 
transhepatic route and by using ultrasound guidance. The decision to deliver trombolytic 
therapy through a percutaneously inserted transhepatic catheter, or through a catheter 
placed through a pre-existing or specially created TIPS, was not a constant but rather 
evolved over time – influenced also by literature suggesting the benefit of additional 
TIPS for thrombolysis.17-19 Thrombolysis was considered successful when vessel patency 
and blood flow were restored, as observed during venography, and considered partially 
successful when flow was restored in some, but not all, thrombosed veins. Thrombolysis 
was considered unsuccessful when no lysis was obtained in any of the occluded vessels. 
Thrombolytic therapy was discontinued in case of resolution of the thrombus or in case of 
severe bleeding. 
 All patients were initially treated by APTT-controlled (APTT ratio 2.2–2.9, reflecting an 
anti Xa activity of 0.3–0.7 U/ml) infusion of unfractionated heparin (UFH) or a therapeutic 
dose of low molecular weight heparin (LMWH, dalteparin, 200 U/kg BW s.c.). Recombinant 
tissue type plasminogen activator (Actilyse®, Boehringer-Ingelheim, Germany), rtPA, 
was used as thrombolytic agent and was delivered by means of a locally placed catheter. 
Patients were treated by continuous infusion of 2-4 mg/hr rtPA, in some cases preceded by 
a 4–10 mg bolus injection. In one patient urokinase was administered. During thrombolysis 
all patients were admitted to an intensive care unit for hemodynamic monitoring. Low dose 
UFH was continued during thrombolytic treatment (10.000 IU/ 24 hours). After thrombolytic 
treatment was stopped, UFH was again administered in a therapeutic dosage and was 
discontinued once the patient was adequately anticoagulated with vitamin K antagonists. 
After discharge from hospital, patients were followed at the outpatient department of our 
hospital.
rESULTS
Patient characteristics
Twelve patients (58% male) with a mean age of 32 years (range 26-53) underwent 
thrombolytic therapy and were included in this study. Six patients had BCS with additional 
thrombosis in the portal system. The majority of patients had an underlying pro-thrombotic 
haematological disorder. Patient characteristics, including etiology and indication for 
thrombolytic therapy, are presented in Table 1. 
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Details of thrombolytic therapy and outcome
Twelve patients were treated with thrombolytic therapy for thirteen thrombotic events. 
One patient (pt. 12) was treated twice, because of renewed thrombosis five days after initial 
successful thrombolysis despite heparin therapy. Route of delivery of the thrombolytic 
agent was percutaneous transhepatic (n = 4), transjugular transhepatic (n = 6) or other 
(n = 3). The total percutaneous transhepatic catheters amounted to eight, in which they 
were either used as a marker catheter to facilitate TIPS placement, or as an indwelling 
catheter trough which the thrombolytic agent was administered. TIPS insertion/revision 
was performed in six patients. Thrombolysis was successful for three thrombotic events in 
two patients (pt. 7 and 12). Therapy was partially successful in four patients (pt. 2, 5, 6 and 
8). Details of thrombolytic therapy are presented in Table 2. Five out of six procedures which 
were combined with a TIPS insertion/revision were (partially) successful.
Complications
Two patients developed minor bleeding, not requiring transfusion, after cessation of 
thrombolytic therapy (pt 2 and 7). Six patients developed major bleeding necessitating 
discontinuation of thrombolytic treatment. In two of these patients, thrombolysis had been 
partially successful at that time (pt. 5 and 8). 
 One patient died directly related to bleeding (pt. 3). This BCS patient had additional 
PVT and MVT and developed a fatal massive sub-capsular liver haemorrhage resulting 
in hypovolemic shock. Patient 11 died two weeks after thrombolytic therapy, which was 
complicated by bacterial peritonitis and renal failure after massive abdominal bleeding. The 
patient eventually died from multiple organ failure. The death of this patient was considered 
to be partly caused by procedure related bleeding.
 Four patients developed major, but nonfatal, bleeding, including retroperitoneal 
bleeding (pt 4), intraperitoneal bleeding (pt 5), massive intra-abdominal bleeding (pt 8) and 
a subcapsular liver haematoma (pt 9) (Table 2). 
Clinical parameters related to outcome
Laboratory evaluation showed a marked decrease of fibrinogen in patient 2, 3, and 11 (pre-
treatment values of 3.6 g/l, 2.2 g/l, and 2.5 g/l, respectively [normal 1.5–3.6 g/l]) to a nadir 
of 0.6 g/l, 0.3 g/l and 0.7 g/l, respectively, during thrombolytic treatment. Patient 5 already 
had a pre-treatment fibrinogen of 0.7 g/l and remained <1.0 g/l during thrombolysis. 
These four patients all developed bleeding complications (of which three major bleeding). 
The two patients with a fatal outcome showed the lowest fibrinogen levels of all patients 
(0.3 g/l and 0.4 g/l) during thrombolytic therapy. None of the four patients without bleeding 
complications had fibrinogen levels <1.0 g/l (Table 3). 
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The Child-Pugh score was obtained for six patients with BCS and two patients with 
liver cirrhosis. Six patients had a Child-Pugh score >7 and were considered to have liver 
dysfunction. Four of these patients developed major bleeding complications, of which 
two were fatal. The two patients with a fatal outcome exhibited the highest Child-Pugh 
scores. Bleeding complications were also observed in four of six patients with a normal liver 
function, of which two were major (Table 3). 
Table 3. Fibrinogen levels and liver function during thrombolytic therapy in relation to bleeding 
complications
 
 
Number of patients
 
major bleeding
n (%)
minor bleeding
n (%)
No complications
n (%)
Fibrinogen <1.0 g/l 4 3* (75%) 1 (25%) 0 (0 %)
Fibrinogen >1.0 g/l 8 3 (38%) 1 (13%) 4 (50%)
Liver dysfunction 6 4* (67%) 0 (0 %) 2 (33%)
No liver dysfunction 6 2 (33%) 2 (33%) 2 (33%)
*Outcome was fatal in two patients.
Follow-up
The mean time of follow-up was 3.7 years (range 3 days – 10.6 years). Survival according to 
Kaplan-Meier analysis at 1, 3 and 5 years was 67% (95% CI: 40%–93%). One patient was lost 
to follow-up. Patient 1 and 4 died 5.6 and 2.9 months after thrombolysis, respectively, due to 
multiple complications of combined BCS and PVT, which were not related to thrombolysis. 
Patient 7 died 7.5 years after thrombolysis from lymphoma. 
DiSCUSSioN
Both systemic and local administration of thrombolytics have been described in the 
treatment of SVT, but the latter is preferred.15,16,20 Despite several successful single-case 
reports and two larger case-series, thrombolytic treatment remains controversial.7-16 In our 
study, one of the largest series on thrombolysis in SVT patients, we report slightly lower 
success rates accompanied by a previously unreported high rate of procedure related 
bleeding. 
 When thrombolytic therapy is indicated, TIPS placement, creating a patent portal 
venous outflow tract to the systemic venous circulation, followed by local administration of 
thrombolytic agents in the portal vein appears an effective approach. This is supported by 
previous reports.17-19 In three out of six TIPS procedures, major bleeding occurred and one 
patients eventually died, however, it is difficult to determine whether this is related to the 
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TIPS procedure itself. The invasive procedure necessary for using local thrombolysis has a 
great overlap with the TIPS procedure. Therefore, it seems prudent to simultaneously create 
a TIPS when performing thrombolysis, as a patent TIPS has been shown to be beneficial in 
terms of clinical improvement and survival in SVT patients.21-23
 The relation between fibrinogen levels and bleeding risk suggests that, for safety reasons, 
it is prudent to monitor fibrinogen levels during thrombolysis and fibrinogen should be 
supplemented if levels fall <1.0 g/l. Our results indicate that liver dysfunction might be a 
risk factor for procedure related bleeding, implying that thrombolysis should be cautiously 
used in these patients. The association between the percutaneous transhepatic approach 
and bleeding concurs with previous reports, where also the transjugular approach was 
preferred.16,24,25
 A limitation of our study is that it is a single-center, retrospective study with a limited 
number of patients. Patients are heterogeneous in terms of etiology, clinical presentation, 
extent of thrombosis, baseline health status and details of thrombolytic therapy. Our study 
population is highly selected from a large number of cases referred to our specialized tertiary 
care center and most of the patients had a deteriorating clinical course before thrombolytic 
therapy was initiated. The strength of our study is that it includes all patients that have been 
treated avoiding publication bias of successful cases. 
 In conclusion, in a series of consecutive patients receiving locally delivered thrombolysis 
for acute, extended SVT we found a previously unreported high rate of bleeding 
complications. These patients generally have a poor prognosis26 and it is up to the treating 
physician to determine whether the potential benefits of thrombolysis outweigh the 
apparent risks associated with the procedure. Based on our findings, and previous reports 
in the literature, we have come to the following preferred approach in patients with acute, 
extended SVT. Start with conventional anticoagulant therapy and in case of insufficient 
results proceed to TIPS placement. If venous flow cannot be restored by either of these 
treatment modalities, local thrombolytic therapy, administered via transjugular approach, 
can be considered. 
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ABSTrACT
Myeloproliferative neoplasms (MPN) are frequently identified as an underlying cause 
in patients with non-cirrhotic portal vein thrombosis (PVT). The aim of this study was 
to describe the long-term outcome of patients with PVT and MPN. A cohort study was 
performed including all adults patients referred to our hospital between 1980 and 2008 with 
noncirrhotic, non-malignant PVT and confirmed MPN. A total of 44 patients (70% female) 
were included, with a median age at PVT-diagnosis of 48 years (range 18–79). In 31 patients 
(70%) PVT was the first manifestation of a MPN. Additional risk factors for thrombosis were 
present in 20 patients (45%). Median follow-up was 5.8 years (range 0.4–21). Twenty-three 
patients (52%) were treated with oral anticoagulants after diagnosis of PVT, of whom 15 
(34%) received long-term therapy. During follow-up, 17 patients (39%) experienced at least 
one episode of gastrointestinal bleeding. Additional thrombotic events occurred in 12 
patients (27%). Twelve patients (27%) had progression of the underlying MPN. Seventeen 
patients (39%) died at a median age of 64 years (range 30–88). Death was directly related 
to end-stage MPN in 8 patients (47%) and to a new thrombotic event in 3 patients (18%). 
No patients died from gastrointestinal bleeding. In conclusion, PVT is often the presenting 
symptom of an underlying MPN, highlighting the need for thorough screening for this 
disease. Recurrent thrombosis is a common and severe complication in patients with PVT 
and MPN. Mortality is primarily related to the underlying MPN and not to complications of 
portal hypertension. 
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iNTroDUCTioN
Development of thrombosis in the extrahepatic portal vein is an uncommon finding. 
The etiology of portal vein thrombosis (PVT) is heterogeneous and involves both local 
and systemic prothrombotic factors.1 Liver cirrhosis and hepatobiliary malignancies are 
considered to be the most important local precipitating factors of PVT.2,3 In the absence of 
cirrhosis or local tumors, PVT has a better survival. Often there is a prominent role of systemic 
thrombophilia in these patients.4,5 The most common systemic risk factor encountered in 
patients with non-cirrhotic, non-malignant PVT is a myeloproliferative neoplasm (MPN).6 
MPNs encompass a group of disorders that share features of increased myeloproliferation, 
resulting in overproduction of mature, functional blood cells. The three main Philadelphia 
chromosome negative MPNs are polycythemia vera (PV), essential thrombocythemia (ET) 
and idiopathic myelofibrosis (IMF).7
 MPNs are found as an underlying cause in approximately 20–30% of the patients with 
non-cirrhotic, non-malignant PVT.8,9 Especially in young adults, development of PVT can be 
a first manifestation of an underlying MPN. However, diagnosis of MPN in these patients can 
be difficult because typical signs in peripheral blood (e.g. elevated hemoglobin or platelets) 
may be absent due to hypersplenism and other consequences of portal hypertension.10 
Although a number of studies have been published concerning the distribution of etiological 
factors and clinical presentation of patients with PVT, little is known about the subgroup 
of cases with confirmed MPN. Due to the rarity of this disease, scarce data is available on 
the long-term outcome of these patients, including the incidence of recurrent thrombosis, 
complications of portal hypertension, survival and causes of death. 
 To describe the natural disease course and main complications, we conducted a 
cohort study of patients with non-cirrhotic, non-malignant PVT and an underlying MPN. 
Additionally, we determined long-term survival and causes of death in these patients.
mETHoDS
Study population
Patients with PVT and MPN were identified using our computerised hospital registration 
system. We selected all adult patients who were registered with a diagnosis of PVT between 
January 1980 and December 2008. Patients with cirrhosis, Budd-Chiari syndrome and/
or overt hepatobiliary malignant disease were excluded. For all patients clinical data was 
collected on medical history, disease presentation, treatment, clinical events during follow-
up and outcome through review of the medical charts. 
 PVT was defined as a partial or complete thrombotic obstruction of the main portal 
vein, as documented by appropriate radiological abdominal imaging (i.e. duplex 
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ultrasound, computed tomography, magnetic resonance imaging or venography) or during 
laparotomy. Date of PVT diagnosis was defined as the date that imaging first demonstrated 
thrombosis. The presence of cirrhosis was excluded through liver biopsy, imaging and/or 
the absence of biochemical evidence of liver failure. Subtype of MPN was retrospectively 
classified according to the WHO 2008 guidelines, confirmed by an expert in the field 
(FWL).11 Diagnostic work-up for MPN included peripheral blood cell counts, bone marrow 
morphological examination, endogenous erythroid colony (EEC) formation assessment, 
erythropoietin levels and/or JAK2V617F mutation analysis. 
 Follow-up was from date of diagnosis of PVT until death, study closure in May 2009, or, 
in case of loss to follow-up, date of last visit.
Statistics
Quantitative data were expressed as median values, whereas percentages were used for 
qualitative data. Differences between subgroups were studied using the Mann Whitney U 
and Chi square test for continuous and categorical variables, respectively. Survival curves 
were calculated using the Kaplan-Meier method and comparison of survival functions 
was based on log-rank testing. Overall survival rates were measured from the date of PVT 
diagnosis and patient survival was censored at death or loss to follow-up. All statistical tests 
were 2-sided, with P-values of <.05 denoting statistical significance. Statistical analyses were 
performed using the Statistical Package for the Social Sciences (SPSS) version 16.0 software 
package for Windows (Chicago, IL).
rESULTS
Patient characteristics
A total of 44 patients with PVT and an underlying MPN were included in this study. Median age 
at diagnosis of PVT was 48 years and 70% of the patients was female. General characteristics 
at time of PVT diagnosis are summarized in Table 1. Based on clinical presentation and results 
of imaging, 13 patients (30%) presented with acute PVT, whereas the remaining 31 patients 
already had signs of a portal cavernoma and/or portal hypertension (e.g. gastroesophageal 
varices, variceal bleeding or splenomegaly) at time of diagnosis, consistent with chronic 
PVT. 
 In 30 patients (68%) diagnosis of MPNs fulfilled WHO 2008 criteria. Three other patients 
without overt features of MPNs were JAK2V617F positive, confirming MPNs in these cases. 
The remaining eleven patients, in whom the current WHO criteria were not strictly met, 
had highly suspect bone marrow and/or laboratory findings. These individuals were all 
diagnosed with MPN by their treating hematologists. Serum erythropoietin levels and/or 
EEC formation were measured in 18 patients (41%). The JAK2V617F mutation was present in 
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26 out of 29 tested patients (90%). Subtype of MPNs was classified as PV in 14 patients, ET in 
12 cases, IMF in 7 patients and as unclassified in 11 patients.
Table 1. General characteristics of 44 patients with PVT and MPN
  Number of patients (%)
Sex – female 31 (70)
Age at PVT diagnosis (years)* 48 (18–79)
PVT prior to MPN diagnosis 31 (70)
Acute PVT 13 (30)
Clinical manifestations at presentation†
 Splenomegaly at imaging 33 (75)
 Abdominal pain 31 (70)
 Ascites 15 (34)
 Variceal bleeding 8 (18)
 Hepatomegaly at imaging 8 (18)
 Asymptomatic 7 (16)
Localization of thrombosis
 Isolated PV 21 (48)
 PV, SMV, SV 15 (34)
 PV, SV 5 (11)
 PV, SMV 3 (7)
Abbreviations: PVT, portal vein thrombosis; MPN, myeloproliferative neoplasm; PV, portal vein; SMV, superior mesenteric 
vein; SV, splenic vein. 
*Median (range).
†At the time of PVT diagnosis, patients can have more than one clinical manifestation.
In 31 patients (70%) PVT was the initial manifestation of an underlying MPN. Of 13 patients 
with a previous diagnosis of MPN, 11 patients had been diagnosed at least one year prior 
to development of PVT. Median time between diagnosis of PVT and subsequent diagnosis 
of MPN in patients not previously known with MPN was 7 months (range 0–175 months). 
In the majority of these cases laboratory values around time of PVT-diagnosis were not 
suggestive of an underlying MPN. An elevated hemoglobin level was present in 2 patients 
(6%) and 9 patients (29%) had thrombocytosis. 
 Out of all the cases, five patients (11%) had a previous history of venous thrombosis 
and ten patients (23%) had a positive family history for thrombosis. Analysis of local and 
systemic prothrombotic factors revealed that 20 patients (45%) had another etiological 
factor besides MPN (Table 2). In 5 cases (11%) more than one additional risk factor for 
thrombosis was present. Use of oral contraceptives was a common systemic risk factor for 
PVT. Among women in the age group of 15 to 49 years, oral contraceptives were used at 
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the time of diagnosis in 11 of 21 patients (52%). Presence of the prothrombin G20210A 
mutation was tested in 29 patients (66%) but was not detected in any of the cases.
Table 2. Additional prothrombotic factors identified in 44 patients with PVT and MPN
  Number of patients (%)
Systemic prothrombotic factors
 Oral contraceptive use* 11 (35)
 Natural anticoagulant deficiency†‡ 4 (14)
 Factor V Leiden mutation‡ 2 (6)
 Antiphospholipid antibodies‡ 1 (4)
 Prothrombin G20210A mutation‡ 0 (0)
 Pregnancy 1 (2)
Local prothrombotic factors
 Abdominal surgery (< 6 months) 4 (9)
 Intra-abdominal infection 3 (7)
Abbreviations: PVT, portal vein thrombosis; MPN, myeloproliferative neoplasm.
*Percentage of female patients is given respectively.
†Protein C, protein S or antithrombin deficiency.
‡Natural anticoagulant deficiency, Factor V Leiden mutation, antiphospholipid antibodies and prothrombin G20210A 
mutation were tested in 28, 35, 25 and 29 patients, respectively.
Follow-up and treatment
Median follow-up time for the total cohort was 5.8 years (range 0.4 – 21 years). Two patients 
(4%) were lost to follow-up at 66 and 76 months after PVT diagnosis, respectively. 
 In total, twenty-three patients (52%) received anticoagulation therapy following 
diagnosis of PVT, consisting of either vitamin K antagonists (VKA), low-molecular-weight 
heparin or unfractionated heparin. Long-term anticoagulation with VKA, considered as 
lifelong, was given in fifteen cases after diagnosis of PVT (34%) whereas in the other eight 
patients anticoagulation therapy was discontinued after a median period of 9 months 
(range 0.5 – 39 months). Treatment with anticoagulation was initiated significantly more 
often in cases presenting with acute PVT as compared to those with chronic PVT (77% vs. 
42%, respectively, P = .034).
 Treatment for the underlying MPN was given in 30 patients (68%) during follow-up after 
PVT. Twenty-two patients (50%) received anti-platelet therapy, consisting of either aspirin 
(n = 19) or clopidogrel (n = 3). In two patients treatment was stopped after 2 and 3 months, 
respectively, due to suspected gastrointestinal bleeding and intolerance for aspirin. Of the 
other 20 patients, 12 cases (27%) received long-term treatment with anti-platelet drugs 
following diagnosis of PVT. Cytoreductive therapy with hydroxyurea was initiated in 21 
cases (48%), with varying dosages and duration of therapy. Other interventions consisted 
Ch
ap
te
r 9
127Long-term follow-up of MPN in PVT | 
of regular phlebotomies (n = 10), treatment with alpha-interferon (n = 8), busulfan (n = 3) or 
anagrelide (n = 1). 
 Of the thirteen patients diagnosed with MPN prior to PVT, seven cases were being 
treated for MPN at the time of PVT. One patient was on hydroxyurea therapy, two patients 
were treated with aspirin, two patients received a combination of aspirin and hydroxyurea 
and in another two patients regular phlebotomies were performed. Levels of hemoglobin 
and platelets in these patients were all within the normal range around time of PVT.
Complications
The most common complications that occurred during follow-up are summarized in 
Table 3. In twelve patients (27%) at least one other thrombotic event occurred in addition 
to PVT with a total of 14 thrombotic events. Most frequent localizations were extension 
of thrombosis into the splenic and/or superior mesenteric vein (n = 3) and ischemic 
stroke (n = 3). Recurrent thrombosis occurred in 3 of 7 patients (43%) carrying additional 
thrombophilic factors as compared to 9 of 37 (24%) patients without thrombophilia 
(P = .37). Three patients experienced a new episode of thrombosis despite treatment 
with VKA at that time. Comparing cases with and without long-term VKA therapy, there 
was no significant difference in the frequency of additional thrombotic events (20% vs. 
31%, P = .50). A new venous thrombosis occurred in 1 of 15 cases (7%) on long-term VKA 
as compared to 7 of 29 cases (24%) not receiving anticoagulation (P = .23). None of the 
patients that developed recurrent thrombosis were being treated with anti-platelet drugs 
when thrombosis developed. A schematic overview of the relationship between long-term 
use of VKA or antiplatelet therapy and the occurrence of new thrombotic events is given in 
Figure 1. After recurrent thrombosis, another 7 patients were started on lifelong treatment 
with either VKA (n = 3) or aspirin (n = 4).
 Around the time of PVT diagnosis an upper gastro-intestinal endoscopy was performed in 
38 patients, of whom 30 patients (79%) had esophagogastric varices. Grade III-IV esophageal 
varices according to Pacquet were found in 18 patients (47%). Overall, 32 documented 
episodes of variceal bleeding occurred in 17 patients (39%), most frequently resulting from 
esophageal varices. Endoscopic treatment was the first-line therapy during active bleeding 
episodes. Variceal bleeding was the presenting symptom of PVT in eight patients (18%) and 
recurrent bleeding occurred in four of these patients. Of 36 patients that had no signs of 
bleeding at presentation, 9 patients (25%) experienced at least one bleeding event during 
follow-up and five cases had recurrent bleeding. Long-term treatment with anticoagulation 
did not appear to influence the risk of variceal bleeding. Of 36 patients without variceal 
bleeding at diagnosis, 16 cases were given long-term anticoagulation therapy. Subsequent 
bleeding episodes during follow-up occurred in two patients on anticoagulation (13%) and 
in seven patients not treated with long-term anticoagulation (35%, P = .25).  
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Table 3. Complications during follow-up of 44 patients with PVT and MPN
  Number of patients (%)
Episode of gastrointestinal bleeding 17 (39)
 Events per person* 1 (1–5)
 Time between PVT and first bleeding event (yrs)†* 2.3 (0.5–5.1)
Additional thrombotic event‡  12 (27)
 Venous thrombosis 9 (20)
 Extension of thrombosis to SMV or SV 3
 Jugular and/or axillary vein thrombosis 3
 Pulmonary embolism 1
 Femoral vein thrombosis 1
 Sinus sagittalis thrombosis 1
 Arterial thrombosis§ 5 (11)
 Ischemic CVA 3
 Arterial thrombosis of lower extremity 1
 Intestinal infarction due to occlusion of celiac artery 1
 Time between PVT and subsequent thrombosis (yrs) 7.5 (0–18)
Progression of MPN 12 (27)
 Secondary myelofibrosis 7 (16)
 Acute myeloid leukemia§ 4 (9)
 End-stage myelofibrosis¶ 5 (11)
 Time between MPN diagnosis and disease progression (yrs) 9.7 (1–17)
Abbreviations: PVT, portal vein thrombosis; MPN, myeloproliferative neoplasm; CVA, cerebral vascular accident. 
*Median (range).
†Only considered in patients that did not present with an episode of bleeding at diagnosis (n = 9).
‡One patiënt experienced two additional episodes of venous thrombosis, one patient experienced two arterial thrombotic 
events. 
§Two patients progressed to AML after developing secondary myelofibrosis.
¶Two patients developed end-stage myelofibrosis after first progressing to secondary myelofibrosis.
Progression of the underlying MPN occurred in 12 patients (27%) after a median period of 
9.7 years (range 1 – 17) following MPN diagnosis. Five patients with PV and two patients 
with ET developed secondary myelofibrosis, of which two cases subsequently progressed 
to acute myeloid leukemia (AML). Additionally, one patient with PV and one patient with 
IMF also developed AML, for a total of four patients with AML. Another three patients with 
IMF progressed to end-stage myelofibrosis. One patient with secondary myelofibrosis 
underwent successful allogenic stem cell transplantation and in one patient AML was 
successfully treated by intensive chemotherapy.
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N = 44
N = 29N = 15
N = 9 N = 6 N = 23 N = 6
patients with PVT and MPN
treatment with VKA no VKA
no aspirin with aspirin no aspirin with aspirin
13 patients known with MPN 
of whom 4 were treated with 
aspirin
arterial thrombosis (n = 2)
venous thrombosis (n = 1)
no thrombotic events arterial thrombosis (n = 2)
venous thrombosis (n = 7)
no thrombotic events
Figure 1. Flow diagram depicting the relationship between treatment with vitamin K antagonists 
(VKA) and/or antiplatelet drugs during follow-up and the occurrence of additional thrombotic events. 
Only long-term treatment, considered as lifelong, was taken into account. PVT, portal vein thrombosis; 
MPN, myeloproliferative neoplasm.
mortality
Seventeen patients (39%) died during follow-up, with a median age at death of 64 years 
(range 30 – 88 years). Table 4 displays the different causes of death. In 8 patients (47%) 
death was directly related to end-stage MPN or AML. A total of five patients, two cases 
with PV and three cases with IMF, died from end-stage myelofibrosis. A new thrombotic 
event was the cause of death in 18% of the cases. One of these patients was receiving 
anticoagulation therapy at the time of death and in another patient treatment with VKA 
had been discontinued 3 months before death. In both patients ischemic stroke was the 
cause of death. The third patient died resulting from intestinal ischemia related to extensive 
thrombosis of the superior mesenteric vein. No patients died as a result of variceal bleeding. 
The overall survival rate was 98% at one year and 88% at five years of follow-up (Figure 2). 
Survival was not significantly different between patients treated with or without long-term 
anticoagulation with VKA (P = .78). Long-term treatment with antiplatelet drugs also did not 
significantly influence survival (P = .38).
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Table 4. Causes of death among 17 patients with PVT and MPN
Cause of death Number of patients (%)
End-stage myelofibrosis 5 (29)
Acute myeloid leukemia 3 (18)
Thrombosis 3 (18)
Sepsis 1 (6)
Other causes 2 (12)
Unknown 3 (18)
Abbreviations: PVT, portal vein thrombosis; MPN, myeloproliferative neoplasm.
Figure 2. Kaplan-Meier survival curve, showing overall survival of 44 patients with non-malignant, 
non-cirrhotic portal vein thrombosis (PVT) and underlying myeloproliferative neoplasm (MPN). The 
number of patients at risk during follow-up is shown along the x-axis.
DiSCUSSioN
In the current cohort study, we have investigated the long-term outcome and survival 
of patients with non-cirrhotic, non-malignant PVT related to an underlying MPN. To our 
knowledge, this study is the largest and most detailed assessment of these patients as yet. 
 The results of our study show that recurrent thrombosis is a severe and clinically 
significant complication. Almost one-third of the patients with PVT and MPN experienced 
an additional thrombotic event during follow-up. In MPN-patients, both arterial and venous 
thrombosis are well-known complications, with the highest rates reported in patients 
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with PV.12-14 Once affected by thrombosis, cases remain at high risk for developing new 
thrombotic events.15,16 A recent study reported a rate of recurrent thrombosis among PV 
and ET patients of 33%, similar to that encountered in this study.17 Extension of thrombosis 
into the splenic vein or superior mesenteric vein occurred relatively frequent in our cohort 
of patients with PVT. This is in line with earlier studies describing that PVT-patients with 
underlying prothrombotic conditions, such as a MPN, may be at particular risk of extension 
of thrombosis.18,19 In addition to increasing morbidity during follow-up, new thrombotic 
events were also related to mortality. In our cohort, 18% of death causes were related to 
a thrombotic event and 47% of deaths were caused by end-stage MPN or AML. Mortality 
in patients with PVT and MPN thus appears to be primarily related to the underlying MPN 
and not to complications of portal hypertension. This has not been recognized previously 
and would support close monitoring of the hematological disease and active collaboration 
between hepatologists and hematologists in the care of these patients. 
 Although variceal bleeding is a common complication in patients with PVT,5,20 our results 
suggests that it is currently well managed. No patients died as a result of variceal bleeding 
even though 39% of the patients experienced at least one episode of bleeding. Overall, we 
could not detect an association between long-term use of anticoagulation and the risk of 
variceal bleeding. This is in line with a previous report, which showed that treatment with 
anticoagulation did not increase the risk or severity of bleeding.18 In contrast to another 
study, we did not find a relationship between variceal bleeding during follow-up and first 
presentation with an episode of bleeding.21 Considering the high incidence of bleeding, 
its associated morbidity and the lack of good predictors of bleeding, regular endoscopic 
examinations and adequate preventive measures appear justified. 
 This study confirms that PVT is often the presenting symptom of an underlying 
MPN, highlighting the need for thorough screening for this disease. Because peripheral 
blood cell counts often remain in normal ranges due to hemodilution, iron deficiency or 
splenomegaly, routine blood cell count testing does not suffice to rule out MPN in these 
patients.10 Identification of the JAK2V617F mutation, present in nearly all patients with PV 
and approximately 50% of the cases with ET or IMF,22 has significantly contributed to the 
detection of MPNs.23,24 Testing for this mutation has now become an important part of 
the work-up of patients presenting with PVT in the absence of cirrhosis or hepatobiliary 
malignancies.25,26 Still, a bone marrow biopsy is often also required as absence of the 
JAK2V617F mutation does not exclude the presence of a MPN. In patients diagnosed 
with PVT in the early part of our study, a complete etiological screening was not always 
performed. Because diagnosis of PVT dated as far back as 1980 and the JAK2V617F mutation 
was not discovered until 2005, JAK2V617F mutation testing was not performed in all 
patients. Of fifteen untested patients for JAK2V617F, eleven patients either died prior to or 
in the year 2005. Therefore, we cannot exclude that in some patients with PVT, especially 
those diagnosed before 2005, the diagnosis of a (latent) MPN may have been missed. 
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Another finding is that in approximately half of the patients, there was coexistence of MPN 
and other prothrombotic factors, underlining the important role of a multifactorial etiology 
in venous thrombosis. For this reason, even in the presence of an overt MPN, physicians 
should be aware of the presence of other risk factors for thrombosis and not refrain from 
thrombophilia screening. It has been suggested that, especially in younger patients with 
MPN, the risk of recurrent thrombosis is significantly higher when additional thrombophilic 
factors are present.17,27 However, we could not confirm this in the current study, but this may 
be due to the small number of patients with thrombophilia. 
 Regarding the optimal treatment of patients with PVT there is much debate, especially 
concerning anticoagulation therapy. Although controlled studies are not available, treatment 
with anticoagulation has been shown to increase the rate of portal vein recanalization in 
patients presenting with acute PVT,8,28,29 and is therefore recommended in these cases.30 
In chronic PVT the role of anticoagulation is less clear as possible beneficial effects of 
preventing extension or recurrence of thrombosis are counterbalanced by potential risks of 
portal hypertension-related bleeding. Similarly, there is no clear consensus on the optimal 
strategy for the prevention of (recurrent) thrombosis in patients with MPN. 
 In this study, there was no mortality due to bleeding in patients receiving anticoagulant 
therapy. Adversely, three patients experienced a new thrombotic event after previous 
anticoagulation therapy was discontinued, which supports the use of anticoagulation 
in patients with PVT and MPN. Still, in three other cases thrombosis recurred despite 
treatment with VKA. Overall, we did not detect a significant effect on survival when we 
compared patients treated with VKA to those that were not. Although the frequency of 
additional thrombotic events and particularly recurrent venous thrombosis appeared lower 
in patients treated with long-term VKA, this failed to reach statistical significance, possibly 
due to the small number of cases. From these results it is therefore not possible to conclude 
whether or not long-term anticoagulation in these patients is indicated. Nevertheless, 
two earlier studies in patients with PVT, with or without MPN, showed that treatment with 
anticoagulation was associated with a lower rate of recurrent thrombosis.18,21
 However, for patients with MPN, treatment options do not only include oral 
anticoagulants but also antiplatelet drugs, cytoreductive therapy or combinations. Recently, 
a large retrospective study of MPN-patients with PV or ET reported that both treatment 
with oral anticoagulation and treatment with antiplatelet drugs were equally effective 
in preventing recurrence in cases with a first venous thrombosis.17 Four MPN-patients in 
our study developed PVT despite aspirin treatment. Remarkably, although the number 
of patients in this cohort is limited, there was no recurrent thrombosis in patients treated 
with anti-platelet drugs. In contrast, a new thrombotic event occurred in 12 of 32 cases 
not receiving long-term aspirin therapy. This suggests that patients with PVT and MPN may 
benefit from long-term treatment with antiplatelet drugs. Obviously, these findings require 
confirmation, if possible, in prospective studies comparing the outcome of long-term 
Ch
ap
te
r 9
133Long-term follow-up of MPN in PVT | 
treatment with VKA to short-term anticoagulation followed by treatment with antiplatelet 
agents, both in terms of bleeding risk and prevention of recurrent thrombosis. Until general 
treatment recommendations become available, awareness of the high rate of thrombosis 
recurrence in PVT-patients with MPN appears crucial and treatment for the underlying MPN 
should probably be actively pursued. 
 Although our study provides several important insights, it has some limitations that 
deserve comment. First, although this is the largest cohort of patients with PVT and 
MPN described until now, the sample size is still relatively small and data was obtained 
retrospectively. Another potential limitation of this study is that the observation period 
ranged from 1980 to 2009. Over this time period, the clinical management of patients with 
PVT and MPN has changed. For example, the awareness of screening for the presence of a 
MPN in patients with PVT has increased over the past years, especially since the discovery 
of the JAK2V617F mutation. Moreover, treatment for MPN has also changed over time. 
Aspirin has become a standard of treatment after landmark trials showed a reduction of 
thrombotic events in patients treated with aspirin.31 Nevertheless, we did not detect a 
significant difference in survival when we compared patients diagnosed before 2000 to 
those diagnosed thereafter (data not shown). Despite these limitations, we believe that 
our findings contribute to the further understanding of this rare combination of disorders, 
especially since large, controlled studies are lacking and hardly feasible.
 In conclusion, this study shows that PVT is often the presenting symptom of an 
underlying MPN, underlining that the presence of a MPN should always be thoroughly 
investigated in these patients. In addition to a high incidence of portal hypertension-related 
variceal bleeding, recurrent thrombosis is also a common and severe complication in 
patients with PVT and MPN. Treatment with antiplatelet drugs may prove to be important in 
the prevention of additional thrombotic events, but this requires further study. Mortality in 
patients with non-cirrhotic PVT and concomitant MPN is primarily related to the underlying 
MPN and not to complications of portal hypertension.
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The objective of this thesis was to investigate the etiology and management of splanchnic 
vein thrombosis (SVT), in particular primary Budd-Chiari syndrome (BCS) and non-cirrhotic, 
non-malignant portal vein thrombosis (PVT). We focussed on myeloproliferative neoplasms 
(MPNs), which are the most frequent underlying risk factors for both disorders. Several 
studies were initiated to provide further insights into the role of MPNs in the etiology of BCS 
and PVT, the challenges concerning the diagnosis of MPNs in this specific patient population 
and the optimal treatment strategy in SVT patients with an underlying MPN. In addition, we 
set out to identify potential new etiological factors and evaluated a controversial treatment 
option, i.e. thrombolysis, for patients with extended thrombosis of the splanchnic veins. 
Several clinical studies are based on data from the European Network for Vascular Disorders 
of the Liver (EN-Vie). Newly diagnosed patients with primary BCS or non-malignant, non-
cirrhotic PVT were consecutively enrolled from nine European countries and general data 
on etiology, clinical presentation and follow-up was collected, which has resulted in two 
unique patient cohorts. Furthermore, several single-center cohort studies from our tertiary 
referral center were performed. 
SiTE-SPECiFiCTY oF THromBoSiS
The haemostatic system ultimately leads to the formation of a blood clot in case of a damaged 
vessel, but also maintains blood in the fluid state within the circulation. It represents a 
balance between procoagulant and anticoagulant factors – a shift in this balance towards 
the anticoagulant side of the spectrum may cause bleeding, whereas a shift towards the 
procoagulant side may result in thrombosis. The majority of hypercoagulable states are 
associated with systemic conditions, but nevertheless lead to a local thrombotic event. 
This implies that certain mechanisms are involved in the site-specificity of thrombosis, i.e. 
that specific risk factors and/or local interaction underlie the development of thrombosis 
at different sites.1 A well-known example of the contribution of local factors to the 
development of venous thrombosis can be observed in deep vein thrombosis (DVT) of the 
lower extremities. The veins of the lower extremities contain venous valves, which guide 
the direction of blood flow and prevent reflux. It is well established that these venous valves 
predispose to DVT through stasis of blood and valve pocket hypoxia.2,3
 In contrast to the vasculature of the lower extremities, the splanchnic vasculature 
does not contain venous valves. This implies that the pathophysiology of thrombosis at 
splanchnic sites must be related to other factors. We reviewed studies on prothrombotic 
factors in common venous thromboembolism (VTE) and SVT and showed that, despite a 
considerable overlap, several interesting differences in underlying prothrombotic factors 
exist.4 Most notably, there is a remarkable high frequency of MPNs and paroxysmal 
nocturnal hemoglobinuria (PNH) in SVT. A unique feature of the splanchnic veins is the 
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exposure of the endothelial cells to gut-derived oral antigens and bacterial components 
from the gastrointestinal tract. Hepatic sinusoidal endothelial cells are known to display 
immune tolerance which prevents them from having an undesirable response to these 
factors, whereas there is no evidence that the endothelial cells of the portal vein are similarly 
protected.5 It has been hypothesized that these endothelial cells may be chronically activated 
or express site-specific genes making them particularly susceptible to disease-specific 
changes of MPNs and PNH, such as an elevated blood viscosity, activated leukocytes and/
or platelets, increased microparticles, hemolysis and activated complement.1 In addition, 
these endothelial cells have been shown to carry the JAK2V617F mutation, suggesting a 
local involvement in the development of BCS.6 
 Interestingly, there are also apparent differences in the risk profiles between BCS and 
PVT. PNH and the Factor V Leiden (FVL) mutation are more strongly associated with the 
development of BCS than with PVT, whereas the opposite is true for the prothrombin 
gene variant. In BCS patients, the FVL mutation has even been specifically associated with 
involvement of thrombosis of the inferior vena cava.7 MPN are the most common cause in 
both BCS and PVT, but the distribution of the three main subtypes of MPN differed between 
BCS and PVT in the EN-Vie cohort.8-10 Polycythemia vera (PV) was the most common 
subtype in BCS, whereas essential thrombocytosis (ET) and myelofibrosis (MF) were more 
often present in PVT patients. Triggered by these findings we performed a meta-analysis, 
in which we showed that MPNs are significantly more frequent in BCS than in PVT and that 
there is indeed a difference in distribution of MPN subtypes, PV being more frequent in 
BCS.11 The prothrombotic effect of high hematocrit values in PV is well established.12 A high 
hematocrit has an important impact on blood viscosity and causes a major disturbance to 
blood flow.13,14 Wautier et al described an increased adhesiveness of red blood cells in PV to 
human umbilical vein endothelial cells and elegantly showed that adhesion was inversely 
related to shear stress.15 The increased adhesion of red blood cells was mediated by erythroid 
Lutheran blood group/basal cell adhesion molecule (Lu/BCAM) and endothelial laminin 
α-5. Variability in the expression of adhesion molecules along the vascular tree along with 
differences in flow conditions might contribute to the site-specificity of thrombosis, as 
suggested by these authors, and might also participate in the higher frequency of PV in BCS.
 The remarkable differences in risk profile between patients with common VTE and SVT, 
along with the more subtle differences between BCS and PVT, clearly support the concept of 
site-specific thrombosis. Studying the interaction between these distinctive prothrombotic 
disorders and vascular bed-specific factors will likely play an essential role in understanding 
the pathophysiology of these disorders. 
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ETioLoGY
myeloproliferative neoplasms
As with other types of venous thrombosis, it is increasingly recognized that non-
cirrhotic, non-malignant PVT and primary BCS are associated with inherited and acquired 
prothrombotic conditions.16 Strikingly, MPNs are associated with an unusually high rate 
of BCS and PVT and are considered to be the most prevalent underlying prothrombotic 
factor in these disorders. Several studies have assessed the prevalence of MPN in BCS, with a 
prevalence ranging from 30% to 50%.17-21 In line with these findings, we report a prevalence 
of MPNs of 33% in a single-center, retrospective cohort study of 40 patients with primary 
BCS.22 In PVT patients, a prevalence of MPNs between 15% and 30% is reported.10,19,23-25 
However, the precise prevalence of MPNs in these disorders is unclear, as peripheral blood 
cell counts often remain within a normal range, due to portal hypertension and its sequelae 
(splenomegaly, hemodilution, iron deficiency).26,27 Despite suggestive features of an MPN, 
fulfilment of usual diagnostic criteria can often be lacking, which is a notorious problem in 
MPN diagnostics in these patients. 
 The discovery of the JAK2V617F mutation in 2005, found in nearly all patients with PV 
and in approximately 50% of patients with ET and MF, represented a crucial advance in the 
diagnostic approach to MPNs.28-31 In 2006, we demonstrated the JAK2V617F mutation in 
41% of BCS patients from our local cohort, which facilitated diagnosis of MPN in patients 
suspect for essential thrombocytosis who failed to meet official MPN criteria. Combined with 
a previous report by Patel et al.,32 these findings clearly showed that JAK2V617F screening 
offered a new diagnostic tool to detect occult MPNs in SVT patients. The high frequency 
of the JAK2V617F mutation in SVT patients was confirmed by other studies, present in 30-
45%17,33,34 and 17-35%10,33,35 of BCS and PVT patients, respectively. All these studies clearly 
demonstrated the added value of JAK2V617F in MPN diagnostics in these patients.
 Many studies have been published on the role of MPNs in the SVT both before and after 
the discovery of JAK2V617F. Inherent to the low incidence of SVT, however, these studies 
often lack statistical power. We therefore performed a meta-analysis, including 1.062 primary 
BCS and 855 non-malignant, non-cirrhotic PVT patients.11 Pooling of studies enabled us to 
show a significantly higher prevalence of both overt MPNs (28.5% vs. 19.4%) and JAK2V617F 
(41.1% vs. 27.7%) in BCS compared to PVT patients. JAK2V617F screening identified MPN 
without characteristic elevated peripheral blood counts in 17.1% and 15.4% of BCS and PVT 
patients, respectively. Presence of JAK2V617F was associated with development of overt 
MPN in 41% and 15% of BCS and PVT patients with these so-called occult MPNs, clearly 
justifying its inclusion in the routine diagnostic work-up of these patients. In contrast, JAK2 
exon 12 and MPL515 mutations were found to be extremely rare in SVT, in agreement with 
their low frequency in MPNs compared to the JAK2V617F mutation.36-40 Screening for these 
mutations is therefore considered dispensable in the routine diagnostic approach of SVT 
patients. 
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Recently, it was shown by several groups that the JAK2V617F, JAK2 exon12 and MPL mutations 
are not acquired randomly, but instead preferentially arise on a specific constitutional JAK2 
haplotype, designated 46/1.33,41-44 To investigate a potential association between the JAK2 
46/1 haplotype and SVT, we performed a case-control study using DNA from 199 BCS and 
PVT patients from the EN-Vie cohort and corresponding healthy controls. We showed that 
the JAK2 46/1 haplotype was associated with the development of JAK2V617F positive SVT-
related MPN, providing additional evidence that this mutation preferentially occurs within 
this particular, inherited haplotype.45 We observed an increased frequency of the JAK2 
46/1 haplotype in JAK2V617F negative patients with a proven MPN (P = .06). In this specific 
subgroup of patients, homozygous carriers of the JAK2 46/1 haplotype had an approximate 
4.7-fold higher chance of MPNs compared to heterozygous carriers or non-carriers. These 
findings suggest a potential role for the JAK2 46/1 haplotype in the etiology and diagnosis 
of SVT-related MPNs. For example, one could consider intensifying screening for MPNs 
during follow up in homozygous carriers of the JAK2 46/1 haplotype to facilitate timely 
recognition and treatment of underlying MPNs. However, the association between the JAK2 
46/1 haplotype and SVT-related MPNs could not be reproduced in a subsequent study.46 
Additional studies are therefore required before definite conclusions on the potential role 
of JAK2 46/1 in the etiology and diagnostic work-up of SVT patients can be drawn.
Fibrinogen γ’: a new risk factor for splanchnic vein thrombosis?
In around 15-25% of SVT patients no underlying condition can be identified,8,10 which 
emphasizes the need to identify new etiological factors. Fibrinogen γ’, a common variant of 
the fibrinogen γ chain, contains a unique extension with both antithrombotic, i.e. inhibition 
of thrombin and platelet aggregation, and prothrombotic properties, i.e. enhancement of 
factor XIII activity and fibrin cross-linking.47 Decreased levels of fibrinogen γ’ and genetic 
variation in fibrinogen γ genes (FGG) have been associated with susceptibility to venous 
thrombosis.48-50 To explore whether these factors also contribute to the development of 
PVT, we performed a case-control study using plasma samples of PVT patients from the 
EN-Vie cohort and healthy controls. Our results showed that fibrinogen γ’ and variation in 
FGG genes can potentially contribute to the development of PVT.51 Fibrinogen γ’ to total 
fibrinogen levels (γ’ ratio) were clearly lower in PVT patients compared to healthy controls. 
The risk of PVT was increased up to 5-fold in individuals with a γ’ ratio lower than the 33rd 
percentile of the distribution in the controls. In addition, a particular γ’ chain gene haplotype 
termed FGG-H2, which was associated with a decreased γ’ ratio in both patients and healthy 
controls, was overrepresented in PVT patients (P = .08). Altogether, these findings show that 
FGG-H2 can potentially contribute to the development of PVT by reducing the γ’ ratio. This 
study establishes additional evidence that a decreased γ’ ratio is associated with an elevated 
risk for venous thrombosis, in this case PVT. Additional studies are needed to extend our 
observations and to determine the clinical relevance of these findings.
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Prompted by these results, we performed a case-control study with BCS patients from 
the EN-Vie cohort and healthy, age- and gender- matched controls.52 In contrast to PVT 
patients, liver synthesis function is often affected in BCS patients due to the venous outflow 
obstruction and subsequent damage of liver parenchymal cells, whereas it is generally 
preserved in patients with non-cirrhotic, non-malignant PVT.16 This may affect pre-mRNA 
splicing, as has been reported for other proteins in patients with chronic liver dysfunction,53 
and therefore influence fibrinogen γ’ levels. To investigate the influence of liver synthesis 
function on the γ’ ratio, we therefore also assessed the γ’ ratio in patients with liver cirrhosis. 
In contrast to our findings in PVT patients, BCS appeared to be associated with an increased 
γ’ ratio compared to controls. However, we showed that the γ’ ratio is strongly dependent 
upon liver function and that the observed elevated γ’ ratio in BCS is likely to be caused by 
liver dysfunction. The γ’ ratio was comparable to controls in the subgroup of BCS patients 
with a preserved liver synthesis function (Child-Pugh A), nor did we observe an association 
between risk of thrombosis and FGG haplotypes, both suggesting that the γ’ ratio is not 
associated with BCS. Hence, our findings argue against a role for fibrinogen γ’ in the etiology 
of BCS. 
 Overall, our data indicate that the fibrinogen γ’ chain may be involved in the 
pathogenesis of PVT, but not of BCS. These findings provide additional evidence that clear 
differences in the risk profile of BCS and PVT patients exist. The different role of fibrinogen 
γ’ in clot formation may be related to differences in shear stress conditions or vascular 
bed specific factors. Clearly, several issues regarding the association between fibrinogen 
γ’ and venous thrombosis deserve further research. Most important, prospective studies 
are required to assess whether fibrinogen γ’ levels already deviate prior to the thrombotic 
event. In addition, the functional role of fibrinogen γ’ in clot formation and the potential 
contribution of vascular bed-specific factors and different shear stress conditions should be 
further investigated. 
multifactorial etiology
The etiology of primary BCS and PVT must be considered multifactorial, even more so than 
in patients with common VTE. The recent EN-Vie studies reported a combination of two or 
more genetic or acquired prothrombotic factors in 46% of BCS and 48% of PVT patients.8,54 
Indeed, 38% and 45% of BCS and PVT patients from our local cohorts with an underlying MPN 
had additional pro-thrombotic factors. Based on these findings, a complete hematological 
work-up, including inherited and acquired thrombophilia, should be performed in BCS and 
PVT patients, even if a prothrombotic factor has already been identified. This is especially 
relevant for the identification of MPNs, which may require additional treatment, such as 
cytoreductive therapy or addition of aspirin to oral anticoagulant treatment.55
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TrEATmENT oF SPLANCHNiC VEiN THromBoSiS
Over the past years, treatment strategies for patients presenting with SVT have significantly 
improved. As in common forms of venous thrombosis, anticoagulant therapy using low 
molecular weight heparin followed by vitamin K antagonists remains the cornerstone of the 
management of both BCS and PVT. For BCS, a stepwise approach has been established.56,57 In 
BCS patients which do not show improvement resulting from medical therapy, percutaneous 
transluminal angioplasty or placement of a transjugular intrahepatic portosystemic shunt 
(TIPS) is warranted, to induce decompression of the liver vasculature. Liver transplantation 
should only be considered in deteriorating BCS patients in whom the disease cannot be 
controlled with the above described options. Although two recent series have demonstrated 
that TIPS is feasible and effective in treating complications of portal hypertension in patients 
with liver cirrhosis and extensive PVT,58,59 there currently is insufficient evidence in favour of 
interventional therapy such as TIPS placement in patients with non-malignant, non-cirrhotic 
PVT.56 For SVT patients with acute, extended thrombosis, often combined thrombosis of 
both portal and hepatic veins, the above described therapeutic options may be unrealistic. 
These individuals generally have a very poor prognosis60 and thrombolytic therapy may be 
considered in such patients. 
Thrombolytic therapy in acute, extended splanchnic vein thrombosis
Both systemic and local administration of thrombolytic agents has been described in the 
treatment of SVT, of which the latter is the preferred option. Several case studies or small 
case series have described successful thrombolytic therapy in SVT patients with a low 
incidence of bleeding complications.61-70 Despite these studies, its use remains controversial 
due to the inherent risks of bleeding complications. We performed a single-center cohort 
study in which we evaluate our experience with local thrombolytic therapy in a series of 
eleven consecutive patients with acute, extended SVT.71 In this study, one of the largest 
series on thrombolysis in SVT patients, we report slightly lower success rates than previously 
described.63,69 However, thrombolytic therapy was accompanied by a previously unreported 
high rate of procedure related bleeding. Pooling and analysis of data from other centres, 
preferably series of consecutive patients to avoid publication bias of successful cases, is 
needed before more extensive conclusions and recommendations can be made. Based on 
our findings, and previous reports in the literature, we advise the following approach in 
patients with acute, extended SVT. Start with conventional anticoagulant therapy and in 
case of insufficient results, proceed to TIPS placement. If venous flow cannot be restored 
by either of these treatment modalities, local thrombolytic therapy, administered via a 
transjugular approach, can be considered. It is up to the treating physicians to determine 
whether the potential benefits of thrombolysis outweigh the apparent risks associated with 
the procedure.
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Long-term treatment in patients with myeloproliferative neoplasms
To study the long-term outcome and optimal management of PVT patients with an 
underlying MPN, we performed a single-center, retrospective cohort study.55 It is well 
established that patients with MPN, after their first thrombotic episode, remain at high risk 
for developing new thrombosis.72-74 Similarly, we showed that recurrent thrombosis is a 
severe and frequent complication in PVT patients with MPN. Almost one-third of these PVT 
patients developed an additional thrombotic event during follow-up, whereas 18% of death 
causes were related to a thrombotic event. In addition, 47% of deaths were caused by end-
stage MPN or transformation to acute myeloid leukemia. Mortality in this group of patients 
thus appears primarily determined by underlying MPNs rather than by complications of 
portal hypertension. 
 There is still debate on the optimal strategy of anticoagulant treatment in PVT patients, 
as potential beneficial effects of preventing extension or recurrent thrombosis may 
be outweighed by the inherent risk of bleeding complications.16,56 Overall, we did not 
observe a significant effect on survival between patients treated with oral anticoagulants 
compared to those who were not. In addition to oral anticoagulants, additional treatment 
options for this specific patient group are available, such as phlebotomy, antiplatelet drugs, 
cytoreductive therapy or combinations. Aspirin has a well-established role in the prevention 
of thrombosis in PV patients,75 and although it has not yet prospectively been shown to 
reduce the incidence of thrombosis in ET, retrospective studies suggested a similar benefit in 
high-risk patients.76-78 The value of treatment with antiplatelet therapy in PVT patients with 
an underlying MPN had not yet been investigated. Although the studied population was 
relatively small, there was no recurrent thrombosis in 12 patients treated with antiplatelet 
drugs. In contrast, recurrent thrombosis occurred in 12 of 32 patients (38%) not receiving 
this long-term treatment. Additional studies are needed to extend these observations, 
preferably of a randomized, prospective design. In these studies, it would be interesting 
to compare the outcome of treatment of PVT and BCS patients with merely anticoagulants 
compared to treatment with oral anticoagulants combined with antiplatelet agents, in 
terms of recurrence of thrombosis and bleeding risk.
FUTUrE rESEArCH 
The studies presented in this thesis have focussed on the etiology and treatment of primary 
BCS and non-malignant, non-cirrhotic PVT. The understanding of the etiology of SVT has 
considerably increased in recent years. However, there are still promising fields to explore.
 Immature platelets represent a small percentage of circulating platelets and are 
hemostatically more active than mature platelets.79 Elevated numbers have been described 
in PV and ET, both characterized by an increased risk of thrombosis, and other thrombotic 
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disorders.80,81 Recently, it was demonstrated that the JAK2V617F mutation is associated with 
an increased number of these immature platelets in patients with PV and ET, which might 
contribute to the prothrombotic phenotype in these patients.82 It would be interesting to 
assess the role of immature platelets in the development of SVT, especially in light of the 
unique role of MPNs in the etiology of SVT. The same applies to microparticles and platelet 
reactivity, which have also been shown to contribute to the development of thrombosis.83-85 
The endogenous thrombin generation potential in SVT patients, which is an overall test 
of coagulation that has been associated with both an increased risk of first86,87 as well as 
recurrent88-91 VTE is another promising area for further study. Finally, one of the classic 
underlying prothrombotic disorders that has received relatively little attention so far is the 
antiphospholipid syndrome. Large studies confirming and quantifying this relation in SVT 
using the updated Sapporo Criteria are still lacking. 
 There is still no clear consensus with regard to the anticoagulant treatment of non-
malignant, non-cirrhotic PVT. Although shown to prevent recurrent thrombosis, it has been 
associated with an increased risk of gastrointestinal bleeding and is currently used with 
relative caution in these patients.56 Nearly all studies on the role of anticoagulant therapy 
in PVT patients had a retrospective design. Prospective, randomized trials are therefore 
urgently needed to fully establish the place of oral anticoagulants in the treatment of PVT 
patients. The introduction of a new class of oral agents, that directly inhibit thrombin or 
factor Xa and do not require laboratory monitoring, has been an important development in 
the field of anticoagulation. Several clinical trials have been published that compare these 
new agents to low molecular weight heparin and vitamin K antagonists in the prevention 
of stroke in atrial fibrillation and treatment of common VTE.92-96 These studies demonstrated 
a similar or even favourable efficacy and safety profile compared to treatment with low 
molecular weight heparin. These findings may ultimately represent a revolution in 
therapeutic options, not only for patients with common venous thrombosis, but also for SVT 
patients. Clinical trials comparing vitamin K antagonist with direct inhibitors of thrombin or 
factor Xa in the treatment of SVT should be actively pursued. 
 Finally, studies are needed that address the optimal treatment strategy of SVT patients 
with an underlying MPN. The role of platelet inhibitors in the treatment of this specific 
subgroup of SVT patients clearly deserves further research. The discovery of JAK2V617F 
has resulted in the development of JAK2 inhibitors. Phase I and II studies show that JAK2 
inhibitors are effective at decreasing constitutional symptoms and reducing spleen size in 
patients with MF.97,98 Data from ongoing phase III trials in MF and PV patients will further 
refine the therapeutic role of these agents in MPN. The role of JAK2 inhibitors needs first to 
be established in MPN before one can speculate on a potential role of these agents in the 
management of SVT patients with an underlying MPN, but results appear promising. 
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SUmmArY 
The term splanchnic vein thrombosis (SVT) is used to indicate both the Budd-Chiari 
syndrome (BCS) and portal vein thrombosis (PVT), which are rare, but potentially life-
threatening, forms of venous thrombosis. In PVT, the extrahepatic portal vein is obstructed, 
whereas primary BCS is characterized by thrombosis of the hepatic veins and/or the 
suprahepatic inferior vena cava, resulting in obstruction of the hepatic venous outflow tract. 
The various chapters of this thesis describe studies that investigated the etiology, clinical 
outcome and management of primary BCS and non-malignant, non-cirrhotic PVT. Several 
studies were based on data from the European Network for Vascular Disorders of the Liver 
(EN-Vie). Newly diagnosed patients with primary BCS or non-malignant, non-cirrhotic PVT 
were consecutively enrolled from nine European countries and general data on etiology, 
clinical presentation and follow-up was collected, which has resulted in two unique patient 
cohorts. Furthermore, several single-center cohort studies from our tertiary referral center 
were performed.
 A review of the risk factors for commonly occurring venous thrombosis, in particular 
deep vein thrombosis and pulmonary embolism, and SVT is presented in chapter 2. The 
results show that both common venous thromboembolism (VTE) and SVT are associated 
with the presence of systemic, inherited or acquired prothrombotic conditions. There are 
many similarities in the risk profiles of patients with common venous thrombosis and SVT. 
However, there are also apparent differences. In particular, MPNs and paroxysmal nocturnal 
hemoglobinuria (PNH) have a remarkable high frequency in SVT. Intriguingly, there are 
even differences in underlying prothrombotic conditions between BCS and PVT patients. 
PNH and the Factor V Leiden mutation are more strongly associated with BCS than with PVT, 
whereas the opposite is true for the prothrombin gene variant. In addition, MPNs are more 
frequent in BCS than PVT. These exceptional differences in risk profiles between patients with 
common venous thrombosis, and even between BCS and PVT patients, support the concept 
of site-specific thrombosis and may prove to be a means towards a better understanding of 
the pathophysiology of these disorders.
 MPNs are the leading predisposing factor for both BCS and PVT. Despite suggestive 
features of an MPN, fulfilment of usual criteria is often lacking, which is a notorious problem 
for diagnosing MPNs in this patient population. In chapter 3 we evaluate 40 BCS patients for 
MPNs and other pro-thrombotic conditions in a retrospective, single-center cohort study. In 
addition, we evaluate the added value of the JAK2V617F mutation in MPN diagnostics. MPNs 
were present in 33% of the patients. In 38% of these patients additional pro-thrombotic 
factors were present, highlighting the necessity of a complete hematological work-up, 
even if a prothrombotic factor has already been identified. This is particularly relevant for 
identifying MPNs, which may require additional treatment, such as cytoreductive therapy or 
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addition of aspirin to oral anticoagulant treatment. Screening for JAK2V617F identified MPN 
patients suspect for essential thrombocythemia, who failed to meet WHO criteria, showing 
that JAK2V617F screening could offer a new tool to detect occult MPNs in these patients. 
Survival of BCS patients did not differ significantly between individuals with and without 
MPNs, although comparison between the groups may have been confounded by extent of 
thrombosis and a difference in performed liver transplantations, both to the detriment of 
non-MPN patients.
 Studies on the role of MPNs in the etiology of SVT have steadily increased over time, 
but interest on this topic has truly gained momentum since the discovery of JAK2V617F 
in 2005. Inherent to the low incidence of SVT, however, these studies often lack statistical 
power. A meta-analysis of these studies is presented in chapter 4, in which the prevalence 
of MPNs, their subtypes as well as JAK2V617F prevalence and its diagnostic role in SVT 
was assessed. Pooling of studies enabled us to show a significantly higher prevalence of 
both overt MPNs (28.5% vs. 19.4%) and JAK2V617F (41.1% vs. 27.7%) in BCS compared to 
PVT patients. Moreover, a remarkable difference in the distribution of underlying MPN 
subtype was observed, polycythemia vera being more frequent in BCS. These differences 
support the theory that the occurrence of thrombosis is not random, but rather the result 
of the interaction of underlying prothrombotic factors and vascular bed-specific factors. 
JAK2V617F screening identified MPN without typical elevated peripheral blood counts 
in 17.1% and 15.4% of BCS and PVT patients, respectively. Presence of JAK2V617F was 
associated with subsequent development of overt MPNs in 41% and 15% of BCS and PVT 
patients, respectively, clearly justifying its inclusion in the routine diagnostic work-up of 
these patients. In contrast, JAK2 exon 12 and MPL515 mutations were found to be extremely 
rare in SVT, and are therefore dispensable in the routine diagnostic approach of these 
patients.
 In 2009, it was demonstrated that JAK2V617F is not acquired randomly, but preferentially 
arises on a constitutional JAK2 haplotype, designated 46/1. In chapter 5 we perform a 
case-control study to investigate a potential association between the JAK2 46/1 haplotype 
and SVT, using DNA samples from BCS and PVT patients from the EN-Vie cohort and 
corresponding healthy controls. The JAK2 46/1 haplotype was associated with JAK2V617F 
positive SVT-related MPN, providing additional evidence that this mutation preferentially 
occurs within this particular haplotype. We also observed an increased frequency of the JAK2 
46/1 haplotype in JAK2V617F negative patients with a proven MPN (P = .06). In this specific 
subgroup of patients, homozygous carriers of the JAK2 46/1 haplotype had an approximate 
4.7-fold higher chance of MPNs compared to heterozygous carriers or non-carriers. The 
JAK2 46/1 haplotype was associated with increased erythropoiesis in JAK2V617F negative 
SVT patients, which is a new finding and supports the theory that the JAK2 46/1 haplotype 
might be functionally different from other JAK2 alleles. Altogether, these findings indicate a 
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potential role for the JAK2 46/1 haplotype in the etiology and diagnosis of SVT-related MPNs 
that requires further exploration. 
Fibrinogen γ’ levels and genetic variation in fibrinogen γ genes (FGG) have been associated 
with susceptibility to venous thrombosis. To assess the potential contribution of these 
factors to the development of PVT, we performed a case control-study using DNA and 
plasma samples from PVT patients from the EN-Vie cohort and healthy controls (chapter 
6). We show that fibrinogen γ’ and variation in FGG genes can potentially contribute to the 
development of PVT. Fibrinogen γ’ to total fibrinogen levels (γ’ ratio) were clearly lower in 
PVT patients compared to healthy controls. The risk of PVT was increased up to 5-fold in 
individuals with a γ’ ratio lower than the 33rd percentile of the distribution in the controls. 
In addition, a particular γ’ chain gene haplotype termed FGG-H2, which was associated 
with a decreased γ’ ratio in both patients and healthy controls, was overrepresented in PVT 
patients (P = .08). Altogether, these findings indicate that FGG-H2 can potentially contribute 
to the development of PVT by reducing the γ’ ratio. 
 In chapter 7, we assess the role of fibrinogen γ’ and FGG haplotypes in BCS using DNA 
and plasma samples from BCS patients from the EN-Vie cohort and healthy, age- and 
gender- matched controls. In contrast to PVT patients, liver synthesis function is often 
affected in patients presenting with BCS, whereas it is generally preserved in patients with 
non-cirrhotic, non-malignant PVT. Importantly, alterations in pre-mRNA splicing have been 
reported for other proteins in patients with chronic liver dysfunction. To investigate the 
influence of liver synthesis function on the γ’ ratio, we therefore also assessed the γ’ ratio 
in patients with liver cirrhosis. In contrast to our findings in PVT patients, BCS appeared 
to be associated with an increased γ’ ratio compared to controls. However, we showed 
that the γ’ ratio is strongly dependent upon liver function. The mean γ’ ratio was equally 
elevated in BCS and liver cirrhosis patients. In addition, the γ’ ratio was similarly increased 
with increasing liver dysfunction in cirrhotics and BCS patients, as represented by the Child-
Pugh classification. The observed elevated γ’ ratio in BCS is therefore likely to be caused by 
liver dysfunction. The γ’ ratio was comparable to controls in the subgroup of BCS patients 
with a preserved liver synthesis function (Child-Pugh A), nor did we observe an association 
between risk of thrombosis and FGG haplotypes, both suggesting that the γ’ ratio is not 
associated with BCS. Hence, our findings argue against a role for fibrinogen γ’ in the etiology 
of BCS. 
 Several case studies or small case series describe successful thrombolytic therapy in SVT 
patients with a low incidence of bleeding complications. Despite these studies, thrombolytic 
therapy remains controversial due to the inherent risk of severe bleeding complications. In 
chapter 8, we present our single-center experience with local thrombolytic therapy in a 
series of eleven consecutive patients with acute, extended SVT. Thrombolytic therapy was 
successful for three thrombotic events and partially successful for four thrombotic events. 
Two patients developed minor procedure related bleeding. Six patients developed major 
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procedure related bleeding, with a fatal outcome in two. With this study, one of the largest on 
this field, we reported slightly lower success rates than previously published, accompanied 
by a previously unreported high rate of procedure related bleeding. Therefore, thrombolysis 
should be reserved for patients in whom the venous flow cannot be restored by using 
conventional anticoagulant therapy, stenting of the thrombosed vessel segment or TIPS 
placement. 
 Chapter 9 describes the results of a single-center retrospective cohort study focusing 
on the long-term outcome and management of 44 PVT patients with an underlying MPN. 
It is shown that recurrent thrombosis is a severe and frequent complication in this specific 
patient group. Almost one-third of the patients developed an additional thrombotic 
event during follow-up, whereas 18% of death causes were related to a thrombotic event. 
In addition, 47% of deaths were caused by end-stage MPN or transformation to acute 
myeloid leukemia. We did not observe a significant effect on survival between patients 
treated with anticoagulants compared to those who were not. The value of treatment with 
antiplatelet therapy in these patients had not yet been investigated. Although the studied 
population was relatively small, there was no recurrent thrombosis in 12 patients treated 
with antiplatelet drugs. In contrast, recurrent thrombosis occurred in 12 of 32 patients (38%) 
not receiving this long-term treatment. The results presented in this chapter show that 
recurrent thrombosis is an important cause of morbidity in this group of patients, and that 
mortality appears primarily determined by underlying MPNs rather than by complications 
of portal hypertension. Additional studies are needed to evaluate the potential benefits of 
antiplatelet therapy in SVT patients with an underlying MPN, preferably of a prospective 
design. 
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SAmENVATTiNG 
Splanchnische veneuze trombose (SVT) is een zeldzame vorm van veneuze trombose, 
gelokaliseerd in het veneuze deel van de splanchnische circulatie en omvat als voornaamste 
entiteiten het Budd-Chiari syndroom (BCS) en vena portae trombose (VPT). In VPT is de 
extrahepatische vena portae geoccludeerd, terwijl primaire BCS wordt gekenmerkt door 
trombose van de hepatische venen en/of de suprahepatische vena cava inferior, resulterend 
in een belemmering van de veneuze uitvloed van de lever. In dit proefschrift worden studies 
beschreven die gericht zijn op het nader in kaart brengen van de etiologie, het ziekteverloop 
en de behandeling bij patiënten met primaire BCS en non-cirrotische, non-maligne VPT. 
Een belangrijk deel van deze studies is gebaseerd op twee unieke patiëntencohorten 
die het resultaat zijn van een Europees samenwerkingsverband (European Network for 
Vascular Disorders of the Liver, EN-Vie), waarbij vanuit negen landen patiëntengegevens 
zijn verzameld van nieuwe gevallen van primaire BCS en non-cirrotische, non-maligne 
VPT. Daarnaast werden verschillende cohortstudies verricht met patiënten uit ons tertiaire 
ziekenhuis. 
 In hoofdstuk 2 wordt een overzicht gepresenteerd van de risicofactoren voor SVT 
en de meer gebruikelijk vormen van veneuze trombose, zoals diep veneuze trombose 
(DVT) en longembolie (LE). Primaire SVT is net als DVT/LE geassocieerd met systemische, 
erfelijke of verworven protrombotische factoren en er blijken veel overeenkomsten in 
de risicoprofielen van deze patiënten te bestaan. Er zijn echter ook duidelijke verschillen 
waarneembaar. Zo hebben MPN en paroxysmale nachtelijke hemoglobinurie  (PNH) een 
opmerkelijk hoge frequentie bij SVT patiënten. Er blijken zelfs evidente verschillen te 
bestaan in de onderliggende protrombotische factoren tussen BCS en VPT patiënten. Zo 
zijn PNH en de Factor V Leiden mutatie sterker geassocieerd met BCS dan met VPT, terwijl 
het tegenovergestelde geldt voor de protrombine gen variant. Daarnaast komen MPN vaker 
voor bij BCS dan bij VPT. De beschreven verschillen in het risicoprofiel tussen patiënten 
met SVT en DVT/LE, en zelfs tussen BCS en VPT patiënten, ondersteunen de theorie dat 
er mogelijk een relatie bestaat tussen bepaalde etiologische factoren en het ontstaan van 
trombose op specifieke locaties in het vaatbed. Het doorgronden van deze opmerkelijke 
verschillen zal zonder enige twijfel leiden tot een beter begrip van de pathofysiologie van 
deze bijzondere ziektebeelden. 
 Myeloproliferatieve neoplasieën (MPN) zijn de meest voorkomende onderliggende 
oorzaak bij zowel BCS als VPT. Het diagnosticeren van MPN bij deze specifieke 
patiëntenpopulatie is complex, aangezien de typische MPN kenmerken vaak ontbreken 
als gevolg van portale hypertensie (splenomegalie, hemodilutie, ijzergebrek). In hoofdstuk 
3 presenteren we een retrospectieve cohort studie waarbij 40 BCS patiënten worden 
geëvalueerd voor MPN en andere protrombotische factoren. Tevens wordt in deze studie 
156 | 
de toegevoegde waarde van de JAK2V617F mutatie in het diagnosticeren van MPN 
onderzocht. Bij 33% van de BCS patiënten was sprake van een onderliggende MPN. Bij 38% 
van deze patiënten met een MPN waren additionele protrombotische factoren aanwezig. 
Deze resultaten benadrukken de noodzaak van een volledige hematologische diagnostiek 
bij BCS patiënten, zelfs als er al een protrombotische factor is geïdentificeerd. Dit is met 
name relevant voor het herkennen van een onderliggend MPN, aangezien deze mogelijk 
additionele behandeling vereist, zoals het toevoegen van aspirine of cytoreductieve 
therapie aan de reguliere antistollingstherapie. Screening voor JAK2V617F identificeerde 
MPN patiënten waarbij een sterke verdenking op essentiële trombocytose bestond, maar 
waarbij niet werd voldaan aan de officiële MPN criteria. Dit suggereert dat screening voor 
JAK2V617F een nieuw diagnosticum kan bieden om occulte MPN te identificeren bij deze 
patiënten. Er werd geen significant verschil in overleving van BCS patiënten aangetoond 
tussen patiënten met en zonder onderliggend MPN. Vergelijking van deze twee groepen 
wordt echter bemoeilijkt door een verschil in uitgebreidheid van trombose en het aantal 
uitgevoerde levertransplantaties tussen de groepen, beiden ten nadele van patiënten 
zonder onderliggend MPN. 
 Sinds de ontdekking van de JAK2V61F mutatie in 2005 is onderzoek naar de rol van MPN 
in de etiologie van SVT in een stroomversnelling geraakt. Inherent aan de lage incidentie van 
deze ziektebeelden is bij deze studies vaak sprake van een gebrek aan statistische power. 
We hebben daarom een meta-analyse van studies uitgevoerd uit de periode januari 1980 
tot augustus 2011 (hoofdstuk 4). Hierin worden de prevalenties van MPN, de verschillende 
subtypes en JAK2V617F bepaald en wordt de toegevoegde waarde van JAK2V617F in de 
MPN diagnostiek gekwantificeerd. Pooling van deze studies stelde ons in staat om een 
significant hogere prevalentie vast te stellen van zowel manifeste MPN (28.5% vs. 19.4%) als 
JAK2V617F (41.1% vs. 27.7%) bij BCS ten opzichte van VPT patiënten. Bovendien werd een 
opmerkelijk verschil in de distributie van de onderliggende MPN subtypes waargenomen, 
waarbij polycythemia vera vaker voorkwam bij BCS patiënten. Deze verschillen steunen de 
theorie dat trombose niet onwillekeurig optreedt, maar dat verschillen in risicofactoren 
en vaatbed-specifieke factoren gerelateerd kunnen zijn aan de locatie van de trombose. 
JAK2V617F screening identificeerde MPN zonder de karakteristiek verhoogde perifere 
bloedwaarden bij respectievelijk 17.1% en 15.4% van de BCS en VPT patiënten. JAK2V617F 
was geassocieerd met de ontwikkeling van manifeste MPN gedurende follow-up bij 
respectievelijk 41% en 15% van deze BCS en VPT patiënten. Deze gegevens tonen duidelijk 
de toegevoegde waarde van JAK2V617F screening aan en rechtvaardigen diens opname in 
de hedendaagse routine diagnostiek van SVT patiënten. JAK2 exon 12 en MPL515 mutaties 
bleken zeer zeldzaam in SVT en screening voor deze mutaties is daarom overbodig in de 
routine diagnostiek van deze patiënten. 
 In 2009 werd aangetoond dat JAK2V617F niet willekeurig wordt verworven, maar bij 
voorkeur ontstaat op een constitutioneel JAK2 haplotype, aangeduid met 46/1. Met behulp 
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van DNA van zowel BCS als PVT patiënten uit het EN-Vie cohort en corresponderende, 
gezonde controles, is onderzoek verricht naar de mogelijke associatie tussen het JAK2 46/1 
haplotype en SVT (hoofdstuk 5). Deze studie laat zien dat het JAK2 46/1 haplotype was 
geassocieerd met JAK2V617F positieve SVT-gerelateerde MPN, wat aanvullend bewijs levert 
dat deze mutatie inderdaad bij voorkeur plaatsvindt in dit specifieke haplotype. Het JAK2 
46/1 haplotype bleek ook in verhoogde mate aanwezig te zijn bij JAK2V617F negatieve 
patiënten met een bewezen MPN (P = .06). In deze specifieke groep van patiënten hadden 
homozygote dragers van het JAK2 46/1 haplotype een ca. 4.7-maal verhoogde kans op een 
onderliggende MPN, vergeleken met patiënten heterozygoot voor het JAK2 46/1 haplotype 
of niet dragers. Tevens bleek het JAK2 46/1 haplotype geassocieerd met een verhoogde 
erythropoiese bij JAK2V617F negatieve SVT patiënten. Dit is een nieuwe bevinding en 
vormt bewijs voor de theorie dat JAK2 46/1 haplotype functioneel verschilt van andere 
JAK2 allelen. De bevindingen in dit hoofdstuk suggereren een mogelijke rol voor JAK2 46/1 
haplotype in de etiologie en diagnose van SVT-gerelateerde MPN. 
 De hoeveelheid fibrinogeen γ’ en genetische variatie in fibrinogeen γ genen (FGG) zijn 
geassocieerd met het optreden van veneuze trombose. Om de potentiële bijdrage van deze 
factoren aan de ontwikkeling van VPT nader te onderzoeken is in hoofdstuk 6 een case-
control studie verricht met behulp van DNA en plasmamonsters van VPT patiënten uit de 
EN-Vie studie en gezonde controles. Deze studie laat zien dat fibrinogeen γ’ en variatie in 
FGG genen mogelijk kunnen bijdragen aan het ontstaan van VPT. De relatieve hoeveelheid 
fibrinogeen γ’ ten opzichte van de totale hoeveelheid fibrinogeen (γ’ ratio) bleek verlaagd bij 
VPT patiënten, waarbij een γ’ ratio in het laagste tertiel correspondeerde met een 5-voudig 
verhoogd risico op VPT. Tevens bleek het FGG haplotype-2, welke was geassocieerd met 
een verlaagde γ’ ratio bij zowel VPT patiënten als controles, oververtegenwoordigd bij 
VPT patiënten (P = .08). Deze bevindingen vormen het eerste bewijs dat FGG-H2 mogelijk 
bijdraagt aan de ontwikkeling van VPT door middel van het verminderen van de γ’ ratio. 
 In hoofdstuk 7 wordt een case-control studie beschreven waarin we de rol van 
fibrinogeen γ’ en FGG haplotypes onderzoeken in BCS patiënten. Voor deze studie werd 
gebruik gemaakt van DNA en plasmamonsters van BCS patiënten uit de EN-Vie studie 
en gezonde, in leeftijd en geslacht overeenkomende controles. De leverfunctie is vaak 
verminderd bij BCS patiënten, terwijl deze over het algemeen niet is aangedaan bij 
patiënten met non-cirrotische, non-maligne VPT. Dit is relevant omdat veranderingen in pre-
mRNA splicing eerder zijn beschreven voor andere eiwitten bij patiënten met chronische 
leverdysfunctie en derhalve van invloed kunnen zijn op de hoeveelheid fibrinogeen γ’ en 
de γ’ ratio. Om de invloed van leversynthese op de γ’ ratio te onderzoeken hebben we de 
hoeveelheid fibrinogeen γ’ en totaal fibrinogeen gemeten bij patiënten met levercirrose. 
In tegenstelling tot de verlaagde γ’ ratio bij VPT patiënten werd bij BCS patiënten juist 
een verhoogde γ’ ratio gevonden. Echter, we tonen aan de γ’ ratio sterk afhankelijk is van 
de leverfunctie. De γ’ ratio was in vergelijkbare mate toegenomen bij BCS patiënten en 
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patiënten met levercirrose. Tevens bleek de γ’ ratio bij BCS en cirrose patiënten gelijkmatig 
te stijgen met het oplopen van de Child-Pugh classificatie, die de ernst van leverdysfunctie 
representeert. De verhoogde γ’ ratio bij BCS patiënten is derhalve waarschijnlijk het 
gevolg van leverdysfunctie. Het feit dat de γ’ ratio bij BCS patiënten met een relatief goede 
leverfunctie vergelijkbaar was met gezonde controles en dat FGG haplotypes niet waren 
geassocieerd met BCS, pleit tegen een mogelijke rol van fibrinogeen γ’ in de etiologie van 
BCS. 
 Verscheidene case-studies en kleine patiënten series beschrijven de succesvolle 
behandeling van SVT patiënten middels trombolytische therapie en rapporteren een 
lage incidentie van bloedingscomplicaties. Desondanks blijft deze therapie controversieel 
vanwege het risico op zeer ernstige bloedingen. In hoofdstuk 8 presenteren wij onze 
ervaring met lokale trombolytische therapie in een serie van 11 opeenvolgende patiënten 
met acute, uitgebreide SVT. Trombolyse was succesvol bij drie van deze patiënten en 
partieel succesvol bij vier patiënten. Bij twee patiënten ontstond een relatief kleine, 
procedure gerelateerde bloeding. Bij zes patiënten trad een grote bloedingscomplicatie op, 
met een fatale uitkomst in twee van deze gevallen. Met deze studie, een van de grootste 
op dit gebied, rapporteren wij een iets lager slagingspercentage van trombolyse dan 
voorheen gerapporteerd, echter vergezeld van een niet eerder gemeld hoog percentage 
bloedingscomplicaties. Trombolyse dient daarom te worden voorbehouden aan patiënten 
bij wie de veneuze flow niet kan worden hersteld door middel van antistolling, percutane 
transluminale angioplastiek met eventuele stentplaatsing of plaatsing van een transjugulaire 
intrahepatische portosystemische shunt. 
 Hoofdstuk 9 beschrijft de resultaten van een cohort studie waarbij het ziektebeloop 
en behandeling van 44 VPT patiënten met een onderliggende MPN nader in kaart wordt 
gebracht. Deze lange termijn vervolg studie laat duidelijk zien dat recidiverende trombose 
een ernstige en frequente complicatie in deze specifieke groep patiënten is. Bij één-derde 
van de patiënten ontwikkelde zich een recidief trombose tijdens follow-up, terwijl 18% 
van de doodsoorzaken gerelateerd waren aan een trombotisch event. Daarnaast waren 
47% van de sterfgevallen veroorzaakt door eindstadium MPN of transformatie naar acute 
myeloïde leukemie. Er werd geen verschil in overleving waargenomen tussen patiënten 
behandeld met en zonder antistolling. Tot op heden was de toegevoegde waarde van 
trombocytenaggregatieremmers bij deze groep patiënten nog niet onderzocht. Alhoewel 
de bestudeerde populatie relatief klein was, werd er bij 12 patiënten behandeld met 
trombocytenaggregatieremmers geen recidief trombose vastgesteld, terwijl dit wel op-
trad bij 12 van de 32 (38%) patiënten die deze behandeling niet kregen. De resultaten in dit 
hoofdstuk laten zien dat recidief trombose een belangrijke bron van morbiditeit en 
mor-taliteit is in VPT patiënten met een onderliggende MPN. Mortaliteit lijkt primair gere- 
lateerd aan de onderliggende MPN in plaats van de complicaties van portale hypertensie. 
Aanvullende studies zijn nodig om de potentiele voordelen van trombocytenaggregatie-
remmers bij SVT patiënten met een onderliggende MPN nader te bestuderen, bij voorkeur 
prospectief van aard. 
159Dankwoord | 
DANKWoorD
Het afronden van dit boekje was niet mogelijk geweest zonder de hulp van anderen. De 
volgende mensen wil ik daarom graag bedanken. 
 Prof.dr. F.W.G. Leebeek, beste Frank, al in mijn eerste jaar van de studie Geneeskunde 
ben ik onder jouw begeleiding begonnen op de lijn van de vasculaire leverziekten. 
Hiermee bood je me de kans en het vertrouwen om mij al vroeg op onderzoek te richten 
en gaf je me bovendien de ruimte om dit op een zelfstandige wijze te doen, iets wat zeker 
niet vanzelfsprekend is voor iemand in die fase van zijn opleiding. Gaandeweg werd 
ik enthousiaster en werd steeds duidelijker dat het hier een eigenlijk om een begin van 
een promotietraject ging. Niet in de laatste plaats door jouw enthousiasme en motivatie. 
Ik heb je begeleiding als buitengewoon prettig ervaren: open, motiverend en met ruimte 
voor zelfstandigheid, maar ook altijd scherp en kritisch. Ik heb enorm veel respect voor je 
drive en doorzettingsvermogen en de manier waarop je je hebt gemanifesteerd in het veld 
van trombose en hemostase. En het feit dat je dit hebt weten te bereiken en toch bovenal 
een echte clinicus bent gebleven. Ik heb veel waarde gehecht aan onze gesprekken. Ik 
hoop dat ik ook na deze promotie hiervoor nog bij je mag aankloppen. Veel dank voor de 
mogelijkheden die je me hebt geboden. 
 Prof.dr. H.L.A. Janssen, beste Harry, ik heb veel bewondering voor de wijze waarop je, 
naast het onderzoek naar Hepatitis B en C, je al jaren geleden hebt toegelegd op de vasculaire 
leverziekten, weesziekten waar maar weinig aandacht en middelen voor beschikbaar 
zijn. Dit heeft uiteindelijk geresulteerd in een bijzondere Europese samenwerking en 
het EN-Vie cohort, inmiddels een begrip in de wereld van vasculaire leverziekten. Het is 
niet verwonderlijk dat hier al vele mooie publicaties uit zijn voortgekomen en zeker nog 
zullen volgen in de toekomst. Zonder jou zou deze bijzondere samenwerking tussen de 
Hematologie en Hepatologie dan ook niet van de grond zijn gekomen. Heel veel dank voor 
je begeleiding tijdens dit onderzoek. 
 Prof.dr. H.J. Metselaar, prof.dr R.J. Porte en prof.dr. P. Sonneveld wil ik bedanken voor het 
plaatsnemen in de kleine commissie. Prof.dr. U.H.W. Beuers, dr. P.A.W. te Boekhorst en Dr. 
P.W. Kamphuisen wil ik bedanken voor het zitting nemen in de promotiecommissie. 
 De stollingsgroep. Moniek, bedankt dat ik altijd bij je kon aankloppen voor een korte 
vraag over statistiek of fibrinogeen. Meestal bleken die vragen toch niet zo kort. Dit heb ik 
zeer gewaardeerd. Dick, stiekem is er niemand meer die over de basale stolling weet dan 
jij, terwijl jij de bescheidenheid zelve bent. Als jij een stuk beoordeelt kom je altijd met 
positieve kritiek en opbouwende opmerkingen, waardoor de stukken altijd beter worden. 
Marieke, altijd scherp tijdens het maandagmiddag werkoverleg, leuk dat we samen dat 
stuk voor ATVB hebben kunnen schrijven. Ana, Tamara, Elim, Simone, Janine, dank voor de 
gezellige tijd. Joyce en Reinilde, dank voor jullie hulp en vooral geduld in het lab. Ik heb het 
oprecht leuk gevonden en denk daar met plezier aan terug. Yvonne, in de korte tijd heb ik 
160 | 
je leren kennen als een fijne en gezellige collega, succes met het voortzetten van het WIN-
onderzoek. Goran, in de eerste jaren van mijn onderzoek een vaste bewoner van de 13e. 
Je bent een bijzonder persoon, ik heb veel respect voor je. Marianne en Eva, toch wel mijn 
maatjes tijdens mijn tijd op de hematologie, alhoewel we eigenlijk nooit met zijn drieën 
tegelijk hebben gewerkt door een combinatie van coschappen en zwangerschap. Eva, in 
de laatste jaren heb je met al je enthousiasme niet alleen een prachtstudie opgezet en een 
zeer mooi proefschrift afgeleverd, maar tussendoor ook nog even een gezin gesticht. Dat 
doet niet iedereen je na. Fijn dat de radiotherapie zo goed bevalt. Marianne, inmiddels weer 
mijn collega in Dordrecht, nu als arts-assistent in de kliniek. Je bent gewoon een heel fijne 
collega. Succes met de laatste loodjes van je promotie. Binnenkort maar met zijn drieën 
naar Ivy. 
 Een maandje of twee heb ik bij de datamanagers op de kamer gezeten. Een beetje gek 
zijn jullie natuurlijk wel, maar jullie dragen voor een groot deel bij aan de gezelligheid op de 
L-vleugel. Anita, daarna kreeg jij mij plots als extra kamergenoot. Het was even aftasten in 
het begin, maar ik heb echt enorm veel gelachen met je. Dat maakte het een fijne plek om 
elke dag te werken. Marc, dank voor de gezellige tijd, veel geluk in Tilburg. 
 Drie van de in dit proefschrift beschreven studies zijn gebaseerd op het EN-Vie cohort. 
Ik wil graag alle betrokken artsen bedanken voor hun medewerking aan de deze unieke 
studie en het includeren van de patiënten. De medeauteurs wil ik graag bedanken voor hun 
waardevolle bijdrage aan de betreffende studies.  
 Dan de personen van de andere afdelingen met wie ik aan de verschillende studies 
heb samengewerkt. Allereerst natuurlijk Sarwa. Ik denk met veel plezier terug aan onze 
samenwerking. Ik heb veel respect voor de wijze waarop je de EN-Vie studie hebt weten 
op te zetten. Een uniek cohort voor patiënten met deze zeldzame ziektebeelden, waarop 
een aantal studies uit mijn proefschrift zijn gebaseerd. Het EN-Vie cohort zal zeker ook nog 
in de toekomst een bron blijken voor mooie publicaties. Dank voor al deze inspanningen, 
maar vooral voor je gezelligheid en advies. Jildou, ook met jou heb ik ook met veel plezier 
samengewerkt. Je heb inmiddels zelf een heel fraai proefschrift afgeleverd en een aantal 
van mijn studies borduren zonder enige twijfel voort op jouw werk, met name het aspect 
van de site-specificity. Edith, het laatste jaar hebben wij met goed resultaat samengewerkt 
aan een aantal studies, veel succes met je verdere promotietraject. Lidia, de meta-analyse 
had aardig wat voeten in de aarde. Dank dat je hiervoor tijd hebt kunnen vrijmaken in je 
drukke agenda, uiteindelijk is het niet voor niets geweest en hebben we een mooi stuk 
kunnen schrijven. 
 Ik wil natuurlijk ook alle medewerkers van het secretariaat van de afdeling Hematologie 
bedanken voor alle ondersteuning tijdens mijn promotie. Ik ben ook dank verschuldigd aan 
het secretariaat van de MDL. 
161Dankwoord | 
 Sinds een klein jaar ben ik werkzaam binnen de afdeling Interne Geneeskunde van het 
Albert Schweitzer Ziekenhuis in Dordrecht. Ik wil de maatschap en groep assistenten graag 
bedanken voor de gezellige werksfeer en samenwerking. 
 Jan-Willem en Jeroen, mooi dat jullie erbij zijn als paranimf tijdens deze promotie. We 
kennen elkaar inmiddels al aardig wat jaren. Tegelijk in 1998 gestart met economie en toch 
zo verschillend terecht gekomen. De één als financial controller, de ander in de private 
equity wereld in Londen. Wie had toen gedacht dat we hier nu zo zouden staan. We zien 
elkaar natuurlijk niet meer zo vaak als vroeger, des te mooier vind ik het om dagen als deze 
samen met jullie te kunnen beleven. 
 Dit boekje was waarschijnlijk niet tot stand gekomen zonder een luisterend oor en 
advies van vrienden. Jullie weten wie ik bedoel. Bedankt daarvoor.   
 Lieve moeder en Cor, Frank en Taco, negen jaar geleden vertelde ik dat ik erover dacht 
om alsnog Geneeskunde te gaan studeren. Vanaf het allereerste moment hebben jullie me 
hierin gesteund. Nu staan we hier en rond ik mijn promotie af. Ik besef mij maar al te goed 
dat dit zonder jullie steun niet mogelijk was geweest en prijs mij rijk dat ik jullie naast me 
heb. 
162 | 
LiST oF PUBLiCATioNS
1. Hoekstra J, Bresser EL, Smalberg JH, Spaander MC, Leebeek FW, Janssen HL. Long-term 
follow-up of patients with portal vein thrombosis and myeloproliferative neoplasms. J 
Thromb Haemost. 2011 Nov;9(11):2208-14.
2. Smalberg JH, Koehler E, Darwish Murad S, Plessier A, Seijo S, Trebicka J, et al. The JAK2 
46/1 haplotype in Budd-Chiari syndrome and portal vein thrombosis. Blood. 2011 Apr 
14;117(15):3968-73.
3. Smalberg JH, Kruip MJ, Janssen HL, Rijken DC, Leebeek FW, de Maat MP. Hypercoagulability 
and hypofibrinolysis and risk of deep vein thrombosis and splanchnic vein thrombosis: 
similarities and differences. Arterioscler Thromb Vasc Biol. 2011 Mar;31(3):485-93.
4. Smalberg JH, Leebeek FW. Superimposed coagulopathic conditions in cirrhosis: 
infection and endogenous heparinoids, renal failure, and endothelial dysfunction. Clin 
Liver Dis. 2009 Feb;13(1):33-42.
5. Smalberg JH, Spaander MV, Jie KS, Pattynama PM, van Buuren HR, van den Berg B, et 
al. Risks and benefits of transcatheter thrombolytic therapy in patients with splanchnic 
venous thrombosis. Thromb Haemost. 2008 Dec;100(6):1084-8.
6. Smalberg JH, De Maat MP, Leebeek FW. Absence of the JAK2 V617F mutation in patients 
with arterial thrombosis without overt myeloproliferative disease. J Thromb Haemost. 
2008 Sep;6(9):1606-7.
7. Smalberg JH, Murad SD, Braakman E, Valk PJ, Janssen HL, Leebeek FW. Myeloproliferative 
disease in the pathogenesis and survival of Budd-Chiari syndrome. Haematologica. 
2006 Dec;91(12):1712-3.
8. Smalberg, J.H. (2005), Marktwerking: eigen vermogen en solvabiliteit van ziekenhuizen, 
Handboek Financiële Bedrijfsvoering in de Zorg, (pp. II 1.11- 1 – 1.11-13).
163Curriculum vitae | 
CUrriCULUm ViTAE
Jasper Hoite Smalberg werd op 10 juli 1980 geboren te Hellevoetsluis. Het middelbaar 
onderwijs werd gevolgd aan het G.S.G. Helinium te Hellevoetsluis, alwaar hij in 1998 zijn 
atheneum diploma behaalde. In september 1998 ging hij Economie studeren aan de Erasmus 
Universiteit Rotterdam na uitgeloot te zijn voor de studie Geneeskunde. Na in 2003 een 
semester gestudeerd te hebben aan de Faculty of Business and Economics van de University 
of Sydney, Sydney (Australië) behaalde hij in september 2004 zijn doctoraal en rondde hij 
deze studie af. In september van dat zelfde jaar begon hij aan de studie Geneeskunde aan de 
Erasmus Universiteit Rotterdam. In 2010 werd het artsexamen cum laude afgerond. Tevens 
behaalde hij gedurende die periode (2006-2010) een Master of Science in Clinical Research 
aan de Netherlands Institute for Health Sciences te Rotterdam. Vanaf maart 2005 tot en 
met januari 2011 was hij werkzaam op de afdeling Hematologie van het Erasmus MC te 
Rotterdam, grotendeels in deeltijd verband naast de studie Geneeskunde en het laatste jaar 
met een voltijd aanstelling als arts-onderzoeker. Gedurende deze periode werden onder 
leiding van Prof.dr. F.W.G. Leebeek van de afdeling Hematologie en Prof.dr. H.L.A. Janssen 
van de afdeling Maag-, Darm- en Leverziekten de studies beschreven in dit proefschrift 
uitgevoerd. In februari 2011 is hij gestart met de opleiding tot Maag-Darm-Leverarts aan 
het Erasmus MC (opleider dr. R.A. de Man). De vooropleiding Interne Geneeskunde volgt 
hij gedurende twee jaar in het Albert Schweitzer ziekenhuis te Dordrecht (opleider dr. E.F.H. 
van Bommel). 

165PhD portfolio | 
PHD PorTFoLio
Summary of PhD training activities
Name PhD student: Jasper Hoite Smalberg
Erasmus MC, Department of Hematology
Research School: COEUR
PhD period: March 2005 – January 2011
Promotores: Prof.dr. F.W.G. Leebeek, Prof.dr. H.L.A. Janssen
General Courses
Master of Science in Clinical Research. Netherlands Institute for Health 
Sciences, Rotterdam, The Netherlands.
2006-2010
Poster Presentations
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